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“People think that epilepsy is divine simply because they don't have any idea what causes epilepsy. 
But I believe that someday we will understand what causes epilepsy, and at that moment, we will 
cease to believe that it's divine. And so it is with everything in the universe” 
Hippocrates – On the Sacred Disease 
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Chapter 1 
Rationale, research aims and thesis outline 
 
 
Rationale 
Epilepsy is a chronic neurological disorder as old as human history, characterized by the occurrence 
of unprovoked seizures. Seizures were originally considered to be of divine or demonic nature, until 
Hippocrates, the forefather of neurology, defied this perception and recognized that they were caused 
by a brain malfunction (Magiorkinis et al., 2010, Breitenfeld et al., 2014). Although a lot of progress 
has been made since then, major knowledge gaps exist to date and a strong social stigma still 
surrounds epilepsy. As the disorder affects 65 million people worldwide and has a substantial 
negative impact on a patient’s life (Table 1), it is considered a major public health concern (Thurman 
et al., 2011, WHO, 2015). In Europe alone 6 million people have epilepsy, and there are 400.000 
newly diagnosed cases each year, i.e. one new case every minute (Perucca et al., 2013). Importantly, 
about 30% of these patients are not adequately aided with the current available treatments (Cross, 
2011, Perucca et al., 2013, WHO, 2015), which continuously drives the search for new, improved 
therapies. To this end, extensive research in animal models is indispensable (Rogawski, 2006). 
 
Table 1 │ Several of the negative aspects of epilepsy. (Perucca et al., 2013, WHO, 2015) 
Ÿ 2-3 times higher
Ÿ 2-10 years
Ÿ Learning problems
Ÿ Sleeping problems
Ÿ Mood disorders
Ÿ Depression and anxiety 
Ÿ Reduced access to life and health insurance
Ÿ Withholding of driving license
Ÿ Barriers to particular occupations
Ÿ Denying of right to marry
Increased mortality
Reduced life expectancy
High risk of comorbidities that reduce quality of life
Reduced human rights
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Current treatment entails the use of anti-epileptic drugs (AEDs). In most cases AEDs directly target 
the imbalance in excitatory and inhibitory neurotransmission, that is the hallmark of the epileptic 
brain (see Chapter 2, Treatment). However, although the pathophysiology of seizures and the 
development of epilepsy after a precipitating event (i.e. epileptogenesis) has been an active field of 
research for decades, the proportion of individuals with pharmacoresistant epilepsy largely remained 
unchanged since the late 1960s (Fattore and Perucca, 2011). It has therefore been suggested recently 
to focus on novel signaling systems to develop drugs that are not only more efficacious but also have 
better tolerability and pharmacokinetics. Moreover, a different approach may help in finding disease-
modifying drugs that can target the early epileptogenic process (Rogawski, 2006, Devinsky et al., 
2013).  
Uric acid is a breakdown product of the purine metabolism that has been linked to an increasing 
number of disorders over the past decades (Kutzing and Firestein, 2008, Alvarez-Lario and 
Macarron-Vicente, 2011). Increased serum uric acid levels are associated with gout, metabolic 
syndrome, hypertension, schizophrenia and bipolar disorder. Decreased serum uric acid levels are 
found in patients with multiple sclerosis, Alzheimer’s and Parkinson’s disease. For many of these 
disorders there is a growing body of evidence indicating that uric acid is not only a marker, but also 
actively influences the underlying pathophysiology. In this regard, uric acid is a therapeutic target in 
gout (Rock et al., 2013), but a therapeutic agent in multiple sclerosis (Markowitz et al., 2009).  
There are indications that uric acid might be involved in epilepsy as well. A number of clinical and 
preclinical epilepsy studies report elevated uric acid levels and, more importantly, suggest that 
lowering uric acid levels has anticonvulsant potential (Stover et al., 1997, Hamed et al., 2004, Togha 
et al., 2007). However, previous literature consistently lacked a uric acid oriented approach and its 
involvement has never been investigated thoroughly. 
Research aims 
The main objective of this dissertation was the investigation of a role for uric acid in 
experimental seizure models. More specifically we aimed to: 
(1) develop and characterize a seizure model that allows to monitor the changes in local uric acid 
levels 
(2) investigate the effects of pharmacological and genetic uric acid modulations on the seizure 
characteristics of this model 
(3) investigate the effects of these manipulations on the seizure-associated inflammatory 
response 
(4) examine if altering uric acid levels changes seizure characteristics in a different seizure 
model 
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Thesis outline 
This chapter comprises the rationale, research aims and outline of the thesis. 
Chapter 2 provides a general introduction describing the key concepts of epilepsy and its treatment 
options. A concise overview is given of the different preclinical models used for seizure and epilepsy 
studies, focusing on the ones used in this thesis.  
Chapter 3 is a critical review of the available clinical and preclinical data on uric acid in epilepsy. 
The link between the molecular actions of uric acid and the pathophysiology of epilepsy is discussed.  
Chapter 4 describes the electrographic, behavioral and neuroinflammatory changes as well as 
changes in local uric acid levels in the intrahippocampal kainic acid model for limbic seizures.  
Chapter 5 addresses the effects of complementary pharmacological and genetic uric acid 
manipulations on the electrobehavioral parameters of the intrahippocampal kainic acid seizure model.  
Chapter 6 focuses on the effects of uric acid manipulations on the seizure-associated 
neuroinflammatory changes in the intrahippocampal kainic acid model.  
Chapter 7 details on the effects of genetic uric acid manipulations in the timed pilocarpine and 
pentylenetetrazole intravenous infusion seizure models.  
Chapter 8 is a general discussion in which the insights obtained in the empirical chapters are 
discussed with respect to the current literature. Future research challenges are marked out.  
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Chapter 2 
General introduction on epilepsy 
 
 
Definitions 
According to the International League Against Epilepsy (ILAE) epilepsy is a neurological disease 
characterized by an enduring predisposition to generate epileptic seizures (Fisher et al., 2005). In 
practice, a patient was previously diagnosed with epilepsy after having at least two unprovoked 
seizures that occur more than a day apart. However, the definition of epilepsy was recently extended 
to include cases that only exhibited one seizure. As such, epilepsy is defined by any of the following 
conditions (Fisher et al., 2014):  
a) at least two unprovoked (or reflex) seizures occurring more than a day apart  
b) one unprovoked (or reflex) seizure and a probability of further seizures similar to the general 
recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years  
c) diagnosis of an epilepsy syndrome 
An epileptic seizure is a transient clinical manifestation of abnormal excessive or synchronous 
activity of neuronal populations in the brain (Fisher et al., 2005). Depending on the extent of 
neuronal involvement and site of origin (i.e. epileptic focus) the characteristics of the seizure differ, 
and can include alterations of consciousness, motor, sensory autonomic or psychic events (Engel, 
2006). When an epileptic seizure prolongs it is termed status epilepticus (SE), and although the 
exact duration for a seizure to be considered SE is heavily debated, a five-minute definition is 
accepted for treatment purposes (Cross, 2014). Brain insults such as SE are a risk factor for 
epileptogenesis (Gordon Boyd et al., 2012), the dynamic process that converts a healthy brain into 
an epileptic one by increasing neuronal excitability via alterations on molecular, cellular and 
structural level (Pitkanen and Lukasiuk, 2011). 
 
12 
 
Invest igat ion  o f  a  ro le  for  ur ic  a c id  in  exper imenta l  se izure  mode ls  
 
 
Diagnosis and classification 
To diagnose epilepsy, the medical history of a patient and seizure symptoms are reviewed. Moreover, 
several tests are done to determine the cause and origin of the seizures, the most imperative one 
being electro-encephalography (EEG) recordings (Smith, 2005). Blood analysis, brain imaging and 
neuropsychological evaluation can then give additional information necessary to subclassify seizures 
and epilepsy syndromes and find appropriate treatment. However, seizure classification is 
challenging, as their presentation not only depends on the seizure origin, but also on the maturity of 
the brain, confounding disease processes, circadian rhythm, medication and triggering factors 
(Panayiotopoulos, 2007). Moreover, the classification is not absolute, and because knowledge and the 
variety of analysis tools is continuously expanding, it has been revised several times since the ILAE 
provided a first recommendation (Engel, 2006, Berg et al., 2010). According to the current ILAE 
classification, seizures fall broadly into two main groups based on their region of onset in the brain, 
i.e. focal and generalized seizures (ILAE, 2015).  
 
Focal seizures originate within one hemisphere and can potentially spread to other ipsilateral and 
contralateral regions. Seizure semiology is highly variable and reflects the ictal onset zone, as well as 
the pattern of propagation. In this regard, seizures can affect sensory, motoric and autonomic 
functions, as well as memory, cognition, emotional state and level of awareness or responsiveness. 
Seizures accompanied by the impairment of awareness or responsiveness are called seizures with a 
‘dyscognitive’ feature, which were earlier termed ‘complex partial seizures’. Generalized seizures 
originate and rapidly propagate within both hemispheres. They can be subdivided based on seizure 
semiology and include absence, tonic, atonic, convulsive and myoclonic seizures. Absence seizures 
are seizures defined by clinical impairment of consciousness and are associated with typical bursts of 
bilateral synchronous spike-wave discharges on the EEG. Tonic and atonic seizures are 
characterized by a sudden increase or loss of muscle tone respectively. Myoclonic seizures are 
associated with brief muscle contractions. Convulsive seizures include clonic and tonic-clonic 
seizures. Clonic seizures are repetitive and prolonged myoclonic seizures and tonic-clonic seizures 
have both a tonic and clonic phase. 
 
The elements that cause epilepsy are multiple and heterogeneous, but can be used to subcategorize it 
into epilepsy syndromes, as this aids in the choice of anti-epileptic treatment (ILAE, 2015). An 
epilepsy syndrome is a unique epilepsy condition defined by a typical age of onset, seizure type and 
EEG features (Engel, 2001). Previously, it was subdivided into ‘symptomatic, idiopathic and 
cryptogenic’ epilepsy syndromes, but these terms were poorly delineated and led to confusion. With 
the current understanding it has been possible to categorize the epilepsy syndromes by their specific 
etiologies, i.e. genetic, structural, metabolic, immune, infectious epilepsy syndromes and epilepsy 
syndromes that have no known cause (Berg et al., 2010, ILAE, 2015). Genetic epilepsy syndromes 
 
13 
 
Invest igat ion  o f  a  ro le  for  ur ic  a c id  in  exper imenta l  se izure  mode ls  
 
 
are a direct result of a known or presumed genetic defect(s) in which seizures are the core symptom 
of the disorder (e.g. Angelman syndrome). Seizures in structural epilepsy syndromes are attributed 
to distinct structural brain abnormalities that can be developmental (e.g. tuberous sclerosis) or 
acquired (e.g. trauma). Metabolic abnormalities are responsible for the increased brain excitability in 
metabolic epilepsy syndromes, such as in mitochondrial disorders. The increased risk of developing 
epilepsy in immune epilepsy syndromes is driven by central nervous system (CNS) inflammation 
(e.g. Rasmussen syndrome). In infectious epilepsy syndromes, infections of the CNS can cause both 
acute symptomatic seizures and epilepsy (e.g. bacterial meningitis). 
Pathophysiology 
Information processing in the CNS occurs through neuronal communication, in which neurons 
encode messages as propagation of action potentials that trigger the release of neurotransmitters at 
synapses to influence firing of connecting neurons (Figure 1). In the normal brain neuronal firing is 
strictly regulated and a constant equilibrium between excitation and inhibition exists (Lowenstein, 
2001). In epilepsy, however, certain areas of the brain are prone to seizures. It is generally believed 
that inhibitory actions in these areas cannot overcome sudden excitatory activity and that a trigger is 
enough to induce uncontrolled hypersynchronous repetitive firing of neurons. The characteristics of 
the seizure are then the result of the abnormal functioning in specific brain regions (see Diagnosis 
and classification). As neurotransmission involves multiple steps and is dependent on multiple 
cellular and molecular players, it is no surprise that the factors that can contribute to 
hyperexcitability are numerous. As such, it can result from changes in the integrity and molecular 
architecture of neuronal cells. Neuronal damage and death evidently results in hampering of normal 
network functioning, but network malfunctions can also be caused by changes in the expression, 
internalization and conductance of ion channels and receptors, alterations in second messenger 
systems or changes in the synthesis, release and clearance of neurotransmitters (Lowenstein, 2001). 
However, as synaptic transmission is also dependent on communication with astrocytes and 
microglia, changes in gliotransmission, due to dysfunctional activation and profileration of glia, can 
also promote an increased excitability (Kettenmann, 2007, Parpura et al., 2012, Devinsky et al., 
2013). Similarly, the blood-brain barrier (BBB) is also pivotal for neuronal functioning by 
maintaining brain homeostasis. In that regard BBB damage and subsequent leakage can enhance 
excitability by stimulating brain inflammation (van Vliet et al., 2015). Moreover, not only 
inflammation but also oxidative stress is also able to increase the excitability of the network (Vezzani 
et al., 2012, Puttachary et al., 2015) (see Chapter 3). On a structural level all these epileptogenic 
changes can result in neurodegeneration, granule cell dispersion, astrogliosis and mossy fiber 
sprouting. Together, these changes then pathologically rewire the network, as is particularly evident 
in hippocampal sclerosis (see Temporal lobe epilepsy) (Pitkanen and Lukasiuk, 2011). 
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Figure 1 │ Basics of neuronal communication. (A) Schematic overview of neurotransmission. An action potential 
generated at the axon hillock progresses through the axon and results in the release of neurotransmitters in the synaptic 
cleft. Binding of these neurotransmitters to receptors in the postsynaptic membrane leads to inhibitory or excitatory 
postsynaptic membrane potentials, which can result in a new action potential at the axon hillock of the subsequent neuron 
and further propagation of the signal, if the combined membrane potential crosses the -55 mV threshold. Adapted from 
That Basic Science. (B) Overview of an action potential showing the various phases as it passes a point on a cell membrane. 
It involves the sequential opening and closing of potassium and sodium channels. Adapted from the Tom Kelley gallery. 
Treatment 
The goal of medical treatment for epilepsy is to render the patient seizure-free without inducing 
intolerable side effects (Glauser et al., 2006). The standard first-line treatment is chronic 
administration of anti-epileptic drugs (AEDs). These drugs mainly target the disturbed 
excitation/inhibition equilibrium by blockage of voltage-gated ion channels, stimulation of the 
inhibitory gamma-aminobutyric acid (GABA)-ergic system or inhibition of the excitatory 
glutamatergic system (Vajda and Eadie, 2014). Depending on seizure type, epilepsy syndrome, 
medical history and age of the patient, monotherapy with a specific AED is started. When no optimal 
response can be achieved, a second monotherapy is commenced. If this too is unsuccessful, a 
combination therapy of AEDs is administered, although the exact way of substitution or combination 
is still controversial (Stephen and Brodie, 2012). Around 60% of the patients respond to 
monotherapy, but only 5% are aided with subsequent regimens if the second AED fails (Brodie and 
Kwan, 2002, Stephen and Brodie, 2012).  
A leading cause for therapy failure are the adverse effects associated with AEDs, which can have a 
considerable negative impact on a patient’s life (Perucca and Gilliam, 2012). They can develop 
acutely or after many years of treatment, and include direct effects on the CNS (fatigue, dizziness, 
double vision, memory problems, irritability, depression), but also cutaneous, haematological, and 
hepatic or pancreatic reactions. Moreover, AED intake has been associated with congenital 
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malformations and with noticeable changes in bodyweight (Perucca and Gilliam, 2012). New AEDs 
are reported to have a more favorable tolerability and toxicity profile compared to the old ones 
(Kanner and Balabanov, 2005). However, today more than 30% of the patients with epilepsy remain 
refractory, even with more than fifteen AEDs available on the market (Arzimanoglou et al., 2010, 
Lee, 2014).  
Refractory epilepsy 
The ILAE defines refractoriness when ‘adequate trials of two tolerated, appropriately chosen and 
used AED schedules, whether as monotherapy or in combination, fail to achieve sustained seizure 
freedom’, which refers to the detrimental drop in probability of seizure freedom in those cases (see 
Treatment) (Kwan et al., 2010). Patients with refractory epilepsy are at high risk of cognitive 
deterioration and psychosocial dysfunctioning (Quintas et al., 2012). Also, they are more prone to 
injuries and mortality compared to the normal population, which can be mainly ascribed to the 
occurrence of sudden unexpected death in epilepsy (SUDEP) (Massey et al., 2014).  
Temporal lobe epilepsy 
An epilepsy syndrome that is particularly difficult to treat is temporal lobe epilepsy (TLE), in which 
seizures originate in the temporal lobe. Given that it is the most common form of focal epilepsy and 
it is resistant in a third of the cases, the share of TLE in refractory epilepsy is considerable (Pascual, 
2007). Depending on the seizure focus, two subtypes can be distinguished: mesial temporal lobe 
epilepsy (MTLE) and neocortical TLE. The seizures in most TLE patients have a mesial origin and 
arise from the first decade of life to early adulthood. They can develop months to years after an 
initial precipitating insult, such as head trauma, febrile seizures, brain tumor, stroke or SE (Berg, 
2008, Tatum, 2012). Moreover, there is a hereditary factor, as MTLE tends to occur more often in 
some families (Wieser, 2004, Maurer-Morelli et al., 2012). Clinical manifestation is variable and can 
be associated with the presence of an aura (depending on the region affected e.g. déjà-vu, epigastric 
rising sensation, panic attack) and/or the loss of consciousness. During the dyscognitive phase of a 
seizure, most patients have a fixed stare and stereotyped involuntary movements such as oral (lip-
smacking) and manual (fumbling of fingers) automatisms (Pascual, 2007).  
The inherent potential of the temporal lobe to be predisposed for seizures is based on the unique 
anatomical-functional organization of the limbic network (Tatum, 2012), a set of interconnected 
nuclei and cortical structures responsible for emotion formation and processing, learning and 
memory (Figure 2). An important structure in this system is the hippocampal formation, which 
consists of three structures each with different histological and functional properties: the dentate 
gyrus, the hippocampus (regions CA1-4) and the subiculum (Figure 2C). A common feature of most 
MTLE patients is the presence of hippocampal sclerosis (HS), a condition in which the 
hippocampal formation shows extensive loss in selective subregions of the hippocampus, but also in 
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its connecting regions (Bonilha et al., 2012, Tatum, 2012). Moreover, HS is associated with extensive 
astrogliosis and synaptic reorganization (known as mossy fiber sprouting), which are both believed 
to contribute to the increased excitability of the limbic circuit (Brandt et al., 2003, Bedner et al., 
2015). It has also been suggested that seizures themselves can aggravate HS, hence forming a self-
reinforcing loop (Sutula and Pitkanen, 2001). As the hippocampus plays a role in higher cognitive 
functions such as memory and learning, MTLE is associated with related cognitive comorbidities 
(Zhao et al., 2014). 
 
Figure 2 │ Schematic overview of the anatomical location of the temporal lobe (A), limbic system (B) and 
hippocampal formation (C) in the human brain. The detailed view of the hippocampus shows the composing sectors: 
dendate gyrus, hippocampus and subiculum. Adapted from Kandel et al. (2000) and Brightfocus Foundation. 
Alternative treatments 
For patients with drug-refractory epilepsy, medicine has taken refuge in alternative treatments, such 
as epilepsy surgery, neurostimulation, dietary treatments and immune-based therapies.  
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Epilepsy surgery involves the removal of the seizure focus (resective surgery) or the interruption of 
the nerve fibers through which seizures spread (disconnective surgery). It is highly curative but only 
advisable if the seizure onset zone can be clearly identified (Wiebe, 2003, de Tisi et al., 2011). 
Surgical removal of the hippocampal formation in MTLE patients leads to seizure freedom in 60-
70% of the cases, although seizures can reappear in the years following the intervention (Giulioni et 
al., 2013). 
Delivering electrical pulses directly or in the vicinity of nerve tissue can also have a therapeutic 
effect. There are different types of neurostimulation that target different parts of the nervous 
system, including stimulation of brain structures and the vagus nerve (Boon et al., 2009). In this 
regard, vagus nerve stimulation, responsive cortical stimulation and stimulation of the anterior 
nucleus of the thalamus are already approved for epilepsy treatment (Nune et al., 2015). However, 
the mechanism of action and optimal stimulation parameters are still to be elucidated (Bergey, 2013, 
DeGiorgio and Krahl, 2013). 
Dietary treatments include the ketogenic diet and the modified Atkins’ diet. They are both high-fat, 
low-carbohydrate diets that increase the production of ketones, which become the main fuel source of 
the body and brain. These diets are associated with a significant seizure reduction in 30-50% of the 
patients and seizure freedom in up to 15% of the patients (Freeman et al., 2006, Kossoff et al., 2006). 
Despite the substantial seizure reduction, these diets are often discontinued due to their restrictive 
nature and high chance of side-effects such as constipation, sluggishness and nausea (Levy et al., 
2012). The mechanism of action is still under debate but presumed to be multifactorial (Huffman and 
Kossoff, 2006).  
Immunological treatments target the immune system, which is increasingly recognized to be 
involved in different epilepsies (Vezzani and Granata, 2005, Vezzani et al., 2012). As such, the use of 
corticosteroids is currently a primary treatment option in infantile spasms. However, it is associated 
with hypertension, weight gain, and more importantly a suppression of the immune system, risking 
overall sepsis (Hancock et al., 2013). However, steroids are also part of the first line treatment of 
autoimmune epileptic encephalitis, a condition resulting from the erroneous production of antibodies 
against endogenous synaptic or cell-surface antigens, such as leucine rich glioma inactivated protein 
1 (LGI1) and the receptors for α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 
gamma-aminobutyric acid (GABA) (Davis and Dalmau, 2013). This treatment is complemented with 
intravenous administration of immunoglobulines and/or plasma exchange, which reduces the effects 
and the number of circulating antibodies respectively. Although this type of epilepsy has an overall 
good response to immunotherapy, the process of recovery is slow and can take up many months 
(Davis and Dalmau, 2013). 
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Aside from the optimization of the therapies stated above, there is a continuous drive to search for 
new AEDs, to decrease the high number of refractory patients, but also to improve the quality of life 
in patients with a suboptimal regimen. It has recently been suggested to focus on other, non-
neuronal mechanisms that aside from anticonvulsive actions also affect the underlying pathology and 
epileptogenesis (Devinsky et al., 2013). This requires extensive preclinical research and hence the 
need for valid animal models (Rogawski, 2006). 
Models of seizures and epilepsy 
Animal models are indispensable in the elucidation of the fundamental mechanisms of epileptic 
seizures and epilepsy. They are essential for devising new diagnostic, therapeutic and preventive 
approaches. As is the case for all disorders, there is no perfect model for epilepsy and different models 
study different aspects of seizure- and epilepsy-related phenomena. They are each associated with 
their own advantages and limitations, which should be carefully evaluated bearing the specific topic 
of research in mind (Engel and Schwartzkroin, 2006). 
In vitro models include whole-brain models and more reduced biological systems, such as brain 
slices and dissociated cell cultures. These simplified, highly controllable models allow a unique 
insight into cellular and molecular mechanisms of seizures. However, simplification is also their 
biggest drawback, as they do not take into account important immunological and metabolic 
contributions to brain function and lack a behavioral component. Moreover, intrinsic and extrinsic 
neuronal connections are severed, which per definition creates an abnormal situation (Pitkanen et al., 
2006).  
These problems are circumvented with in vivo models, where intact animals are used, mostly rats 
and mice. Depending on the research focus, they fall into two categories: acute seizure models and 
chronic epilepsy models. In acute models focal or generalized seizures are evoked by audiogenic, 
chemical or electrical stimuli in an otherwise healthy brain. They are ideal to reliably study the 
development, maintenance and termination of seizures. Together with the fact that the timing of 
seizure onset can be controlled by the researcher, they are considered good models for the initial 
screening of potential AEDs. However, as these models are established by an artificial induction of 
seizures, they do not represent a chronic epileptic condition and hence do not give information on the 
mechanisms underlying spontaneous seizure generation, i.e. ictogenesis (Pitkanen et al., 2006).  
Chronic models are associated with a permanent epileptogenic disturbance, which is present 
whether or not seizures are occurring. As such, they represent more closely the pathophysiology of 
human epilepsy. Moreover, they also offer the opportunity to study epileptogenesis and the 
associated structural and functional changes, which is impossible in acute models. For these reasons, 
chronic epilepsy models are considered the next step in the preclinical evaluation of potential AEDs. 
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Many models exist that reproduce the traits of specific human focal or generalized epilepsies, in 
which two different subtypes can be distinguished: genetic models and acquired models. Genetic 
models include models in which specific genes for ion channels, transporters and neurotransmitters 
pathways are manipulated but also spontaneous models where the underlying gene deficiency has not 
yet been identified (Burgess, 2006, Noebels, 2006). One example of a spontaneous model is the 
Genetic Absence Epilepsy in Rats from Strasbourg (GAERS), that is characterized by episodes of 
behavioral unresponsiveness and symmetrical, generalized electroencephalographic spike and wave 
discharges typical for human absence epilepsy (Marescaux et al., 1992). Acquired models are of 
particular interest to study MTLE. Here limbic seizures develop in previously healthy rodents 
through the process of chemical/electrical kindling or after an initial insult, which can be a brain 
infarction, traumatic brain damage, febrile seizures or SE (Kharlamov et al., 2003, Dube et al., 2007, 
Pitkanen et al., 2009, Gorter et al., 2015). A drawback of chronic epilepsy models is the necessity of 
long monitoring periods, because of the unpredictable onset and timing of seizures, making them 
technically challenging and labor intensive. 
Two acute seizure models were used in this thesis and are highlighted in the sections below. 
The intrahippocampal kainic acid model of limbic status epilepticus 
Kainic acid (KA) (2-carboxy-4-isopropenylpyrrolidin-3-ylacetic acid), is a nondegradable, excitotoxic 
analogue of glutamate isolated from Digenea simplex, a red alga found in tropical and subtropical 
waters. It induces seizures by increasing excitatory neurotransmission through the AMPA- and KA-
subtypes of glutamate receptors, which are most densely located in the limbic system (Bleakman and 
Lodge, 1998). Simultaneously, KA causes neuronal cell damage, mostly in the hippocampal hilus and 
CA1 and CA3 cell layers of the hippocampal formation (Wang et al., 2005). The chronic 
intrahippocampal KA model is a commonly used model for MTLE as it is considered to be highly 
isomorphic with the human disorder, producing unilateral hippocampal sclerosis and recurrent 
spontaneous seizures after KA-induced SE (Bragin et al., 1999, Raedt et al., 2009). Aside from that, 
focal administration of KA is also used widely to study acute focal seizures and SE with secondary 
generalizations (Velisek, 2006). We adapted the intrahippocampal kainic acid mouse model of limbic 
SE (Bouilleret et al., 1999) by infusing kainic acid in the hippocampus using microdialysis (see Box 1) 
instead of injecting a bolus, to allow continuous measurement of the changes in the local 
extracellular environment (Figure 3A). By adding video-EEG monitoring, this set-up has a lot of 
advantages. It allows to quantify electrobehavioral changes, while simultaneously monitoring (and 
manipulating) local biochemical changes. After the experiment, the brain tissue can be processed to 
investigate SE-triggered processes, maximizing the information obtained per animal. Finally, the use 
of mice allows genetic interventions, as these are the main species used for targeted gene 
manipulation. The main limitations are related to the use of microdialysis, specifically the related 
probe recovery and tissue damage (see Box 1). 
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Box 1: Principles of microdialysis 
Microdialysis is a minimally-invasive sampling technique that is used for in 
vivo continuous measurement of free, unbound analyte concentrations 
in blood and living tissue. A microdialysis probe is implanted in the tissue of 
interest which is continuously perfused with an aqueous solution that closely 
resembles the surrounding extracellular fluid (perfusate). It consists of a shaft 
and a semi-permeable membrane at the tip, where dialysis takes place. Dialysis 
is the process of passive diffusion of small molecules (circles in figure) between 
the extracellular tissue fluid and the perfusate over a semipermeable 
membrane. The concentration gradient between the extracellular tissue fluid 
and the perfusate determines the direction of movement of the molecules, 
allowing to use the probe as local delivery (green circles in figure) as well as 
sampling tool (red circles in figure). At predefined intervals the fluid 
(dialysate) is collected for analysis by an adequate technique, such as high-
performance liquid chromatography (HPLC) (Fagugli et al., 2002). 
The composition of the perfusate is highly important in microdialysis. If the 
perfusate has a lower concentration in any of the present permeable molecules 
compared to the extracellular environment this will result in their local 
depletion, thereby disturbing homeostasis. However, it is impossible to have a 
solution that has the exact same concentration for all solutes of the 
surrounding tissue. Therefore, most perfusates are made with the ionic composition and pH of plasma or cerebral spinal 
fluid (CSF) (Chefer et al., 2009). 
Another key element is the relative probe recovery, which defines the proportional difference in concentration between 
the highest concentration of substance and the lowest concentration of substance. The concentration of a collected analyte 
will represent only a fraction of the true concentration in the extracellular fluid and vice versa for infusion of a component, 
as a full equilibrium between both can be never established. Probe recovery is dependent on a number of factors, including 
flow rate of the perfusate, properties of the analyte, properties of the probe membrane, tissue factors and temperature. The 
relative recovery of an analyte is inversely proportional with the perfusion flow rate as this allows more diffusion to take 
place. Although it improves the probe recovery, low flow rates are restricted by the minimal sample volume needed for 
solution analysis. Important probe membrane properties include the membrane material used and the size of the 
membrane surface, of which the latter is directly proportional to the probe recovery. However, the surface area of the probe 
will be often limited by the size of the structure under study. The molecular weight, the hydrophobicity (‘stickyness’) and 
the tertiary structure are the most important analyte characteristics that influence probe recovery. A higher molecular 
weight and greater hydrophobic properties result in lower relative recoveries, because of the resulting decrease in the 
diffusion coefficient and hindrance by the membrane respectively. Due to a lower fluid volume, higher diffusional path and 
potential binding of analyte with cell surface proteins, recovery from tissue is generally lower than in an in vitro set-up. If 
analytes are cleared rapidly from the extracellular space however (as for neurotransmitters), this lowers the resistance to 
diffusion and hence increases the recovery. Finally, a higher temperature increases the diffusion coefficient and accordingly 
increases the probe recovery. (Chefer et al., 2009) 
To determine the absolute concentration of an analyte, it is necessary to have an estimate of the relative probe recovery, 
that approximates the real probe recovery as close as possible. In this regard, both in vitro and in vivo (e.g. the flow rate and 
internal standard) empirical methods exist. Furthermore, implantation of the probe induces a ‘trauma layer’ that can also 
influence analyte concentration. It compromises the BBB, induces gliosis and disturbs the microcirculation (Benveniste, 
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1989, Georgieva et al., 1993, Clapp-Lilly et al., 1999). To ensure that these processes have stabilized and an equilibrium 
between the perfusate and tissue fluid can be achieved, a minimal 12 hour interval between probe implantation/perfusion 
and start of the experiment has to be respected. In that regard, absolute data always has to be interpreted with caution. On 
a last note, the analyte is sampled from a relatively large region, because of the dimensions of the microdialysis probe. The 
original site of release can be far away and it is hence not possible to determine the cellular origin. As such, the detected 
analyte can originate from neuronal, neuron-glia and/or neurovascular communication. (Chefer et al., 2009) 
A detailed description of the methodology and characterization of this model can be found in the 
manuscript included in Chapter 4. 
The timed intravenous infusion seizure model 
The timed intravenous (i.v.) infusion seizure model is an acute seizure model and is considered an 
extremely sensitive screening method to investigate the effects of a compound on seizure 
susceptibility (Loscher, 2009). In this model, the animal is infused i.v. with a chemoconvulsant, 
commonly pentylenetetrazole (PTZ) or pilocarpine, but also KA, at a constant flow rate while it can 
move freely (De Bundel et al., 2011, Loyens et al., 2012, Portelli et al., 2012). PTZ induces seizures 
by acting predominantly on the GABAA receptor, antagonizing GABAergic inhibition, while the 
convulsant effect of pilocarpine is related to its agonistic function on the muscarine cholinergic 
receptor (Oses et al., 2007, Curia et al., 2008, Portelli et al., 2012, Rambo et al., 2013). To prevent 
pilocarpine-induced peripheral effects such as salivation, tremor and diarrhea, a muscarine antagonist 
that is unable to pass the BBB is injected 30 minutes prior to infusion (Curia et al., 2008, Portelli et 
al., 2012). 
The constant flow of these chemoconvulsants elicits an array of rapidly progressing behaviors, which 
depend on the type of chemoconvulsant used. On the one hand, PTZ infusion sequentially induces 
ear twitching, myoclonic twitching, clonus of the forelimbs, clonic convulsion with loss of righting 
reflexes (falling), tonic hindlimb extension and finally death. On the other hand, infusion with 
pilocarpine sequentially elicits shivering, rearing, falling, tonic hindlimb extension and death. For 
each mouse, the dose needed to evoke these behavioral endpoints is calculated taking into account 
the concentration of the solution, the infusion rate, the infusion duration and the weight of the 
animal (Figure 3B) (Vermoesen et al., 2011). Hence, the dose represents the threshold for a specific 
behavioral endpoint for an individual animal. Anticonvulsant agents will delay the appearance of 
seizure behavioral endpoints and accordingly increase the dose needed. Compounds with 
proconvulsant characteristics will do the opposite, resulting in an earlier onset of the endpoints and 
accordingly a lower dose.  
The major advantages of this model are its sensitivity and reproducibility in individual animals, 
vastly limiting the number of animals needed. Moreover, there tends to be a good correspondence 
between the actions in this model and clinical experience for several drugs (Loscher, 2009). Another 
advantage is that this model can also be used to identify genotypic differences in seizure 
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susceptibility of transgenic mice (Loyens et al., 2011, Portelli et al., 2012). However, as for any 
seizure model, this model also has some limitations. Compounds that act on the same receptor as 
PTZ or pilocarpine or have haemodynamic effects will lead to false results and as mentioned 
previously, death is eminent within minutes, excluding the animals from further use (Loscher, 2009).  
 
Figure 3 │ Overview of the two seizure models used in this thesis. (A) The intrahippocampal kainic acid (KA) 
model of limbic status epilepticus. KA is infused intrahippocampally through a microdialysis probe to evoke a limbic 
status epilepticus. Electroclinical changes can be observed using video-EEG, while simultaneously sampling the local 
extracellular analyte concentration in the dialysates. (B) The timed intravenous infusion seizure model. Pilocarpine 
(Pilo) or pentylenetetrazole (PTZ) is continuously infused in the lateral tail vein at a constant rate. During infusion, the 
animal is allowed to move freely and the latencies to different behavioral endpoints are timed. The dose needed to evoke an 
endpoint represents the seizure threshold and is determined according to the formula given in the figure. Proconvulsants 
lower the dose needed to evoke an endpoint, anticonvulsants increase the dose. 
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Chapter 3 
At the interface of oxidative stress and inflammation: 
a potential role for uric acid in epilepsy 
Lisa Thyrion, Robrecht Raedt, Jeanelle Portelli, Kristl Vonck, Paul Boon 
Neuropharmacology, Under review 
 
 
Abstract 
As the available anti-epileptic drugs fail to control seizures in one third of the epilepsy patients, there 
is a need for therapies with a different mechanism of action. Targeting inflammation is considered a 
promising strategy and recently also oxidative stress has become a field of interest. Identifying new 
players in these areas is hence becoming an important line of research. In this context, uric acid, a 
purine breakdown product that is increasingly recognized to act as a pro-oxidans and pro-
inflammatory danger signal in a variety of disorders, may be more than an innocent bystander in 
epilepsy. In light of this, we revise the existing clinical and experimental data on uric acid in epilepsy 
and discuss the potential mechanisms by which it can contribute to excitability. We end by 
suggesting possible directions for future research. 
Key words: uric acid, excitability, allopurinol, danger signal, oxidant, (pre)clinical data 
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Introduction 
Epilepsy 
Epilepsy is a chronic neurological disorder characterized by unprovoked recurrent seizures that 
affects more than 65 million people worldwide (Moshe et al., 2015). The disease process, known as 
epileptogenesis, involves a cascade of specific molecular and cellular changes that convert a healthy 
brain into a hyperexcitable one and is often triggered by a precipitating insult, such as head trauma 
or status epilepticus (Pitkanen and Lukasiuk, 2011). Although the majority of the patients enter 
remission after treatment with the available anti-epileptic drugs (AEDs), 20-30% of the patients fail 
to respond to treatment even after multidrug therapy (Lee, 2014). The patients have refractory 
epilepsy and are at high risk of cognitive deterioration, psychosocial dysfunction and sudden 
unexpected death in epilepsy (SUDEP) (Quintas et al., 2012, Massey et al., 2014). Another issue with 
AEDs on the market is that they only treat seizures, but fail to affect epileptogenesis (Moshe et al., 
2015). Findings drugs with a different mechanism of action is hence of an extremely high priority in 
epilepsy research, not only to find new, improved ways to treat seizures, but also to find disease-
modifying drugs that can affect the underlying process (Perucca et al., 2013).  
In the last decades, numerous studies have revealed that oxidative stress and inflammation 
contribute to epileptogenesis and seizure susceptibility in chronic epilepsy. Therefore, there is 
considerable interest to identify new players in these processes (Vezzani and Viviani, 2014, 
Puttachary et al., 2015). A potential therapeutic target might be uric acid, a molecule at the interface 
of oxidative stress and inflammation (Rock et al., 2010, Kang and Ha, 2014).  
Uric acid in health and disease 
Uric acid is a weak organic acid that is generated from the metabolism of endogenous and dietary 
purines, which can be found in e.g. RNA and DNA. In the majority of mammals, uric acid is further 
converted to the more soluble allantoin by the liver-specific enzyme urate oxidase (Figure 1). In 
humans, however, two independent mutations rendered the urate oxidase gene nonfunctional, which 
resulted in tenfold higher serum uric acid (SUA) levels compared to other mammals (Oda et al., 
2002). High levels are further preserved by the well-described uric acid-specific transport system of 
the human kidney, that allows net reabsorption of ca. 90% of the filtered uric acid (Mandal and 
Mount, 2015). In contrast to the peripheral situation, the regulation of uric acid homeostasis in the 
brain is not fully understood. Uric acid is thought to be actively transported over the BBB since 
several uric acid transporters are present in cerebral tissue and cerebral uric acid levels are 
maintained at 10% of the SUA levels (Tomioka et al., 2013). Most likely, uric acid is also produced 
locally in the brain however, as its synthesizing enzyme, xanthine oxidase, is present in the brain 
(O'Neill and Lowry, 1995).  
 
 
29 
 
Invest igat ion  o f  a  ro le  for  ur ic  a c id  in  exper imenta l  se izure  mode ls  
 
 
Uric acid traditionally was considered an inert waste product, but this has been challenged by 
numerous reports that link hyperuricemia to disease. On the one hand, hyperuricemia has shown to 
be associated with a decreased risk of neurodegenerative diseases, such as multiple sclerosis, 
Parkinson’s disease and Alzheimer’s disease. Higher uric acid levels have shown to impede disease 
progression and improve prognosis in these disorders (Guo et al., 1999, Hooper et al., 2000, Alvarez-
Lario and Macarron-Vicente, 2011, Chen et al., 2013). On the other hand, hyperuricemia has shown 
to be associated with an increased risk of a number of diet-related diseases including gout, 
hypertension, metabolic syndrome and cardiovascular disease (Kutzing and Firestein, 2008, Alvarez-
Lario and Macarron-Vicente, 2011) but also with an increased risk of bipolar disorder (Albert et al., 
2015). The link between uric acid and disease is well-known to be causative in gout (Rock et al., 
2013), but increasing evidence suggests that this is the case for other disorders as well, such as 
cardiovascular disease (Alvarez-Lario and Macarron-Vicente, 2011, Kang and Ha, 2014). 
This review evaluates the preclinical and clinical evidence for a potential causal link between uric 
acid and epilepsy.  
I 
Figure 1 │ A simplified schematic of the purine catabolism leading to the production of uric acid and the potential 
link of uric acid modulated systems to brain excitability. Xanthine oxidase (XO) converts hypoxanthine to xanthine 
and xanthine to uric acid. Guanine deaminase (GD) converts guanine to xanthine. Urate oxidase (UOx) converts uric acid 
into the easily excretable allantoin in non-hominid mammals. IMP: inosine monophosphate, AMP: adenosine 
monophosphate, GMP: guanosine monophosphate, XMP: xanthine monoposphate. 
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Epilepsy-related increases in uric acid levels in patients and seizure 
models 
Patient studies 
Uric acid levels in epilepsy patients have been investigated in a number of studies (Table 1). 
However, in none of these studies uric acid was causally linked to the pathophysiology of epilepsy. 
Uric acid was considered in an acute postictal context as a marker of oxidative stress (Stover et al., 
1997), increased metabolism (Manzke et al., 1981, Aiyathurai et al., 1989, Rodriguez-Nunez et al., 
2000) or because of its role in disorders associated with seizures, such as nephropathy (Warren et al., 
1975, Luhdorf et al., 1978, George et al., 2012, Makki et al., 2013). The results of these studies 
mostly point in the same direction and report an acute increase in uric acid levels after convulsive 
seizures (Table 1). Moreover, they indicate that this increase occurs both peripheral (serum, urine) 
and central (cerebrospinal fluid (CSF)). The study of Aiyathurai (1989) showed that uric acid levels 
decreased again by the third post-seizure day suggesting that seizure-induced increases in uric acid 
are transient. It needs mentioning that some studies excluded patients with gout, hypertension or 
abnormal blood chemistry, thereby favoring epilepsy patients with uric acid levels within the normal 
range (Tan et al., 2009, Menon et al., 2014). 
In the chronic interictal state, uric acid changes were analyzed in context of the chronic effects of 
AEDs on vascular risk factors. Several anti-epileptic treatments have shown to alter SUA levels 
(Krause et al., 1987, Hamed et al., 2004, Pylvanen et al., 2006, Aycicek and Iscan, 2007, Hamed et al., 
2007, Tan et al., 2009, Menon et al., 2014). Carbamazepine and phenytoin, for example, are shown to 
establish a reduction in SUA while valproate and the ketogenic diet result in an increase (Schwartz et 
al., 1989, Katsiki et al., 2014). Although this in itself might seem controversial in light of a potential 
role for uric acid in epilepsy, AED-induced changes in SUA levels are not necessarily related to their 
anticonvulsive actions, but can be merely due to the numerous the side-effects of these AEDs 
(Perucca and Gilliam, 2012). SUA levels depend on the dietary intake of purines, endogenous uric 
acid biosynthesis and the rate of excretion of uric acid through renal and extra-renal pathways 
(Kutzing and Firestein, 2008, Ichida et al., 2012). Any side-effect that relates to changes in food 
intake, metabolism or renal and gastrointestional function will hence influence SUA levels, making 
SUA data in treated patients unreliable to adequately investigate a relationship between uric acid and 
the chronic epileptic state. Some of the side effects of valproate for example include nausea, gastric 
irritation, diarrhea, hepatic and pancreatic dysfunction, weight gain and renal tubular dysfunction 
(Knights and Finlay, 2014). In this regard, four studies determined uric acid levels in an untreated 
epileptic population in addition to healthy controls, allowing to exclude the effects of AEDs on SUA 
levels (Hamed et al., 2004, Aycicek and Iscan, 2007, Hamed et al., 2007, Menon et al., 2014). Two of 
these studies showed an elevation of SUA levels in at least a subset of epileptic patients (Hamed et 
al., 2004, Hamed et al., 2007). Tan et al. (2009) excluded patients with gout, hypertension or 
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abnormal blood chemistry, however, thereby favoring epilepsy patients with uric acid levels within 
the normal range. 
Animal studies 
Despite the high heterogeneity in the regimens for seizure induction, the majority of the preclinical 
studies also show that intracerebral uric acid levels are acutely increased in response to seizures (Beal 
et al., 1991, Layton et al., 1998, Oses et al., 2007, Rambo et al., 2013), although two studies did not 
find any change in uric acid in response to seizures (Mueller and Kunko, 1990, Waterfall et al., 1995) 
(Table 1). Elevated uric acid levels were reported in the CNS as late as 7 and 10 days after the 
chemoconvulsant regimen, suggesting a long-lasting increase (Beal et al., 1991, Oses et al., 2007).  
Causes of epilepsy-related uric acid increases 
Different factors have been suggested to contribute to the increase in uric acid in response to seizure-
activity. While increased muscle breakdown and altered renal secretion (e.g. due to seizure-
associated sweating and hyperthermia) are thought to be responsible for systemic increases in uric 
acid levels after status epilepticus (Warren et al., 1975, Makki et al., 2013), cerebral increases in uric 
acid levels have been linked to seizure activity and seizure-induced neuronal injury, cell death and 
BBB leakage (Beal et al., 1991, Stover et al., 1997, Layton et al., 1998, Rambo et al., 2013).  
Seizures in conditions associated with uric acid imbalances 
Interestingly, the occurrence of epileptic seizures have been described in several disorders that are 
associated with increased uric acid levels. Tumor lysis syndrome (TLS) is the consequence of 
cytotoxic tumor treatment resulting in cell lysis and rapid release of intracellular contents into the 
blood stream. The occurrence of seizures is a diagnosing factor and recently SUA levels have been 
shown to be highly predictive for the development of TLS (Ejaz et al., 2015). Deficiency of 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) is an inborn error of the purine 
metabolism and in its most extreme form the cause of Lesch-Nyhan syndrome. Patients with Lesch-
Nyhan show increased uric acid levels and a wide variety of neurological manifestations, including 
delayed motor development, cognitive and attention deficits, self-injurious behavior but also epileptic 
seizures in 8% of the cases (Jinnah et al., 2006). This is about ten times higher than the prevalence in 
the normal population (Thurman et al., 2011). In addition, hyperuricemia observed in pregnant 
women with preeclampsia has been put forward as an independent predictor for the onset of seizures 
and the development of eclampsia (Livingston et al., 2014, Taweesuk and Tannirandorn, 2014). 
Seizures have also been described in other hyperuricemic conditions, such as kidney failure, 
metabolic syndrome, hypertension and gout although these are less well documented. Conversely, 
seizures are rarely described in disorders associated with hypouricemia, an exception being 
molybdenum cofactor deficiency, which is associated with seizures in neonates (Arnold et al., 1993). 
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The anticonvulsive potential of allopurinol 
A consensus from the studies discussed above is that systemic and intracerebral uric acid levels are 
increased, sometimes persistent, after epileptic episodes. In addition, clinical conditions associated 
with high levels of uric acid are associated with an increased risk for seizures. This section will 
discuss the effects of uric acid lowering drugs on seizure activity, with a main focus on allopurinol, an 
inhibitor of the enzyme xanthine oxidase/dehydrogenase (Figure 1). Several studies have 
investigated allopurinol as an add-on therapy in epilepsy and although informational, their results 
should be interpreted with caution, as it has other effects, besides lowering uric acid, that might 
affect seizures. As such, allopurinol can decrease the levels of the proconvulsant quinolonic acid 
(Coppola and Pascotto, 1996) and increase the levels of the endogenous anticonvulsants adenosine 
and inosine (Togha et al., 2007, Kovacs et al., 2015).  
Patient studies  
A study by Coleman and colleagues was the first to show that hyperuricemic patients suffering from 
refractory epilepsy were seizure-free for at least 8 years, after normalizing uric acid biochemistry 
with allopurinol (Coleman et al., 1986). Since then, numerous studies have shown that allopurinol 
can be beneficial as add-on therapy in patients with epilepsy (Table 2). Both in children and adults 
seizure reduction and even seizure freedom was reported when it was added to the AED regimen (De 
Marco and Zagnoni, 1988, Guzeva et al., 1988, Tada et al., 1991, Zagnoni et al., 1994, Togha et al., 
2007) and several groups have suggested that allopurinol was specifically efficient in reducing 
secondarily generalized tonic-clonic seizures (De Marco and Zagnoni, 1988, Tada et al., 1991, 
Zagnoni et al., 1994, Togha et al., 2007). Overall, allopurinol was generally well-tolerated and was 
only associated with mild side-effects, such as nausea, dizziness or abdominal pain in a minority of 
the patients (Tada et al., 1991, Zagnoni et al., 1994). 
In contrast to the abovementioned studies, some studies failed to demonstrate an additional 
therapeutic benefit of allopurinol add-on treatment (Sussman et al., 1987, Sander and Patsalos, 1988, 
So and Ptacek, 1988, Coppola and Pascotto, 1996). This might be because the actions of allopurinol 
are most pronounced in hyperuricemic conditions, which was not a premise in the add-on trials. 
Arguing against this however is a lack of correlation between uric acid concentration or reduction 
and seizure reduction after allopurinol add-on treatment (Tada et al., 1991, Zagnoni et al., 1994, 
Coppola and Pascotto, 1996). This latter observation could indicate that the therapeutic actions of 
allopurinol is due to other physiological changes than a decrease in uric acid. 
Animal studies 
The few existing animal studies that have tested the anticonvulsant potential of allopurinol are 
extremely heterogeneous in their set up and present contradictory findings. Three studies suggest an 
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anti-epileptic effect of allopurinol (Mikhailov and Gusel, 1983, Wada et al., 1992, Murashima et al., 
1998). Two of these studies indicated that allopurinol preferentially targets secondarily generalized 
seizures, which is in line with clinical findings. In cats, allopurinol reduced the severity of fully 
kindled, generalized seizures (Wada et al., 1992). In addition, it prevented the induction of seizures 
during 24 hours in a genetic mouse model for secondarily generalized seizures (EL mice) 
(Murashima et al., 1998). Two studies, however, could not demonstrate any anti-epileptic effect of 
allopurinol (Hoppe et al., 1984, Parada-Turska et al., 2004) (Table 2). Parada-Turska and colleagues 
reported that, besides a lack of effect of allopurinol alone, add-on therapy with allopurinol did not 
increase the seizure-reducing effects of AEDs in the maximal electroshock seizure (MES) mouse 
model, a model for primary generalized seizures. Taken together, this might suggest that allopurinol 
primarily acts on secondarily, but not primary generalized seizures. Only one of these studies 
determined SUA levels and found that these were slightly, but non-significantly, lower in the 
allopurinol-treated group compared to the control group (Murashima et al., 1996). 
Potential mechanisms of excitability: inflammatory and oxidative actions 
of uric acid 
Epilepsy often develops after an initial precipitating insult, such as head trauma, febrile seizures, 
brain tumor, infection, stroke or status epilepticus. These damaging insults are associated with 
increased oxidative stress and inflammation. Both these processes increase brain excitability and 
contribute to the establishment of chronic epilepsy during epileptogenesis (Vezzani et al., 2012, 
Puttachary et al., 2015). Since uric acid is released upon cell damage (Shi et al., 2003) and plays a role 
in oxidative stress and inflammation (Rock et al., 2013, Kang and Ha, 2014), it is likely to play a role 
in epileptogenesis. This chapter will give a short overview on oxidative stress and inflammation in 
epileptogenesis and discuss a possible role of uric acid herein.  
Oxidative stress 
A brain insult, such as a seizure or a traumatic brain injury, leads to the production of reactive 
oxygen/nitrogen species (ROS/RNS), which causes damage to lipids, proteins and nucleic acids 
(Cardenas-Rodriguez et al., 2013). Cumulatively, this is known as oxidative stress. The subsequent 
arrest in mitochondrial function and energy metabolism compromises cell viability, which in turn 
promotes lipid peroxidation, reactive gliosis and aberrant rearrangements in neural circuitry that 
promote the establishment of hyperexcitable networks (Puttachary et al., 2015). Moreover, oxidative 
stress promotes seizure susceptibility in experimental models and patients with chronic epilepsy. 
This suggests that anti-oxidants could be employed, not only to target epileptogenesis, but also as an 
add-on therapy in chronic epilepsy (Puttachary et al., 2015).  
36 
Invest igat ion  o f  a  ro le  for  ur ic  a c id  in  exper imenta l  se izure  mode ls  
 
 
 
 
.
S
tu
d
y
S
tu
d
y
 d
e
si
g
n
A
ll
o
p
u
ri
n
o
l 
re
g
im
e
n
C
o
le
m
an
 e
t 
al
.,
 1
9
8
6
6
-1
2
 y
ea
r 
fo
ll
o
w
-u
p
 c
as
e 
st
u
d
ie
s 
3
.4
 -
 1
2
 m
g
/
k
g
/
d
ay
af
te
r 
v
s 
b
ef
o
re
 (
u
ri
n
e)

1
0
0
%

h
y
p
er
u
ri
co
su
ri
a 
ch
il
d
re
n
 (
n
 =
 3
)
S
u
ss
m
an
 e
t 
al
.,
 1
9
8
7
*
1
-3
 m
o
n
th
 f
o
ll
o
w
-u
p
3
0
0
 m
g
/
d
ay
af
te
r 
v
s 
b
ef
o
re
 (
6
0
%
)

1
0
0
%
=
ag
e 
o
r 
se
x
e 
n
ot
 s
p
ec
if
ie
d
 (
n
 =
 5
)
S
o
 a
n
d
 P
ta
ce
k
, 
1
9
8
8
*
4
 m
o
n
th
 f
o
ll
o
w
-u
p
>
 3
0
0
 m
g
/
d
ay
n
ot
 s
p
ec
if
ie
d
-
8
%

m
al
e 
+
 f
em
al
e 
ch
il
d
re
n
 a
n
d
 a
d
u
lt
s 
(n
 =
 1
3
)
9
2
%
=
G
u
z
ev
a 
et
 a
l.
, 
1
9
8
8
st
u
d
y
 d
es
ig
n
 n
ot
 s
p
ec
if
ie
d
4
-5
 m
g
/
k
g
/
d
ay
n
ot
 s
p
ec
if
ie
d
-
3
6
%

m
al
e 
+
 f
em
al
e 
ch
il
d
re
n
 (
n
 =
 3
8
)
6
4
%
=
S
an
d
er
 a
n
d
 P
at
sa
lo
s.
, 
1
9
8
8
3
 m
o
n
th
 o
p
en
 u
n
co
n
tr
o
ll
ed
 t
ri
al
3
0
0
 m
g
/
d
ay
af
te
r 
v
s 
b
ef
o
re

1
0
0
%
=
m
al
e 
+
 f
em
al
e 
ad
u
lt
s 
(n
 =
 1
2
)
D
e 
M
ar
co
 a
n
d
 Z
ag
n
on
i, 
1
9
8
8
1
 y
ea
r 
o
p
en
 u
n
co
n
tr
o
ll
ed
 t
ri
al
1
5
0
-3
0
0
 m
g
/
d
ay
n
ot
 s
p
ec
if
ie
d
-
6
7
%

m
al
e 
+
 f
em
al
e 
ch
il
d
re
n
 a
n
d
 a
d
u
lt
s 
(n
 =
 6
4
)
2
5
%
=
8
%

T
ad
a 
et
 a
l.
, 
1
9
9
1
1
 y
ea
r 
o
p
en
 u
n
co
n
tr
o
ll
ed
 t
ri
al
3
-1
5
 m
g
/
k
g
/
d
ay
re
sp
o
n
d
er
s 
=
5
5
%

m
al
e 
+
 f
em
al
e 
ch
il
d
re
n
 a
n
d
 a
d
u
lt
s 
(n
 =
 3
1
)
v
s 
n
on
re
sp
o
n
d
er
s
3
6
%
=
6
%

Z
ag
n
on
i e
t 
al
.,
 1
9
9
4
4
 m
o
n
th
 d
o
u
b
le
-b
li
n
d
, 
p
la
ce
b
o
-c
o
n
tr
o
ll
ed
 r
an
d
o
m
iz
ed
 
1
5
0
 m
g
/
d
ay
 (
<
2
0
 k
g
)
al
lo
p
u
ri
n
ol
 v
s 
p
la
ce
b
o

2
8
%

cr
o
ss
-o
v
er
 t
ri
al
3
0
0
 m
g
/
d
ay
 (
>
 2
0
 k
g
)
6
0
%
=
m
al
e 
+
 f
em
al
e 
ch
il
d
re
n
 a
n
d
 a
d
u
lt
s 
(n
 =
 8
4
)
1
2
%

C
o
p
p
o
la
 a
n
d
 P
as
co
tt
o
, 
1
9
9
6
 3
 m
o
n
th
 d
o
u
b
le
-b
li
n
d
, 
p
la
ce
b
o
-c
o
n
tr
o
ll
ed
, 
cr
o
ss
-o
v
er
 t
ri
al
 
1
0
 m
g
/
k
g
/
d
ay
 -
 w
ee
k
 1
al
lo
p
u
ri
n
ol
 v
s 
p
la
ce
b
o

4
7
%

m
al
e 
+
 f
em
al
e 
ch
il
d
re
n
 (
n
 =
 1
7
)
1
5
 m
g
/
k
g
/
d
ay
 a
ft
er
re
sp
o
n
d
er
s 
=
3
0
%
=
v
s 
n
on
re
sp
o
n
d
er
s
2
3
%

T
o
g
h
a 
et
 a
l.
, 
2
0
0
7
6
 m
o
n
th
 d
o
u
b
le
-b
li
n
d
, 
p
la
ce
b
o
-c
o
n
tr
o
ll
ed
 t
ri
al
 
3
0
0
 m
g
/
d
ay
n
ot
 s
p
ec
if
ie
d
-
6
6
%

m
al
e 
+
 f
em
al
e 
ad
u
lt
s 
(n
 =
 3
8
)
3
4
%
=
S
U
A
 l
e
v
e
ls
H
U
M
A
N
 S
T
U
D
IE
S
S
e
iz
u
re
 f
re
q
u
e
n
c
y
37 
Invest igat ion  o f  a  ro le  for  ur ic  a c id  in  exper imenta l  se izure  mode ls  
 
 
  
T
a
b
le
 
2
 
│
 
C
li
n
ic
a
l 
a
n
d
 e
x
p
e
ri
m
e
n
ta
l 
e
p
il
e
p
sy
 
st
u
d
ie
s 
o
n
 a
ll
o
p
u
ri
n
o
l 
e
ff
ic
a
cy
. 

 i
n
cr
ea
se
d
; 
=
 u
n
ch
an
g
ed
; 

 d
ec
re
as
ed
 (
>
 2
5
%
);
 %
 f
ra
ct
io
n
 o
f 
p
at
ie
n
ts
 a
ff
ec
te
d
. 
*
ab
st
ra
ct
. 
i.
p
. 
in
tr
ap
er
it
o
n
ea
l;
 p
.o
.: 
p
er
 o
ra
l;
 S
U
A
: s
er
u
m
 u
ri
c 
ac
id
 
S
tu
d
y
S
e
iz
u
re
 m
o
d
e
l
A
ll
o
p
u
ri
n
o
l 
re
g
im
e
n
M
ik
h
ai
lo
v
 a
n
d
 G
u
se
l,
 1
9
8
3
p
en
ic
il
li
n
i.
p
.,
 2
5
 o
r 
5
0
 m
g
/
k
g
n
ot
 s
p
ec
if
ie
d
-
ac
ti
v
it
y
 p
en
ic
il
li
n
-i
n
d
u
ce
d
 

ra
ts
ac
u
te
ly
ep
il
ep
to
g
en
ic
 f
o
ci
H
o
p
p
e 
et
 a
l.
, 
1
9
8
4
h
y
p
er
b
ar
ic
 o
x
y
g
en
 m
o
d
el
 f
o
r 
g
ra
n
d
 m
al
 s
ei
z
u
re
s 
n
ot
 s
p
ec
if
ie
d
n
ot
 s
p
ec
if
ie
d
-
la
te
n
cy
 o
x
y
g
en
-
=
n
ot
 s
p
ec
if
ie
d
in
d
u
ce
d
 s
ei
z
u
re
s
W
ad
a 
et
 a
l.
, 
1
9
9
2
el
ec
tr
ic
al
 h
ip
p
o
ca
m
p
al
 k
in
d
li
n
g
i.
p
.,
 5
 o
r 
5
0
 m
g
/
k
g
n
ot
 s
p
ec
if
ie
d
-
se
v
er
it
y
 o
f 
in
d
u
ce
d

m
al
e 
+
 f
em
al
e 
ca
ts
ac
u
te
ly
 s
ei
z
u
re
s 
(5
0
 m
g
/
k
g
 o
n
ly
)
M
u
ra
sh
im
a 
et
 a
l.
, 
1
9
9
6
-8
m
u
ta
n
t 
m
o
d
el
 f
o
r 
se
co
n
d
ar
y
 g
en
er
al
iz
ed
 s
ei
z
u
re
s
p
.o
.,
 7
5
 m
g
/
k
g
al
lo
p
u
ri
n
ol
 (
+
) 
=
se
iz
u
re
s 

m
al
e 
E
L
 m
ic
e
ch
ro
n
ic
 (
ev
er
y
 o
th
er
 d
ay
)
v
s 
al
lo
p
u
ri
n
ol
 (
-)
ev
o
k
ed
 w
it
h
in
 2
4
h
P
ar
ad
a-
T
u
rs
k
a 
et
 a
l.
, 
2
0
0
4
m
ax
im
al
 e
le
ct
ro
sh
o
ck
-i
n
d
u
ce
d
 c
o
n
v
u
ls
io
n
s
i.
p
. 
5
, 
1
5
 o
r 
4
5
 m
g
/
k
g
n
ot
 s
p
ec
if
ie
d
-
el
ec
tr
ic
al
 s
ei
z
u
re
 
=
m
al
e 
S
w
is
s 
m
ic
e
ac
u
te
ly
 o
r 
ch
ro
n
ic
 
th
re
sh
o
ld
(5
 c
o
n
se
cu
ti
v
e 
d
ay
s)
S
U
A
 l
e
v
e
ls
E
ff
e
c
t
A
N
IM
A
L
 S
T
U
D
IE
S
38 
Invest igat ion  o f  a  ro le  for  ur ic  a c id  in  exper imenta l  se izure  mode ls  
 
 
Numerous enzymatic (e.g. superoxide dismutase (SOD)) and non-enzymatic (e.g. ascorbate) anti-
oxidative defense mechanisms exist (Puttachary et al., 2015). Uric acid can act as a non-enzymatic 
anti-oxidant, by blocking the formation and actions of peroxynitrite (ONOO-), a RNS that is formed 
through the reaction of a superoxide radical (O2-) and nitric oxide (NO). Peroxynitrite is a powerful 
oxidant that causes oxidation/nitrosylation of proteins and DNA/RNA, inactivation of enzymes and 
the peroxidation of lipids (Pacher et al., 2007). Uric acid lowers peroxynitrite formation by 
preventing the degradation of SOD, the converting enzyme of O2- (Kutzing and Firestein, 2008). 
Furthermore, uric acid can inhibit the iron-dependent oxidation of ascorbate, preventing further 
increases of free radicals (Sevanian et al., 1991). Aside from these direct scavenging effects, the 
protective actions of uric acid against oxidative stress are suggested to be dependent on an astroglia-
mediated mechanism. (Du et al., 2007). There are several indications that the anti-oxidative actions 
of uric acid are limited to the hydrophilic environment of biological fluids. In this regard, 
intracellular uric acid is believed to be pro-oxidative rather than anti-oxidative, as shown in cultured 
cells and animal models of renal and vascular disease (Sautin and Johnson, 2008, Alvarez-Lario and 
Macarron-Vicente, 2011, Kang and Ha, 2014). As pro-oxidans, the different radicals of uric acid 
increase oxidative damage, mainly to lipids, by reacting with other radicals. In addition, uric acid is 
able to engage an intracellular system that promotes the production of superoxide radicals through 
NADPH oxidase. The intermediate steps leading to NADPH oxidase activation are still 
incompletely understood, although it has been put forward that its pro-inflammatory characteristics 
might be involved (Sautin and Johnson, 2008). 
Inflammation 
Communication between neurons and glia is pivotal to maintain homeostasis in the brain and both 
astrocytes and microglia are essential in monitoring neuronal activity and health (Kettenmann, 2007, 
Parpura et al., 2012). When neurons are endangered or impaired, glia become activated in an attempt 
to limit injury and promote healing. Dysfunctional neuroglial communication can contribute to 
hyperexcitability of neuronal networks (Devinsky et al., 2013). Activated glia release pro-
inflammatory cytokines which upregulate excitatory transmission and downregulate inhibitory 
transmission in various ways (Galic et al., 2012). A central cytokine in this regard is IL-1β. IL-1β not 
only affects neuronal survival, but also influences neurotransmission and neuroglial communication 
through rapid effects on receptor-gated ion channels and long-lasting effects on expression levels of 
transcription molecules, such as NF-kB (Vezzani and Baram, 2007). Similar to anti-oxidant therapies, 
several preclinical studies show that anti-inflammatory therapies might have potential in targeting 
epileptogenesis and reduce spontaneous seizures in chronic epilepsy (Vezzani et al., 2013).  
Danger associated molecular patterns or DAMPs are endogenous danger signals that alert the 
immune system in response to damaged and dying cells. DAMPs were recently found to affect 
excitability as well (Matzinger, 1994, Maroso et al., 2010). Uric acid acts as a pro-inflammatory 
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DAMP in an increasing number of disorders (Kono et al., 2010, Kool et al., 2011, Rock et al., 2013). 
The inflammatory pathway through which it acts, is best described in gout (Rock et al., 2013). Uric 
acid is a weak acid and hence principally exists as sodium salt at physiological pH. It is present at a 
higher concentration inside the cell (4 mg/ml) compared to the interstitial fluid compartment (6 
mg/dl), resulting in a steep increase in the local extracellular concentration after cell damage. When 
the concentration exceeds the crystallization threshold (7 mg/dl), it crystallizes into monosodium 
urate (MSU) crystals, which is its presumed pro-inflammatory active state. When an MSU crystal 
engages the cell membrane and is phagocytosed, the NLRP3 inflammasome is activated through yet 
an incompletely understood process, that involves at least two different mechanisms (Rock et al., 
2013) (Figure 2). Activation of the inflammasome results in the cleavage and activation of caspase-1, 
which in turn converts pro-IL-1β into its biologically active form IL-1β. Apart from the well-
established contribution of IL-1β to excitability, other components of the pathway contribute to 
epilepsy as well, in particular caspase-1 and more recently NLRP3 (Vezzani et al., 2010, Meng et al., 
2014). Importantly, not all inflammatory processes induced by uric acid are NLRP3-dependent, 
indicating that there are other ways through which it may operate. In an experimental model for 
allergic asthma the adjuvant effects of uric acid do not require the inflammasome, but act through 
Syk- and PI3-kinases (Kool et al., 2011). Engagement of MSU crystals to cholesterol in lipid 
membranes activates same pathway in dendritic cells (Ng et al., 2008). 
The two faces of uric acid 
Although oxidative stress and inflammation were discussed as two separate topics in the paragraphs 
above, both processes are highly intertwined. The neurodegeneration induced by increases in 
ROS/RNS promotes the release of gliotransmitters of neighboring glial cells, which in turn can 
further increase oxidative stress and neurodegeneration by overstimulating astroglial glutamate 
release into excitotoxic amounts. It is hence logic to assume that the pathways through which uric 
acid affects excitability are intertwined as well.  
 
In gout uric acid is solely considered a harmful agent (Rock et al., 2013), while in multiple sclerosis it 
is considered a therapeutic agent (Markowitz et al., 2009). This has lead to the belief that a molecular 
switch might exist that changes the molecular feature of uric acid from benefactor to malefactor 
(Kang and Ha, 2014). Although the exact conditions are unknown, this switch likely depends on the 
micro-environment: e.g. the extent of the insult, the duration of oxidative stress, the affected organ 
and tissue location, the timing in the disease process, uric acid concentration and formation of MSU 
crystals (Kang and Ha, 2014). The anticonvulsive potential of allopurinol indicates that the pro-
oxidant/pro-inflammatory actions of uric acid might prevail in epilepsy, suggesting it is a 
therapeutic target.  
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Figure 2 │ Monosodium urate (MSU) crystal induced activation of the NLRP3 inflammasome. MSU-containing 
phagosomes activate the NLRP3-inflammome through at least two different mechanisms.  Production of reactive oxygen 
species (ROS): internalized particles are believed to stimulate phagocytes to produce ROS, possibly through a 
mitochondrial-dependent pathway. However, it is unclear how ROS activate the NLRP3-inflammasome.  The release of 
proteolytic cathepsins: in analogy with other irritant particles, internalization of MSU crystals could result in the rupture 
of phagosomes, resulting in the release of phagocytic proteases (cathepsins). The resulting internal cell damage is believed 
to activate the NLRP3-inflammasome, possibly by cleaving it into its active state or by generating a stimulatory ligand 
(e.g. ROS). Upon activation, the inflammasome oligomerizes into large structures called ‘specks’ and cleaves pro-caspase-1 
into its active form, which cleaves pro-IL-1β into the biologically active form IL-1β. Small panel: The NLRP3 
inflammasome is made up of three components: the NOD-like receptor protein NLRP3, ASC and pro-caspase 1. The NLR 
protein is thought to determine the specificity and control the activity of the complex. The leucine-rich repeats (LRR) are 
thought to be involved in substrate recognition and the pyrin domain (PYD) is responsible for the interaction with the 
scaffolding protein ASC. The CARD domain of ASC allows the association with the third component of the inflammasome, 
the inactive zymogen of the enzyme caspase 1: pro-caspase 1. ASC, apoptosis-associated speck-like protein containing a 
CARD; NLRP3: NACHT, LRR and PYD domains-containing protein. (Rock et al., 2013)  
 
 
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Conclusions and future perspectives 
The classic view of uric acid as an inert waste product is increasingly challenged by the growing 
number of conditions where it is shown to be an active player. Several findings indicate that uric acid 
might contribute to seizure susceptibility as well. Firstly, uric acid levels increase after seizures, and 
may remain elevated in chronic epilepsy. Secondly, the uric acid lowering agent allopurinol has anti-
seizure potential. Lastly, uric acid is involved in inflammatory and oxidative molecular pathways that 
are thought to contribute to the pathophysiology of epilepsy. To corroborate the contribution of uric 
acid to epileptogenesis and the development of seizures however, more in-depth evidence is needed 
on several levels.. 
First, a more extensive analysis of the intracerebral uric acid concentration in seizure models and 
epilepsy patients is needed. Measuring uric acid levels in surgery-obtained brain specimens of drug-
resistant epilepsy patients would be of particular interest, as this has strengthened the involvement 
for other danger signals in the past (Maroso et al., 2010). The presence of MSU crystals could then 
be considered indicative for the involvement of a uric acid-dependent inflammatory pathway. 
Secondly, the effect of more selective uric acid manipulations on seizure characteristics should be 
investigated to confirm the results found with allopurinol. In this regard, urate oxidase is a 
promising target. Preclinical studies in asthma and liver injury, for example, tested urate oxidase and 
allopurinol alongside each other and showed they had similar effects (Kool et al., 2011, Kono et al., 
2014). Moreover, genetic overexpression and disruption of urate oxidase has shown that uric acid is 
more than a marker in Parkinson’s disease, and that it actively protects against several features of a 
mouse model for hemiparkinsonism (Chen et al., 2013). In a similar way, uric acid could be targeted 
in acute seizure models and chronic models for (drug resistant) epilepsies to investigate the effects on 
seizure characteristics and the development of spontaneous recurrent seizures. 
Once the contribution and nature of a uric acid-mediated effect in epilepsy has been established, one 
could then revisit its potential as therapeutic and disease-modifying target and look into its 
mechanism of action. 
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Research Aims 
(1) develop and characterize a seizure model that allows to monitor the changes in local uric acid 
levels 
(2)  investigate the effects of pharmacological and genetic uric acid modulations on the seizure 
characteristics of this model 
(3)  investigate the effects of these manipulations on the seizure-associated inflammatory response 
(4)  examine if altering uric acid levels changes seizure characteristics in a different seizure model 
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Chapter 4 
Induction of the NLRP3 inflammasome after 
intrahippocampal kainic acid induced status epilepticus 
in freely moving mice: a link with uric acid 
Lisa Thyrion, Robrecht Raedt, Griet Glorieux, Wytse Wadman, Sophie Janssens, Bart N. 
Lambrecht, Lars E. Larsen, Mathieu Sprengers, Wouter Van Lysebettens, Jean Delbeke, Evelien 
Carrette, Kristl Vonck, Paul Boon 
Neuroscience letters, Under review 
 
Abstract 
Inflammation is increasingly recognized to contribute to the epileptogenic process that occurs after a 
precipitating insult, such as status epilepticus. Uric acid has long been considered a waste product, 
but is increasingly shown to act as a pro-inflammatory danger signal. The objective of our study was 
to analyze if uric acid is released in a mouse model for limbic status epilepticus and if markers of the 
NLRP3 inflammasome pathway, the best described inflammatory pathway triggered by uric acid, 
were induced. Limbic status epilepticus was induced by infusion of kainic acid in the hippocampus of 
freely moving mice. Microdialysis was used to monitor changes in extracellular levels of uric acid 
during status epilepticus. One day after kainic acid infusion, expression of inflammatory markers was 
analyzed using RT-qPCR. Status epilepticus was associated with uric acid release and the induction 
of the expression of NLRP3 and ASC, two components of the inflammasome, and several 
downstream inflammatory cytokines. Interestingly, the extent of uric acid release correlated with the 
amount of epileptic discharges on the EEG and NLRP3 induction. This demonstrates that the 
release of uric acid depends on the severity of limbic status epilepticus and correlates with the 
induction of the NLRP3-dependent inflammatory pathway. Our data shed new light on uric acid as a 
potential player in the epileptogenic process, which may have therapeutic implications.  
Key words: uric acid, seizures, inflammation, hippocampus, microdialysis, video-EEG 
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Introduction 
Epilepsy is the second most common neurological disorder after stroke and affects 1% of the world 
population (Hauser et al., 1993). Temporal lobe epilepsy (TLE) is the most common form of epilepsy 
and highly pharmacoresistant to the currently available anti-epileptic drugs. TLE often develops 
after a precipitating brain insult, such as trauma, encephalitis and status epilepticus (SE) (Berg, 2008, 
Tatum, 2012). These brain insults initiate a cascade of molecular and cellular changes that increase 
the excitability of the neuronal network, with a growing number of molecular players and pathways 
being identified (Pitkanen and Lukasiuk, 2011). A large knowledge gap still exists however, and a 
better understanding of the insult-triggered processes leading to epilepsy is necessary to find 
improved and possible disease-modifying therapies (Loscher and Brandt, 2010). 
Danger signals are endogenous molecules that are released upon a brain insult by stressed or 
damaged cells (Matzinger, 1994). Upon release in the extracellular environment they induce a pro-
inflammatory response that can increase brain excitability and contribute to the development of 
epilepsy (i.e. epileptogenesis) (Maroso et al., 2010, Vezzani et al., 2013). Although uric acid has long 
been considered a mere waste product, it is increasingly shown to act as a pro-inflammatory danger 
signal in multiple disorders (Kono et al., 2010, Kool et al., 2011, Rock et al., 2013). The best 
described inflammatory pathway triggered by uric acid involves signaling through the NLRP3 
inflammasome, a universal detector of danger (Di Virgilio, 2013, Rock et al., 2013). At high 
concentrations uric acid crystallizes into monosodium urate (MSU) crystals, that triggers the 
assembly of NLRP3 with the scaffolding protein ASC. This results in the recruitment and activation 
of caspase-1 and the subsequent cleavage of pro-IL-1β into its biologically active form (Rock et al., 
2013). IL-1β plays a major role in the pro-inflammatory response to tissue injury and its 
involvement in epileptogenesis and the pathogenesis of seizures is well established. It can increase 
brain excitability by both non-conventional intracellular pathways and the induction of NF-kB-
mediated expression of downstream players (Vezzani et al., 2012). 
This study investigated whether experimental SE is associated with the release of uric acid and the 
subsequent induction of the NLRP3 inflammasome. For this purpose, we adapted the 
intrahippocampal kainic acid mouse model (Bouilleret et al., 1999) to infuse kainic acid in the 
hippocampus using microdialysis instead of injecting a bolus. This adaptation allowed to 
continuously measure changes in extracellular uric acid levels during SE. One day after SE 
induction, expression of the NLRP3 inflammasome and downstream inflammatory markers involved 
in excitability was evaluated.  
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Material and methods 
Animals 
Male C57BL/6 JolaHsd mice (n = 36) (Harlan, Horst, The Netherlands) were housed at controlled 
temperature (21°-22°C) and relative humidity (40-60%) conditions with a fixed 12-hour light/dark 
cycle (lights-on period from 7 AM to 7 PM) and food and water available ad libitum. Treatment and 
care were in compliance with the guidelines of the European Ethical Committee (decree 
86/609/EEC). The study protocol was approved by the Animal Experimental Ethical Committee of 
Ghent University (ECD 09/61). The weight of the animals was 20-30 g at the start of the 
experiment. 
Chemicals and solutions 
Modified Ringer’s solution, the perfusion solution used for microdialysis, consisted of 147 mM NaCl, 
2.3 mM CaCl2 and 4 mM KCl (all Sigma Aldrich, Schnelldorf, Germany) in ultrapure water. The 
solution was filtered through a 0.2 μm membrane and stored at 4°C (one week shelf life). Kainic acid 
(KA; R&D systems, Abingdon, United Kingdom) was dissolved in modified Ringer’s solution at a 
concentration of 4 mg/ml, filtered through a 0.2 µm membrane filter and kept in aliquots at -20°C. 
On the day of use it was diluted further with modified Ringer’s solution to a concentration of 500 
µg/ml. 
Induction of limbic status epilepticus 
Anesthetized mice (isoflurane: 5% induction, 1.5% maintenance) were implanted with a custom-made 
polyimide-coated bipolar electrode (wire Ø 70 µm) with 0.5 mm tip separation, in which the deepest 
electrode contact was placed in the upper blade of the left dentate gyrus in the septal hippocampus 
(coordinates relative to bregma: anterioposterior: -1.8 mm; mediolateral: -1.0 mm, dorsoventral: -2.0 
mm). Screw electrodes were placed epidurally over the right frontal and the right parietal cortex, the 
latter functioning as ground. An anchor screw was placed epidurally over the left frontal cortex and 
another one over the left parietal cortex. An obturator-enclosed guide cannula was placed in the 
septotemporal transition zone of the hippocampus (coordinates relative to bregma: anterioposterior: -
3.3 mm ; mediolateral: -2.8 mm ; dorsoventral: -2.3 mm). After a recovery period of one week mice 
were connected to the EEG set-up and the guide cannula obturator was replaced with a microdialysis 
probe (CMA/7; 2 mm membrane length; theoretical cut-off 6 kDa; CMA, Kista, Sweden). The probe 
was continuously perfused with modified Ringer’s solution at a flow rate of 1.25 µl/min. A minimal 
12 hour interval between probe implantation and the start of the experiment was respected to ensure 
integrity of the blood brain barrier (Benveniste, 1989), absence of excessive reactive gliosis in the 
tissue surrounding the microdialysis probe (Georgieva et al., 1993) and stable exchange of molecules 
between the dialysate and the brain parenchyma (Clapp-Lilly et al., 1999). At the inlet (internal 
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volume: 3.6 µl) and outlet (internal volume: 3.9 µl), the probe was connected to 35 cm of FEP-tubing 
(internal volume 4.2 µl) (CMA). The next day, at 11 AM, a 500 µg/ml KA solution was infused for 
3.2 minutes, after which the solution was switched back to modified Ringer’s solution (n = 18). In the 
non-KA control group, infusion with modified Ringer’s solution was not interrupted (n = 15). 
Taking into consideration an estimated microdialysis probe recovery of 10%, we aimed to deliver 200 
ng of KA, which corresponds to the dose that Bouilleret and colleagues administered by bolus 
injection for the induction of SE in anesthetized mice (Bouilleret et al., 1999). Taking into account 
the internal volume of pre-inlet FEP tubing and inlet, KA entered the brain 6.3 minutes after the 
start of its infusion.  
Video-EEG monitoring 
After probe placement, mice were connected to the video-EEG monitoring set-up. Their head cap 
was connected to a headstage carrying a unity gain preamplifier. A flexible cable (Product# 363-363 
6T (CS), Plastics one, Düsseldorf, Germany) and a 6-channel commutator (Product# SL6C, Plastics 
one) connected the headstage with a custom-built amplifier. The amplified (500x) analog EEG 
signals (referenced to ground) were digitized at a sampling rate of 2 kHz using a data acquisition 
card (NI-USB-6259, National Instruments, Zaventem, Belgium) and data were stored onto a hard-
drive for later offline analysis. Video images were captured with an infrared-sensitive camera 
(CAMCOLBUL5, Velleman, Gavere, Belgium) coupled to a video card (USB Live 2.0, Hauppage, 
Dartford, United Kingdom) using a freeware program (VirtualDub). Both video and EEG were 
recorded on the same computer and were time-stamped for later off-line synchronization. Video-
EEG was continuously monitored during 400 minutes, from 100 minutes prior to KA infusion until 
300 minutes after infusion. EEG was analyzed using a Matlab-based routine. 
EEG-analysis 
An automated detection algorithm was used to detect epileptic spikes in the hippocampal EEG. 
According to this algorithm, raw hippocampal EEG-data was digitally filtered with a band pass filter 
between 1-50 Hz. The threshold for spike detection was set as 3 times the standard deviation of the 
EEG amplitude during the first 50 minutes of baseline recording, with every upward crossing 
considered to be a spike. Latency to start of seizure activity was defined as time between entry of KA 
in the brain and the appearance of the first epileptic spike in the hippocampal EEG. SE duration was 
defined electrographically as time between the first epileptic spike and the moment spike frequency 
dropped below 1 Hz for more than one hour (Grimonprez et al., 2015). To assess the progression of 
electrographic epileptic activity, mean spike frequency was analyzed in 10-minute epochs using 
automated spike detection.  
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Video-analysis 
Clinical seizures were counted and scored based on a modified scale of Racine (Racine, 1972): (2) head 
nodding (3) unilateral forelimb clonus (4) bilateral forelimb clonus with rearing (5) rearing and 
falling, loss of postural control (6) running and bouncing. Clinical seizures with score 1 (immobility, 
eye closure, staring) were not included because they could not be discriminated from continuous 
abnormal background behavior. 
Measurement of uric acid 
Dialysate sampling started simultaneous with video-EEG monitoring at 8.30 AM. The microdialysis 
probe was continuously perfused with modified Ringer’s solution, except during infusion with KA 
(see higher). Hippocampal dialysates were collected in 50 minute epochs. Two baseline samples were 
collected before and six samples after KA infusion. Uric acid was quantified in the dialysates by 
HPLC using a Waters Alliance 2695 HPLC device (Waters, Zellik, Belgium) connected to a Waters 
996 photodiode array detector according to an adapted protocol described by Fagugli and colleagues 
(Fagugli et al., 2002). Data acquisition and processing were performed using Empower software 
(Waters). Analyses were performed on a reverse-phase XBridge C8 column (3.5 µm, 150 mm x 4.6 
mm, Waters) with an Ultrasphere ODS guard column (5 µm, 5 mm x 4.6 mm, Beckman Instruments, 
Fullerton, CA). The chromatographic separation consisted of a linear gradient of methanol and 
ammonium formate buffer (50 mM, pH 3.0) from 0 to 100% methanol in 15 min at a flow rate of 1 
mL/min. Forty-five microliter of dialysate was automatically injected. Uric acid was analyzed by UV 
detection at 300 nm. Standard solutions were used to perform calibration curves for uric acid 
quantification. For concentrations below the limit of detection (LOD; 0.119 µM) the LOD itself was 
used. 
RNA-isolation and RT-qPCR 
Twenty-six hours after KA infusion, mice were deeply anesthetized with 5% isoflurane and 
decapitated. The brains were quickly removed and placed in ice-cold phosphate buffered saline (PBS; 
100 mM, pH 7.4). Using cooled microdissection material the left (infused) hippocampus was isolated 
and immediately frozen in liquid nitrogen. Frozen hippocampal tissue was homogenized in QIAzol 
(Qiagen) with a homogenizer (IKA) and total RNA was extracted using the RNeasy Lipid Tissue kit 
(Qiagen). An additional ethanol-precipitation step was performed to increase purity of the samples. 
RNA concentration and purity was verified using Nanodrop. Genomic DNA was removed using a 
TURBO DNAse kit (Ambion) and first strand cDNA synthesis was performed using the Superscript 
III first strand synthesis system for RT-qPCR (Invitrogen), both according to manufacturer’s 
instructions. Real-time quantitative polymerase chain reactions (RT-qPCR) were done using the 
Fast SYBR master mix kit (Applied Biosystems) or SensiFastTM SYBR No-Rox kit (Bioline). 
Primers were designed making use of Primerbank (www.pga.mgh.harvard.edu/primerbank) (Table 
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1). All reactions were performed in triplicate and plates were run on an ABI Prism 7900 HT 
Sequence Detection System (Applied Biosystems) or on a Lightcycler 480 (Roche). Relative 
expression was calculated using an improved version of the ΔΔ-Ct-method (Livak and Schmittgen, 
2001). Data were normalized to the geometric average of multiple internal standard genes 
(Vandesompele et al., 2002). Values represent the average normalized relative expression values, 
with the expression level of animals infused with modified Ringer’s solution set to 1. Two samples 
were left out because of instability of the internal standard genes.  
Histology 
Mice (n = 3) were given an overdose of pentobarbital (Nembutal, 180 mg/kg) and were 
transcardially perfused with cold PBS (100 mM) and a cold 4% paraformaldehyde/0.2% 
glutaraldehyde solution in PBS next (both pH 7.4). Brains were post-fixed overnight, cryoprotected 
in an increasingly higher sucrose solution (10 – 20 – 30%), snap-frozen in -30°C isopentane and 
stored in liquid nitrogen. Coronal frozen sections of 40 µm were made and the location of the depth 
electrode and cannula were verified on the brain slices (Figure S1). 
Statistical analysis 
Values are expressed as (geometric) mean and the corresponding 95% confidence interval (CI). 
Statistical analyses were performed in SPSS Statistics version 22. Uric acid changes were compared 
using a two-way ANOVA with dialysate collection period as within group factor and treatment as 
between group factor, with post-hoc Bonferroni-Holm correction. Expression levels were compared 
using independent t-tests. Correlation analyses were done using Spearman’s Rho, excluding one 
significant outlier as determined by the Grub’s test. Differences were considered significant at the 5% 
level.  
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Table 1│ Primersequences used for qPCR-amplification. 
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Results 
Intrahippocampal kainic acid infusion induces status epilepticus 
Intrahippocampal infusion with modified Ringer’s solution did not induce any epileptic activity. 
Intrahippocampal infusion with kainic acid resulted in a status epilepticus in all animals without 
mortality. Mean latency to SE was 2.9 (2.3-3.5) minutes. The number of epileptic spikes increased 
steeply initially and reached a maximum between 40 and 50 minutes after kainic acid infusion. 
Thereafter epileptic spiking decreased slowly until a steep decrease marked the end of the SE. 
Epileptic spikes kept occurring afterwards, albeit at low frequency (< 1 Hz) (Figure 1). The average 
SE duration was 166 (143-190) minutes. Qualitative analysis of the EEG revealed that the initial 
phase of the SE was characterized by the occurrence of discrete electrographic seizures (Figure 1b), 
after which the frequency and complexity of epileptic spikes increased to become continuous (Figure 
1c). Over time, spiking became interspersed with increasingly longer low-voltage periods (Figure 
1d).  
After the occurrence of the first epileptic spike, all kainic acid infused mice showed increased 
explorative behavior, extensive scratching and grooming and periods of staring. Against this 
background of continuous mild behavioral changes more severe clinical seizures occurred, with a 
variable recurrence between animals. On average, the SE was associated with 11 (8-14) clinical 
seizures (≥ Racine stage 2), and all animals displayed two or more convulsive (Racine stage 3-6) 
seizures. The first and last clinical seizure appeared 28 (17-39) and 147 (109-184) minutes after 
kainic acid infusion respectively.  
Hippocampal levels of extracellular uric acid increase during status epilepticus 
Mean uric acid concentration in baseline dialysate samples was comparable in control (0.23 µM (0.14 
µM – 0.40 µM)) and kainic acid infused animals (0.37 µM (0.25 µM – 0.54 µM)). In contrast to 
continuous infusion with modified Ringer’s solution, kainic acid infusion resulted in an increase in 
extracellular uric acid levels that largely paralleled seizure activity, with a maximum of 1.38 µM 
(0.96 µM – 2.00 µM) between 50 and 100 minutes after infusion (p < 0.001, F = 11.548, two way 
ANOVA) (Figure 2). This fourfold increase was followed by a steady decline in uric acid 
concentration over the subsequent collections. The overall change in uric acid levels (area under 
curve) correlated with the total amount of spikes (p < 0.05, ρ = 0.510). 
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Figure 1 │ Progression of KA-induced electrographic status epilepticus. Mean spike frequency per epoch was 
calculated as the spike count per epoch divided by its time (i.e. 600 seconds). Plot represents the geometric mean spike 
frequency (black) and 95% CI (grey) (n = 18). Red dotted line represents cut-off of 1 Hz that marks the end of the status 
epilepticus. (a-d) Electroencephalography (EEG) traces of 10 minute epochs illustrating typical EEG-recordings during 
KA-induced status epilepticus. (a) baseline, normal EEG (b) discrete seizures (c) continuous spiking (d) low-complexity, 
low-frequency spiking. Hc: hippocampus, Cx: cortex.  
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Figure 2│ Progression of extracellular uric acid levels in the hippocampal region per 50-minute collection. Plot 
represents the geometric mean (dark color) and 95% CI (light color) **p < 0.01, two-way ANOVA, post-hoc Bonferroni-
Holm. KA: kainic acid. UA: uric acid. RIN: modified Ringer’s solution (nKA = 18, nRIN = 15). 
Status epilepticus induces expression of the NLRP3 inflammasome and downstream 
cytokines 
In animals infused with kainic acid, expression levels of both NLRP3 and ASC were more than twice 
as high compared to control animals (p < 0.05 and p < 0.001 respectively) (Figure 3). The relative 
expression of NLRP3 correlated with the overall change in uric acid levels (area under curve) (p = 
0.045, ρ = 0.543) and with the number of spikes during the first collection period (p < 0.05, ρ = 
0.582). Levels of CASP1 were increased by a third, although this was only a non-significant trend (p 
= 0.073). Several downstream target genes involved in excitability were also upregulated. mRNA 
levels of IL-6 and TNF were upregulated fivefold (p < 0.001) and sixfold (p < 0.001) respectively, 
while expression of IL-1β, IL-1α and COX2 was induced almost three times (p < 0.01, p < 0.001 and 
p < 0.001 respectively). Expression of IL-1 receptor antagonist (IL-1Ra) was eightfold increased (p < 
0.001). 
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Figure 3 │ Changes in expression levels of NLRP3 inflammasome components (left) and downstream inflammatory 
markers (right) in the ipsilateral hippocampus 26h after KA infusion as determined with RT-qPCR. Analysis was 
performed on total RNA-extracts of mice infused unilaterally with kainic acid (KA) (n = 15) or infused continuously with 
modified Ringer’s solution (n = 10-12). mRNA expression levels are normalized relative to the geometric mean of the 
internal standard genes HMBS, RPL13a and TBP. For each cytokine, fold differences were calculated relative to the 
average cytokine levels in modified Ringer’s infused control animals, which were set at 1. One significant outlier was 
excluded from the IL-1β (RIN) group (Grubb’s test, p < 0.05). Bars represent geometric mean. Error bars represent 95% 
CI. * p < 0.05, ** p < 0.01, independent t-tests. 
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Discussion 
In animal studies, SE is frequently induced as experimental trauma to model the underlying 
mechanisms leading to acquired epilepsy (Dudek et al., 2006). Intrahippocampal bolus injection of 
kainic acid is widely appreciated for induction of limbic SE in mice, because the subsequent 
epileptogenic process, seizure characteristics and histopathology resemble those of human TLE 
(Bouilleret et al., 1999, Riban et al., 2002, Meier et al., 2007, Pernot et al., 2011). Using a 
microdialysis probe placed in the hippocampus of freely moving mice, we aimed to deliver a similar 
amount of kainic acid as previously described for a single bolus injection (Bouilleret et al., 1999, 
Riban et al., 2002, Pernot et al., 2011). Analogous to our results, they reported the recurrence of 
isolated spikes and epileptic discharges (Riban et al., 2002, Pernot et al., 2011) and described a 
similar progression of the SE (Bouilleret et al., 1999). The duration of SE after intrahippocampal 
bolus injection was longer compared to our study, with the duration ranging from five (Bouilleret et 
al., 1999) to over ten hours (Riban et al., 2002, Pernot et al., 2011). This is likely due to the different 
genetic background of the mice and/or the properties of the microdialysis procedure. The 
pharmacokinetics and dynamics of microdialysis-based kainic acid infusion are highly different 
compared to bolus injection. In case of microdialysis a smaller volume is administered over a longer 
time period and a larger surface, which could result in a lower local concentration of kainic acid.  
Using this intrahippocampal KA model, we demonstrated that limbic SE is associated with increased 
extracellular levels of uric acid and increased expression of NLRP3 inflammasome components and 
inflammatory markers. The overall change in uric acid levels positively correlated with the total 
amount of epileptic spikes and the relative expression of NLRP3. 
Limbic SE is associated with the release of uric acid in the hippocampus 
During SE local extracellular uric acid levels transiently increased up to four times the initial 
concentration. The amount of uric acid release was strongly associated with the amount of spiking 
and largely paralleled spiking activity. This is similar to a previous study where the extracellular 
uric acid levels doubled in the piriform cortex after intraperitoneal KA injection in rats (Layton et al., 
1998). Analogous to our study, the steady increase aligned with seizure activity in their study. 
Moreover, when they injected midazolam to block the seizures, uric acid increases were abolished, 
indicating that it was a seizure related feature and not associated with other excitotoxic effects of 
kainic acid (Layton et al., 1998). Likely, SE-induced cellular damage and the associated increased 
turnover of purine-containing molecules, such as DNA and RNA, are responsible for the release of 
uric acid (Layton et al., 1998). SE-associated opening of the blood brain barrier could also account for 
this increase, as the concentration in plasma is ten times greater compared to that in the central 
nervous system (Tomioka et al., 2013). Similarly, the intracellular uric acid concentration is higher 
than the extracellular concentration, so active release from the intracellular uric acid pool might also 
contribute (Rock et al., 2013). 
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NLRP3 inflammasome components are induced after limbic SE and correlate with 
uric acid release 
One day after kainic acid infusion, the hippocampal expression of inflammasome components NLRP3 
and ASC was induced. In line with our findings, Meng and colleagues reported increased protein 
levels of NLRP3 in the hippocampus 24 hours after SE induced by amygdala stimulation. Using a 
knock-down technique they showed that chronic suppression of the NLRP3-inflammasome results in 
neuroprotection, decreased inflammation and suppression of the development and severity of 
spontaneous recurrent seizures (Meng et al., 2014). Our study showed that the induction of 
inflammasome expression positively correlated with the amount of released uric acid during SE. This 
suggests that lowering uric acid levels might also affect epileptogenesis in rodent models for post-
traumatic epilepsy. Aside from the inflammasome components, expression of downstream 
inflammatory markers IL-1β, IL-1α, IL-1Ra, IL-6, TNF and COX2 was also increased one day after 
kainic acid infusion. This is in accordance with previous reports that showed increased levels of these 
markers after administration of different chemoconvulsants, including kainic acid, both on mRNA 
and protein level (Pernot et al., 2011; Vezzani et al., 2012; Zhang and Zhu, 2011), which reinforces 
the reliability of this model.  
Conclusions 
Taken together, the intrahippocampal KA model can be considered a valuable model for limbic SE 
which not only avoids anesthesia and restraint, but also permits simultaneous manipulation and 
sampling of the local environment. In this study we employed this model to show that uric acid is 
released during SE and that the markers of its inflammatory pathway are induced the day after kainic 
acid infusion. Together with the fact that the release of uric acid correlates with SE severity and the 
relative expression of NLRP3, these results hint on a role for uric acid in epileptogenesis. 
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Supporting information 
 
Figure S1 │ Histological verification of bipolar depth-electrode (A) and microdialysis probe (B) placement in the left dorsal 
and septotemporal hippocampus respectively. Bar 500 µm. Blue arrow indicates the lower tip of the electrode/probe. DG: 
dentate gyrus, CA: cornu Ammonis.   
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Research Aims 
(1)  develop and characterize a seizure model that allows to monitor the changes in local uric 
acid levels:  
(2)  investigate the effects of pharmacological and genetic uric acid modulations on the seizure 
characteristics of this model 
(3)  investigate the effects of these manipulations on the seizure-associated inflammatory 
response 
(4)  examine if altering uric acid levels changes seizure characteristics in a different seizure 
model 
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Chapter 5 
Uric acid is released in the brain during seizure 
activity and increases severity of seizures in a mouse 
model for acute limbic seizures  
Lisa Thyrion, Robrecht Raedt, Jeanelle Portelli, Pieter Van Loo, Wytse J. Wadman, Griet Glorieux, 
Bart Lambrecht, Sophie Janssens, Kristl Vonck, Paul Boon 
Experimental Neurology, 2016; 277:244-51 
 
Abstract 
Recent evidence points at an important role of endogenous cell-damage induced pro-inflammatory 
molecules in the generation of epileptic seizures. Uric acid, under the form of monosodium urate 
crystals, has shown to have pro-inflammatory properties in the body, but less is known about its role 
in seizure generation. This study aimed to unravel the contribution of uric acid to seizure generation 
in a mouse model for acute limbic seizures. We measured extracellular levels of uric acid in the brain 
and modulated them using complementary pharmacological and genetic tools. Local extracellular 
uric acid levels increased three to four times during acute limbic seizures and peaked between 50 and 
100 minutes after kainic acid infusion. Manipulating uric acid levels through administration of 
allopurinol or knock-out of urate oxidase significantly altered the number of generalized seizures, 
decreasing and increasing them by a twofold respectively. Taken together, our results consistently 
show that uric acid is released during limbic seizures and suggest that uric acid facilitates seizure 
generalization. 
Key words: acute limbic seizures; kainic acid; video-EEG; uric acid; allopurinol; urate oxidase 
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Introduction 
Epilepsy is a disabling neurological disorder that affects up to 65 million people worldwide and is 
characterized by spontaneous and recurrent occurrence of seizures (Thurman et al., 2011). Although 
epileptic seizures are generally thought to be caused by an increased state of brain excitability, it is 
much less clear what is causing this hyperexcitability (Devinsky et al., 2013). Danger associated 
molecular patterns (DAMPs) are normal cell constituents that are released into the extracellular 
milieu during cellular stress or damage which subsequently activate the immune system (Matzinger, 
1994). Recently, DAMPs have been shown to be able to increase excitability in the brain (Maroso et 
al., 2010). Uric acid is a purine degradation product that has multiple functions in the body (Fang et 
al., 2013). Soluble uric acid is well known for its anti-oxidant capacity, but its crystallized form is 
known to act as a DAMP in several disorders, such as gout, asthma and liver injury (Kono et al., 
2010, Alvarez-Lario and Macarron-Vicente, 2011, Kool et al., 2011, Rock et al., 2013). There are 
some indications that uric acid might play a role as a DAMP in epilepsy as well. In epilepsy patients, 
uric acid levels acutely increase upon generalized seizures (Warren et al., 1975, Luhdorf et al., 1978, 
Stover et al., 1997) and can be chronically elevated when untreated (Hamed et al., 2004, Hamed et al., 
2007). Uric acid was also reported to increase in the brain in two animal models, 100 minutes 
(Layton et al., 1998) and one week (Beal et al., 1991) after kainic acid (KA) administration. 
Furthermore, several components of the inflammatory signaling pathway downstream of uric acid 
have been shown to affect seizure characteristics in animal models for epilepsy, i.e. caspase-1 
(Vezzani et al., 2010) and NLRP3 (Meng et al., 2014). Notably, this pathway leads to the activation 
of IL-1β, a central pro-inflammatory cytokine involved in excitability (Vezzani et al., 2011). Finally, 
a number of studies suggest that allopurinol, an inhibitor of uric acid production, is effective as 
anticonvulsive therapy (Wada et al., 1992, Zagnoni et al., 1994, Murashima et al., 1998, Togha et al., 
2007), indicating that uric acid is not just an epiphenomenon but might actively contribute to the 
underlying pathophysiology.  
 
In this study we investigated the role of uric acid in the generation of limbic seizures in a 
intrahippocampal KA mouse model. To do this, hippocampal uric acid levels were monitored during 
seizures using microdialysis and the effect of pharmacologically and genetically manipulating uric 
acid levels on their severity was investigated.  
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Material and methods 
Chemicals and solutions 
Modified Ringer’s solution, the perfusion fluid used for microdialysis, consisted of 147 mM NaCl, 2.3 
mM CaCl2 and 4 mM KCl (all Sigma Aldrich, Schnelldorf, Germany) in ultrapure water and was kept 
at 4°C (one week shelf life). KA (R&D systems, Abington, United Kingdom) was dissolved in 
modified Ringer’s solution at a concentration of 4 mg/ml and kept in aliquots at -20°C. It was 
diluted further with modified Ringer’s solution to a concentration of 500 µg/ml on the experimental 
day. Allopurinol (Sigma Aldrich, Schnelldorf, Germany) was suspended in a saline:Tween 20 solution 
(9:1) at 10 mg/ml and stored at 4°C (one week shelf life). Uric acid (Sigma Aldrich, Schnelldorf, 
Germany) was prepared in modified Ringer’s solution at a concentration of 1.6 mg/ml and was 
freshly made every day.  
Animals 
The male C57BL/6 JolaHsd mice that were used for the pharmacological experiments were obtained 
from Harlan (Horst, The Netherlands). Mice with genetically altered uric acid levels were obtained 
by targeting urate oxidase (UOx), the enzyme responsible for uric acid breakdown. Hemizygous UOx 
overexpressing (UOx OE) mice (C57BL/6 background) were obtained from Kenneth Rock, 
Department of Immunology, University of Massachusetts, Worcester, USA. The UOx transgene in 
these mice is driven by a strong constitutive (β-actin) promoter (Kono et al., 2010). Hemizygous 
UOx knock-out (UOx KO) mice were purchased from The Jackson Laboratory (B6;129S7/J 
background, Maine, USA) and crossbred. Offspring of these breedings were then genotyped for 
homozygosity and bred separately. The UOx KO mice have a constitutive disruption of the UOx 
gene, by insertion of a neomycin gene into exon 3. Allopurinol (200 mg/l) was provided in the 
drinking water of UOx KO breeding pairs and pups until 8 weeks of age to prevent lethality due to 
hyperuricemia (Wu et al., 1994). All mice were bred at the animal house of Ghent University 
Hospital and were housed at controlled temperature (21-22°C) and relative humidity (40-60%) 
conditions. They had a fixed 12-hour light/dark cycle (lights-on period from 7 AM to 7 PM) and 
food and water available ad libitum. Treatment and care were in compliance with guidelines from the 
European Committee (decree 86/609/EEC). The study protocol was approved by the Animal 
Experimental Ethical Committee of Ghent University (ECD 09/61). All animals were 3-5 months 
old at the start of the experiments. 
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Induction of limbic seizures 
Anesthetized mice were implanted with a custom-made polyimide-coated bipolar electrode (wire Ø 
70 µm) with 0.5 mm tip separation, in which the deepest electrode contact was placed in the upper 
layer of the left dentate gyrus in the septal hippocampus (coordinates relative to bregma: 
anterioposterior: -1.8 mm; mediolateral: -1.0 mm, dorsoventral: -2.0 mm). An obturator-enclosed 
guide cannula was placed in the septotemporal transition zone of the hippocampus (coordinates 
relative to bregma: anterioposterior: -3.3 mm ; mediolateral: -2.8 mm ; dorsoventral: -2.3 mm). After 
a recovery period of one week the mice were connected to the EEG set-up and the guide cannula 
obturator was replaced with a microdialysis probe (CMA/7; 2 mm membrane length; theoretical cut-
off 6 kDa; CMA, Kista, Sweden) which was continuously perfused with modified Ringer’s solution at 
a flow rate of 1.25 µl/min. The next day, at 11 AM, a 500 µg/ml KA solution was infused for 3.2 
minutes, after which the solution was switched back to modified Ringer’s solution. With this 
protocol 2 µg KA was infused trough the microdialysis probe. Taking into consideration an 
estimated microdialysis probe recovery of 10%, we aimed to deliver 200 ng of KA, which is the dose 
frequently used for induction of status epilepticus by bolus injection (Bouilleret et al., 1999). This 
procedure results in a limbic status epilepticus with secondary generalized seizures and is not 
associated with any mortality (Fig. S1, Movies S1-5). A control group, in which mice were 
continuously infused with modified Ringer’s solution, but not with KA, was included to control for 
potential effects of microdialysis on the uric acid level in the region of the probe. 
Video-EEG analysis 
Latency between the start of intrahippocampal KA infusion and the appearance of the first epileptic 
spike on the hippocampal EEG was determined as well as the total duration of epileptic activity. The 
latter parameter was defined as time between the first epileptic spike and the moment that spike 
activity dropped below a frequency of 1 Hz for more than one hour (Grimonprez et al., 2015). 
Clinical seizures were counted in this period and scored based on a modified scale of Racine (Racine, 
1972) (Movie S1-5): (stage 2) head nodding (stage 3) unilateral forelimb clonus (stage 4) bilateral 
forelimb clonus with rearing (stage 5) rearing and falling, loss of postural control (stage 6) running 
and bouncing. Clinical seizures with score 1 (extensive grooming, hyperactivity, eye closure, staring) 
were not included because they could not be discriminated from continuous abnormal background 
behavior. Clinical seizures with stage 2 were considered as partial seizures, seizures with stage 3-6 
were grouped as generalized seizures (Raedt et al., 2009).  
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Measurement of uric acid 
Uric acid was quantified by HPLC using a Waters Alliance 2695 HPLC device (Waters, Zellik, 
Belgium) connected to a Waters 996 photodiode array detector according to an adapted protocol 
described by Fagugli and colleagues (Fagugli et al., 2002). Data acquisition and processing were 
performed using Empower software (Waters). Analyses were performed on a reverse-phase XBridge 
C8 column (3.5 µm, 150 mm x 4.6 mm, Waters) with an Ultrasphere ODS guard column (5 µm, 5 
mm x 4.6 mm, Beckman Instruments, Fullerton, CA). The chromatographic separation consisted of a 
linear gradient of methanol and ammonium formate buffer (50 mM, pH 3.0) from 0 to 100% 
methanol in 15 min at a flow rate of 1 mL/min. Forty-five microliter of dialysate was automatically 
injected. Uric acid was analyzed by UV detection at 300 nm. Standard solutions were used to 
perform calibration curves for uric acid quantification. For concentrations below the limit of 
detection (LOD; 0.112 µM) the LOD itself was used. 
Protocol design 
A schematic overview of the protocol design is shown in Figure 1. Video-EEG monitoring and 
dialysate sampling started at 8.30 AM. Hippocampal dialysates were sampled in 50 minute periods. 
Each experiment started with the collection of two baseline samples in which only modified Ringer’s 
solution was perfused. After KA infusion (or at the equivalent timepoint in the non-KA group) 
another six dialysates were collected. To test the electroclinical effects of lowering uric acid levels, 
animals were injected i.p. with either a 100 mg/kg suspension of allopurinol (ALLO) or its dissolving 
solution (9:1 saline:Tween 20 solution; SAL-T) 30 minutes before KA infusion. To test the 
electroclinical effects of uric acid increases, animals were infused in the left hippocampus with a 1.6 
mg/ml uric acid solution for 200 minutes at a flow rate of 1.25 µl/min, starting 50 minutes before 
KA infusion. This was compared to animals infused with modified Ringer’s solution (RIN). To verify 
how much uric acid exited the probe, the relative probe recovery was analyzed in vitro (CMA, Lee et 
al., 2003). To do this, a microdialysis probe was placed in a vial containing modified Ringer’s solution 
(62.5 µl) and perfused with the 1.6 mg/ml uric acid solution at a flow rate of 1.25 µl/min for 50 
minutes. The uric acid concentration in the vial was determined. This was repeated three times for 
two independent probes. Based on these experiments the recovery was estimated to be 10.5% (Mean 
probe recovery for probe 1: 0.18 ± 0.06 mg/ml; for probe 2: 0.21 ± 0.07 mg/ml). Because uric acid 
infusion interferes with the local uric acid measurement, no dialysates were collected in the mice 
upon infusion with uric acid since it is not possible to assess the amount of endogenous uric acid 
release in this case. To test the effects of genetic uric acid alterations, UOx OE mice and UOx KO 
mice were compared to their wildtype controls (WT). Sampling and video-EEG monitoring ended 
five hours after KA infusion (4 PM), unless epileptic activity was still ongoing. In the latter case, 
monitoring was stopped only after the SE had ended.  
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Figure 1 │ Schematic overview of experimental protocols. Hippocampal dialysates were collected during 50-minute 
epochs and analyzed for uric acid (UA) concentration. In the non-KA control group modified Ringer’s solution was 
continuously infused throughout the microdialysis experiment. In all other experimental groups KA was infused in the 
hippocampus after two baseline dialysate collections. After KA infusion (or at the equivalent timepoint) another six 
dialysates were collected. The different experimental approaches to alter uric acid levels are indicated in the figure: 
pharmacologically, uric acid levels were decreased using allopurinol (, 100 mg/kg i.p., 30 min before KA-infusion, ALLO) 
and increased by infusion of a 1.6 mg/ml uric acid solution (—) during 200 minutes starting 50 minutes before KA-
infusion; genetically, the urate oxidase (UOx) gene, which encodes the enzyme responsible for uric acid breakdown, was 
targeted. UOx knock-out (KO) mice and UOx overexpressing (OE) mice were used to study increased and decreased uric 
acid levels respectively. □: 50 minute dialysate collections; white: baseline; grey: post KA. KA: kainic acid, SAL-T: saline-
tween, WT: wildtype 
Statistical Analysis 
For all experiments, the number of animals (n) analyzed are represented. All data are expressed as 
the mean ± standard error of mean (SEM). Statistical analyses were performed in SPSS Statistics 
version 22. Parametric tests were used when data was normally distributed, and non-parametric tests 
were used otherwise. Comparisons between single groups (mean uric acid concentration, number of 
seizures, duration and latency) were analyzed with an independent t-test (parametric) or a Mann-
Whitney U test (non-parametric). Within group evaluation of changes in uric acid concentration 
across collection periods was done using a one-way ANOVA for repeated measures (parametric) or 
Friedman’s test (non-parametric). For between group evaluation of differences in uric acid 
concentration and number of generalized seizures across collection periods a two-way ANOVA with 
treatment/genotype as between-subject factor and time (i.e. collection) as within-subject factor was 
used (parametric). In case of non-parametric testing, Mann-Whitney U tests were done at each 
timepoint (i.e collection period). In case of multiple (post-hoc) comparisons, the p-values were 
corrected using a Bonferroni-Holm correction (parametric) or Dunn’s test (non-parametric). 
Differences were considered significant at the 5% level.  
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Results 
Control animals, infused with modified Ringer’s solution, did not display epileptic activity and had 
stable levels of uric acid in the hippocampus over the total duration of the experiment (overall 
average 0.33 ± 0.01 µM, Figure S2). All mice that were intrahippocampally infused with kainic acid 
developed a status epilepticus without mortality.  
Hippocampal uric acid increases during seizures and contributes to the number of 
subsequent seizures  
KA-infused animals (SAL-T) displayed a significant increase in extracellular uric acid levels during 
the first 200 minutes (i.e. 4 collection periods) after KA infusion with a maximum of 1.40 ± 0.21 µM 
between 50 and 100 minutes after infusion. This 3.5x increase, relative to baseline uric acid 
concentration, was followed by a steady decline in uric acid concentration over the subsequent 
collections (Figure 2A). In order to investigate the effect of pharmacologically blocking uric acid 
increases on seizure activity, mice were treated with allopurinol (100 mg/kg, i.p.), an inhibitor of 
xanthine oxidase. As part of the purine degradation pathway this enzyme is responsible for the 
catalysis of xanthine into uric acid. Mean uric acid concentration in baseline conditions was 
comparable in both groups (SAL-T: 0.40 ± 0.06 µM; ALLO: 0.41 ± 0.07 µM) (Figure 2A). 
Allopurinol treatment blocked the transient KA-induced uric acid increase and even reduced its 
levels below baseline concentrations during the entire follow-up (Figure 2A; χ2 = 23.876, p = 0.001). 
This treatment did not affect latency and duration of epileptic activity nor the number of partial 
seizures. However it significantly decreased the number of generalized seizures by half (Figure 2B,C; 
SAL-T: 8.3 ± 1.6; ALLO: 4.1 ± 0.5; t = 2.274, p = 0.041). The progression of generalized seizures 
over time was also different compared to the saline treated animals (F = 5.563, p = 0.008). In the 
allopurinol treated group, generalized seizures were restricted to the first 100 minutes, whereas 
saline treated animals also displayed seizures after this period (Figure 2A).  
Infusion of uric acid does not increase seizures 
To next investigate the effect of uric acid increases on seizures, mice were infused with uric acid in 
the hippocampus. Mean uric acid baseline concentrations were comparable between treatment and 
control groups: 0.52 ± 0.12 µM (RIN) vs. 0.62 ± 0.09 µM (UA) (Figure 3A). Based on the recovery 
rate of the probe (10.5%), the average local concentration achieved for a 50 minute-collection was 
1000 µM during uric acid infusion and 20 µM during peak measurement in the control condition. We 
hence infused 50 times more uric acid than what was released during peak measurement over a 
period of 200 minutes (4 collections). However, this increase had no effect on KA induced 
electroclinical changes (Figure 3A-C).  
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Figure 2 │ Blocking the release of uric acid during limbic seizures. (A) Progression of absolute hippocampal uric acid 
(UA) levels (line plot) and generalized seizures (bar plot) per 50-minute collection. Within group comparisons showed that 
uric acid levels were significantly higher than baseline during the first 200 minutes (collection 1-4) after kainic acid (KA) 
infusion in the saline treated (SAL-T) control animals only. Between group comparison showed that for all six dialysates 
after KA infusion, the level of uric acid was significantly reduced in the allopurinol treated (ALLO) mice compared to SAL-
T control mice. Compared to SAL-T there were significantly less generalized seizures during the third collection after KA 
infusion.  = i.p. injection of 100 mg/kg allopurinol. #significantly different from mean baseline concentration; 
*significantly different from concentration in SAL-T group for that collection. (B) Number of partial and generalized 
seizures. The number of generalized seizures was significantly lower in the ALLO group (*) compared to the SAL-T 
control group. (C) Latency to first epileptic spike (upper panel) and duration of epileptic activity (lower panel). nSAL-T = 8, 
nALLO = 7. All values represent mean ± SEM. *,# p < 0.05, **,## p < 0.001. 
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Figure 3 │ Infusion of uric acid during limbic seizures. (A) Progression of absolute hippocampal uric acid (UA) levels 
(line plot) and generalized seizures (bar plot) per 50-minute collection. Uric acid measurements were not possible in the 
uric acid-infused group from the moment of infusion onwards. Within group comparisons showed that uric acid levels were 
significantly higher than baseline during entire follow up (collection 1-6) after kainic acid (KA) infusion in the animals 
infused with modified Ringer’s solution (RIN). — i.h. uric acid infusion. #significantly different from mean baseline 
concentration. (B) Number of partial and generalized seizures. (C) Latency to first epileptic spike (upper panel) and 
duration of epileptic activity (lower panel). KA: kainic acid;; nRIN = 10, nUA = 11. All values represent mean ± SEM. # p < 
0.05, ## p < 0.001 
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Overexpressing urate oxidase decreases hippocampal uric acid but does not decrease 
seizures 
To test the effect of genetic uric decreases on limbic seizures, UOx OE mice were compared to their 
wildtype controls. Compared to their controls, mean baseline uric acid levels in the hippocampal area 
of the UOx OE mice were twofold decreased (Figure 4A; WT: 0.44 ± 0.07 µM, UOx OE: 0.18 ± 0.04 
µM; t = 3.135, p = 0.009). Although UOx OE mice still displayed an increase in uric acid levels after 
KA infusion, the peak was less pronounced and regressed more rapidly (Figure 4A; within group F = 
5.402, p = 0.041; between group, F = 3.551, p = 0.037). Uric acid levels reached a maximal 
concentration of 1.63 ± 0.23 µM and 0.64 ± 0.18 µM in the wildtype and the UOx OE mice 
respectively. The decreased uric acid levels in these animals had no significant effect on limbic 
seizures (Figure 4A-C).  
Genetic disruption of uricate oxidase increases hippocampal uric acid and increases 
seizures 
Finally, UOx KO mice were compared to their wildtype controls, to assess the effect of genetic uric 
acid increases on limbic seizures. Compared to their controls, mean baseline uric acid levels in the 
hippocampal area of the UOx KO mice were fivefold increased (Figure 5A; WT: 0.37 ± 0.08 µM, UOx 
KO: 2.06 ± 0.37 µM; U = 5, p = 0.013). In UOx KO animals the KA-induced uric acid peak was 
higher, delayed and had a slower regression (Figure 5A; within group F = 9.051, p = 0.002; between 
group F = 6.443, p = 0.005). Uric acid levels reached a maximum during the third dialysate 
collection, between 100 and 150 minutes after start of KA infusion. Peak uric acid concentration was 
9.44 ± 1.97 µM, compared to 2.02 ± 0.24 µM in the wildtype animals (t = 3.209, p = 0.007). The 
number of generalized seizures in UOx KO mice was twice as high compared to wildtype animals 
(Figure 5B; WT: 6.1 ± 0.7, UOx KO: 11.6 ± 1.7; t = -2.940, p = 0.011) but the number of partial 
seizures was unaffected. This difference resulted from an overall increase in generalized seizures 
throughout the entire follow-up period (Figure 5A; F = 3.186, p = 0.034). Latency to the first 
epileptic spike after the start of intrahippocampal KA infusion was delayed in UOx KO animals 
compared to their wildtype counterparts (Figure 5C; WT: 1.60 ± 0.23; UOx KO: 2.56 ± 0.32; t = -
2.444, p = 0.024).  
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Figure 4 │ Hippocampal uric acid levels and limbic seizures in urate oxidase overexpressing mice. (A) Progression 
of absolute hippocampal uric acid (UA) levels (line plot) and generalized seizures (bar plot) per 50-minute collection. 
Within group comparisons showed that uric acid levels were significantly higher than baseline during the first 100 minutes 
(collection 1-2) after kainic acid (KA) infusion in the wildtype (WT) animals only. Between group comparison showed the 
level of uric acid was significantly reduced in the uricase overpressing (UOx OE) mice compared to WT group both during 
baseline (collection 2) and after KA-infusion (collection 2 and 3). #significantly different from mean baseline concentration; 
*significantly different from concentration in WT group for that collection. (B) Number of partial and generalized seizures. 
(C) Latency to first epileptic spike (upper panel) and duration of epileptic activity (lower panel). nWT = 7, nUOx OE = 7. All 
values represent mean ± SEM. *,# p < 0.05, **,## p < 0.001 
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Figure 5 │ Hippocampal uric acid levels and limbic seizures in urate oxidase knock-out mice. (A) Progression of 
absolute hippocampal uric acid (UA) levels (line plot) and generalized seizures (bar plot) per 50-minute collection. Within 
group comparisons showed that uric acid levels were significantly higher than baseline for both wildtype (WT; collection 2-
3) and uricase knock-out (UOx KO; collection 1-6) animals after kainic acid (KA) infusion. Between group comparison 
showed that for all dialysates before and after KA infusion, the level of uric acid was significantly increased in the UOx KO 
mice compared to their WT counterparts. Compared to WT mice there were significantly more generalized seizures during 
the second collection after KA infusion. #significantly different from mean baseline concentration; *significantly different 
from concentration in WT group for that collection. (C) Latency to first epileptic spike (upper panel) and duration of 
epileptic activity (lower panel). The latency was significantly (*) longer in UOx KO mice compared to the WT mice. nWT = 
11, nUOx KO = 11. All values represent mean ± SEM. *,# p < 0.05, **,## p < 0.001 
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Discussion 
In the present study we investigated the role of uric acid in the generation of limbic seizures. Local 
uric acid changes were monitored during seizure activity and the effect of complementary 
pharmacological and genetic uric acid manipulations on seizure characteristics were studied. 
First, we found that local extracellular uric acid levels transiently increased three- to fourfold during 
limbic seizures, and peaked between 50 and 100 minutes after KA infusion. A previous study which 
injected KA intraperitoneally (16 mg/kg) in rats resulted in extracellular uric acid increases in the 
piriform cortex within 100 minutes (Layton et al., 1998). Importantly, they showed that prevention 
of seizures using midazolam largely inhibited uric acid release, indicating that seizure activity and 
not KA was the predominant cause of uric acid release (Layton et al., 1998). It is unclear whether this 
also holds for the intrahippocampal KA model, however, because the local concentration of KA and 
extent of the excitotoxic lesion is different compared to the intraperitoneal KA model (Levesque and 
Avoli, 2013).  
Secondly, we found that allopurinol treatment and disruption of the UOx gene resulted in a twofold 
decrease and a twofold increase in the number of generalized seizures respectively. Together, these 
results suggest that uric acid promotes secondary generalization of seizures induced by 
intrahippocampal KA administration. Secondarily generalized tonic-clonic seizures (SGTCS) occur in 
30% of the patients with refractory focal epilepsy and are a major cause of sudden unexpected death 
in epilepsy (Hemery et al., 2014). A recent study suggested that targeting SGTCS might present an 
important parameter for add-on treatment choice in these group of patients (Hemery et al., 2014). In 
this regard, our report indicates that targeting uric acid can be of particular interest in suppressing 
these type of seizures. This is in line with studies in patients with intractable epilepsy that found that 
allopurinol is most effective against SGTCS (De Marco and Zagnoni, 1988, Tada et al., 1991, 
Zagnoni et al., 1994, Togha et al., 2007). In addition, allopurinol also proved to be efficient in 
reducing the severity of generalized seizures after hippocampal kindling in cats (Wada et al., 1992) 
and in blocking secondarily generalized seizures in EL mice (Murashima et al., 1998). Interestingly, 
the administration of allopurinol and the disruption of the UOx gene resulted in a differential time 
profile in their manipulation of the number of generalized seizures. One hypothesis could be that uric 
acid only contributes to the secondary generalization of seizures in a later phase. In this scenario, the 
first phase of the status epilepticus is determined by KA alone, while the increasing levels of uric acid 
that develop during the status epilepticus stimulate further generalization. This would explain why 
the actions of allopurinol are only evident after the peak in uric acid concentration and why in UOx 
KO animals – that have chronically increased levels of uric acid basally – the number of generalized 
seizures is already increased at the start of the status epilepticus. 
80 
Invest igat ion  o f  a  ro le  for  ur ic  a c id  in  exper imenta l  se izure  mode ls  
 
 
In contrast to allopurinol administration and disruption of UOx, our study could not demonstrate 
effects of intrahippocampal uric acid administration nor of UOx overexpression on the number of 
generalized seizures in the intrahippocampal KA model. A number of factors could account for this 
discrepancy. Firstly, intrahippocampal administration of uric acid might not have increased 
secondary generalization of hippocampal seizures because it did not diffuse far enough to affect brain 
regions responsible for seizure generalization, such as thalamus and substantia nigra (Gale, 1992, 
Blumenfeld et al., 2009, Yoo et al., 2014). In contrast, increases in uric acid levels are likely to extend 
beyond the region of the microdialysis probe in UOx KO mice (Chen et al., 2013). Secondly, the UOx 
OE mice displayed only a modest phenotype. The release of uric acid in these animals was not 
blocked to the same extent as with allopurinol treatment. There was still an induction of uric acid 
which at peak level was in average 1.5 times higher than baseline levels. Moreover, compared to UOx 
KO mice, the chronic change in uric acid levels was smaller (twofold vs. fivefold) and perhaps too 
small to evoke any effect. Thirdly, it is possible that the reduction of generalized seizures in response 
to allopurinol treatment is not directly related to a decrease in uric acid levels but rather to other 
effects of blocking xanthine oxidase, such as increases in adenosine and inosine. Both compounds 
have been reported to reduce seizure susceptibility (Boison, 2012, Kovacs et al., 2015). In that 
scenario the condition in the UOx KO mice, where an acute fivefold increase of uric acid is 
superimposed onto chronically elevated levels, would be the only setting where uric acid affects 
seizure generalization.  
This may be related to the multiple actions of uric acid. On the one hand, the soluble form of uric 
acid acts as an anti-oxidant, but causes oxidative stress when levels are reduced (Fang et al., 2013). 
On the other hand, at high concentration, monosodium (MSU) crystals are formed, that can trigger 
the inflammatory response that can lead to an increased excitability (Vezzani et al., 2012). Not much 
is known about the formation of MSU crystals in vivo and even less outside the context of gouty 
arthritis, although the concentration of uric acid is considered a major contributing factor. In that 
regard, crystallization in the joint is assumed to occur above a threshold of 405 µM in humans (Rock 
et al., 2013), although it is becoming evident that the crystallization threshold is heavily dependent 
on other factors, such as temperature, pH, local calcium concentration, and mechanical stress. As 
such, gout is known to develop in patients with serum uric acid levels below 405 µM (Martillo et al., 
2014). As the membrane of the microdialysis probe does not allow passage of the MSU crystals it is 
impossible to measure or administer MSU crystals in our experiments. It is hence possible that the 
pro-inflammatory MSU crystals are only formed in the UOx KO mice. Future histological studies 
will be necessary to unequivocally determine the presence of MSU crystals in the brain (Weaver et 
al., 2009). 
In UOx KO mice the latency to seizure activity was delayed, which indicates that the fivefold 
chronical increase in uric acid levels in the brain can, in a seemingly contradictory fashion, increase 
the threshold for seizure initiation as well. Although difficult to explain at this time, one can 
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speculate that an increased anti-oxidative potential in these animals could play a role here, although 
this only seems to be the case in this particular setting. In any case, these results suggest that the 
different functions attributed to uric acid may occur simultaneously. 
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Supporting information 
 
Figure S1 │ (A) Example EEG of kainic acid (KA) induced status epilepticus (SE), and example EEGs 
corresponding (B) partial (stage 2) and (C) generalized (stage 3-6) seizures. The initial phase of the status epilepticus 
was characterized by the occurrence of discrete electrographic seizures, after which spiking increased in frequency and 
became more continuous. Over time, spiking became interspersed with increasingly longer low-voltage periods until the 
EEG only displayed periodic high-voltage epileptiform discharges. Seizures with a Racine score of 3 to 6 were associated 
with an increased frequency (> 4 Hz) and complexity of epileptic spikes, clearly distinguishable from background 
epileptiform activity. Head nodding (Racine stage 2) was similarly associated with a less uniform shorter alteration in 
frequency and/or amplitude. Red arrows indicate the start (first spike) and end (< 1 Hz spike frequency) of hippocampal 
status epilepticus. Scale bars = 5 mV. Hc: hippocampus, Cx: cortex.  
 
Figure S2 │ Extracellular hippocampal uric acid concentration in the non-KA control group. Progression of absolute 
hippocampal uric acid levels per 50-minute collection in animals continuously infused with modified Ringer’s solution. nnon-
KA= 9. All values represent mean ± SEM. 
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Movie S1-5 │ Examples of seizures associated with KA-induced status epilepticus. (1) Stage 2 - head nodding (2) 
Stage 3 - unilateral forelimb clonus (3) Stage 4 - bilateral forelimb clonus with rearing (4) Stage 5 - rearing and falling (5) 
Stage 6 - running and bouncing. KA: kainic acid. Videos can be found online: doi: 10.1016/j.expneurol.2016.01.001. 
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Research Aims 
(1) develop and characterize a seizure model that allows to monitor the changes in local uric acid 
levels:  
(2) investigate the effects of pharmacological and genetic uric acid modulations on the seizure 
characteristics of this model 
(3) investigate the effects of these manipulations on the seizure-associated inflammatory 
response 
(4) examine if altering uric acid levels changes seizure characteristics in a different seizure 
model 
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Chapter 6  
Effects of uric acid in a mouse model for acute limbic 
seizures: expression of inflammatory markers and 
inflammasome components 
Lisa Thyrion, Robrecht Raedt, Sophie Janssens, Bart Lambrecht, Kristl Vonck, Paul Boon 
 
 
 
Abstract 
A growing body of evidence points at an active contribution of pro-inflammatory processes to 
neuronal excitability, with a newly identified involvement of endogenous pro-inflammatory danger 
signals. We have previously shown that uric acid, a well-known danger signal in the periphery, is 
released in the brain and is involved in the generation of seizures in a mouse model for acute limbic 
seizures. In the present study we evaluated whether experimental manipulations of uric acid in the 
acute limbic seizure model has an impact on the inflammatory state of the brain, by analyzing the 
hippocampal expression of relevant inflammatory markers one day after seizure induction. In order 
to gain further insight into the potential inflammatory pathway of uric acid, expression of 
components of the NLRP3 inflammasome was also examined. Our results show that manipulations of 
uric acid levels changes the inflammatory state upon induction of acute limbic seizures but only in 
those conditions where manipulation of uric acid also affected the seizure state. 
Key words: uric acid, urate oxidase, allopurinol, inflammation, RT-qPCR, mouse 
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Introduction 
Despite being an active field of research for decades, about one third of the epilepsy patients still does 
not achieve seizure freedom with the available treatment modalities (Moshe et al., 2015). To conceive 
more effective medication, novel therapeutic targets need to be identified. This compels to a better 
understanding of the mechanisms underlying hyperexcitability (Devinsky et al., 2013). In this 
regard, there is a growing body of evidence that points to a significant contribution of pro-
inflammatory danger signals to epilepsy (Vezzani and Viviani, 2014). Recent evidence shows that the 
pro-inflammatory danger molecule HMGB1 can be targeted to reduce seizures (Maroso et al., 2010). 
In accordance, we have shown that uric acid, another danger signal with pro-inflammatory actions 
(Rock et al., 2010), is released in the brain during acute limbic seizures and affects seizure 
generalization in animals where uric acid levels were pharmacologically and genetically altered 
(Thyrion et al., 2016). More specifically, we were able to show that allopurinol-induced decrease in 
uric acid levels reduced seizure generalization, while uric acid increases, resulting from a disruption 
in the urate oxidase (UOx) gene, promoted seizure generalization. In the latter case, the latency to 
the onset of seizures was, seemingly contradictory, also delayed.  
 
The inflammatory pathway of uric acid involves assembly of the NLRP3 inflammasome with the 
scaffolding protein ASC, the subsequent recruitment and activation of caspase-1 and the resulting 
cleavage of pro-IL-1β and pro-IL-18 into their biologically active form (Rock et al., 2013). IL-1β is 
well-recognized to increase excitability and influences neurotransmission and neuroglial 
communication through both rapid effects on receptor-gated ion channels and long-lasting effects on 
expression levels of transcription molecules, such as NF-kB (Vezzani and Baram, 2007). The latter 
induces the expression of downstream players, including several members of the IL-1 family, IL-6, 
TNF and COX-2, which all have been shown to affect excitability in various stages of experimental 
epilepsy (Vezzani et al., 2012).  
 
As seizure-induced inflammation can further increase excitability, this can potentially contribute to 
seizure precipitation in the future (Vezzani and Viviani, 2014). In order to evaluate if the seizure-
induced release of uric acid affects the post-ictal inflammatory state of the brain, we analyzed 
changes in hippocampal expression of inflammatory markers and inflammasome components, that 
have been shown to increase in our seizure model (see Chapter 4), upon experimental modulation of 
uric acid. 
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Material and methods 
Chemicals and solutions 
Modified Ringer’s solution, the perfusion fluid used for microdialysis, consisted of 147 mM NaCl, 2.3 
mM CaCl2 and 4 mM KCl (all Sigma Aldrich, Schnelldorf, Germany) in ultrapure water and was kept 
at 4°C (one week shelf life). Kainic acid (KA) (R&D systems, Abington, United Kingdom) was 
dissolved in modified Ringer’s solution at a concentration of 4 mg/ml and kept in aliquots at -20°C. 
It was diluted further with modified Ringer’s solution to a concentration of 500 µg/ml on the 
experimental day. Allopurinol (Sigma Aldrich, Schnelldorf, Germany) was suspended in a 
saline:Tween 20 solution (9:1) at 10 mg/ml and stored at 4°C (one week shelf life). Uric acid (Sigma 
Aldrich, Schnelldorf, Germany) was prepared in modified Ringer’s solution at a concentration of 1.6 
mg/ml and was freshly made every day.  
Animals 
The animals used for this study are the same animals used in Chapter 5. The male C57BL/6 JolaHsd 
mice that were used for the pharmacological experiments were obtained from Harlan (Horst, The 
Netherlands). Mice with genetically altered uric acid levels were obtained by targeting urate oxidase 
(UOx), the enzyme responsible for uric acid breakdown. Hemizygous UOx overexpressing (UOx OE) 
mice (C57BL/6 background) were obtained from Kenneth Rock, Department of Immunology, 
University of Massachusetts, Worcester, USA. The UOx transgene in these mice is driven by a 
strong constitutive (β-actin) promoter (Kono et al., 2010). Hemizygous UOx knock-out (UOx KO) 
mice were purchased from The Jackson Laboratory (B6;129S7/J background, Maine, USA) and 
crossbred. Offspring of these breedings were then genotyped for homozygosity and bred separately. 
The UOx KO mice have a constitutive disruption of the UOx gene, by insertion of a neomycin gene 
into exon 3. Allopurinol (200 mg/l) was provided in the drinking water of UOx KO breeding pairs 
and pups until 8 weeks of age to prevent lethality due to hyperuricemia (Wu et al., 1994). All mice 
were bred at the animal house of Ghent University Hospital and were housed at controlled 
temperature (21-22°C) and relative humidity (40-60%) conditions. They had a fixed 12-hour 
light/dark cycle (lights-on period from 7 AM to 7 PM) and food and water available ad libitum. 
Treatment and care were in compliance with guidelines from the European Committee (decree 
86/609/EEC). The study protocol was approved by the Animal Experimental Ethical Committee of 
Ghent University (ECD 09/61). All animals were 3-5 months old at the start of the experiments.  
Induction of limbic seizures 
Induction of limbic seizures was done as previously described (see Chapter 5). In brief, an obturator-
enclosed guide cannula was placed in the septotemporal transition zone of the hippocampus 
(coordinates relative to bregma: anterioposterior: -3.3 mm ; mediolateral: -2.8 mm ; dorsoventral: -2.3 
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mm). After a recovery period of one week the mice were connected to the set-up and the guide 
cannula obturator was replaced with a microdialysis probe (CMA/7; 2 mm membrane length; 
theoretical cut-off 6 kDa; CMA, Kista, Sweden) which was continuously perfused with modified 
Ringer’s solution at a flow rate of 1.25 µl/min. The next day, at 11 AM, a 500 µg/ml KA solution 
was infused for 3.2 minutes, after which the solution was switched back to modified Ringer’s 
solution.  
Measurement of uric acid 
Hippocampal dialysates were sampled in 50 minute periods. Experiments were started collecting two 
to three baseline samples in which only modified Ringer’s solution was infused. After KA infusion (or 
at the equivalent timepoint in the non-KA control group) another six dialysates were collected. Uric 
acid was quantified by HPLC using a Waters Alliance 2695 HPLC device (Waters, Zellik, Belgium) 
connected to a Waters 996 photodiode array detector according to an adapted protocol described by 
Fagugli and colleagues (Fagugli et al., 2002). Data acquisition and processing were performed using 
Empower software (Waters). Analyses were performed on a reverse-phase XBridge C8 column (3.5 
µm, 150 mm x 4.6 mm, Waters) with an Ultrasphere ODS guard column (5 µm, 5 mm x 4.6 mm, 
Beckman Instruments, Fullerton, CA). The chromatographic separation consisted of a linear 
gradient of methanol and ammonium formate buffer (50 mM, pH 3.0) from 0 to 100% methanol in 15 
min at a flow rate of 1 mL/min. Forty-five microliter of dialysate was automatically injected. Uric 
acid was analyzed by UV detection at 300 nm. Standard solutions were used to perform calibration 
curves for uric acid quantification. For concentrations below the limit of detection (LOD; 0.112 µM) 
the LOD itself was used. For the pharmacological studies, values depict the mean uric acid level of 
six collections during seizure activity (KA) or during the equivalent time (RIN). Due to the low 
number of animals and lack of consistency in RIN animals in the genetic studies, mean values of the 
three baseline collections (BAS) of the animals infused with KA were used instead of uric acid levels 
obtained from dialysates of RIN animals.  
Experimental set-up 
To pharmacologically test the effects of lowering uric acid levels on seizure-induced inflammation, 
animals were injected intraperitoneally with either a 100 mg/kg suspension of allopurinol or its 
dissolving solution (9:1 saline:Tween 20 solution) 30 minutes before KA infusion. To 
pharmacologically test the effects of increases in uric acid levels, animals were infused in the left 
hippocampus with a 1.6 mg/ml uric acid solution for 200 minutes at a flow rate of 1.25 µl/min, 
starting 50 minutes before KA infusion. This was compared to animals continuously infused with 
modified Ringer’s solution. To test the effects of genetic uric acid alterations, UOx OE mice and UOx 
KO mice were compared to their wildtype controls (WT). All treatments were shown to alter the 
local uric acid levels during seizure activity (Thyrion et al., 2016).  
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RNA isolation and RT-qPCR 
Isolation of RNA and RT-qPCR was done as previously described (see Chapter 4). In brief, 
hippocampal tissue was isolated and snap-frozen twenty-six hours after KA infusion. Frozen 
hippocampal tissue was homogenized total RNA was extracted using the RNeasy Lipid Tissue kit 
(Qiagen). An additional ethanol-precipitation step was performed to increase purity of the samples, 
which was verified using Nanodrop. Genomic DNA was removed using a TURBO DNAse kit 
(Ambion) and first strand cDNA synthesis was performed using the Superscript III first strand 
synthesis system for RT-qPCR (Invitrogen), both according to manufacturer’s instructions. Real-
time quantitative polymerase chain reactions (RT-qPCR) were done using the Fast SYBR master 
mix kit (Applied Biosystems) or SensiFastTM SYBR No-Rox kit (Bioline). Primers were designed 
making use of Primerbank (www.pga.mgh.harvard.edu/primerbank) (see Chapter 4; IL-18: Fw-
GACTCTTGCGTCAACTTCAAGG Rv-CAGGCTGTCTTTTGTCAA CGA). All reactions were 
performed in triplicate and plates were run on an ABI Prism 7900 HT Sequence Detection System 
(Applied Biosystems) or on a Lightcycler 480 (Roche). Relative expression was calculated using an 
improved version of the ΔΔ-Ct-method (Livak and Schmittgen, 2001). Data were normalized to the 
geometric average of internal standard genes (HMBS, TBP and RPL13a) (Vandesompele et al., 
2002). Values represent the average normalized relative expression values, with the expression level 
of wildtype/nontreated animals infused with modified Ringer’s solution. Two samples were left out 
because of instability of the internal standard genes. 
Statistical analysis 
For all experiments, the number of animals (n) analyzed are represented. Values are expressed as 
mean ± standard error of mean (SEM). Statistical analyses were performed in SPSS Statistics version 
22. Expression data was analyzed with a two-way analysis of variance (ANOVA) with 
treatment/genotype and seizures as independent factors. Uric acid data was analyzed using 
(in)dependent t-tests. Post-hoc testing was corrected using the Bonferroni-Holm method. 
Differences were considered significant at the 5% level. 
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Results 
Effect of allopurinol treatment on seizure-induced inflammation 
The display of seizures was associated with an increased expression of ASC (1.00 ± 0.09 vs. 2.1 ± 
0.11), IL-1α (1.00 ± 0.13 vs. 2.79 ± 0.30), IL-1Ra (1.00 ± 0.56 vs. 7.05 ± 2.85), IL-6 (1.00 ± 0.25 vs. 3.59 
± 0.84), TNF (1.00 ± 0.14 vs. 5.95 ± 1.00) and COX2 (1.00 ± 0.14 vs. 2.62 ± 0.35) and a decreased 
expression of IL-18 (1.00 ± 0.06 vs. 0.79 ± 0.03 (Figure 1). Treatment with allopurinol showed a 
trend to further decrease the expression of IL-18 (0.79 ± 0.03 vs. 0.61 ± 0.10) and attenuated the 
induction of the expression of IL-1Ra (7.05 ± 2.85 vs. 0.74 ± 0.14), IL-6 (3.59 ± 0.84 vs. 1.28 ± 0.04), 
TNF (5.95 ± 1.00 vs. 2.21 ± 0.47) and COX2 (2.62 ± 0.35 vs. 1.39 ± 0.13) in animals that displayed 
seizures, but did not alter the inflammatory response in animals continuously infused with modified 
Ringer’s solution. 
Figure 1 │ Allopurinol does not affect the inflammatory state in animals infused with modified Ringer’s solution, but 
decreases seizure-induced inflammation in animals infused with kainic acid. mRNA expression levels are normalized relative 
to the geometric mean of the internal standard genes. For each gene, fold differences were calculated relative to the average 
expression levels in modified Ringer’s infused control animals injected with saline-Tween, which were set at 1. The results of the 
two-way ANOVA showed a main effect of seizures on the expression of ASC (p < 0.01), IL-1α (p < 0.01), IL-1β (p = 0.086, trend), 
IL-18 (p < 0.01), IL-1Ra (p < 0.05) and IL-6 (p < 0.01); a main effect of treatment on the expression of IL-1Ra (p < 0.01) and IL-6 
(p = 0.059, trend) and an interaction between seizures and treatment on the expression of TNF (p < 0.05) and COX2 (p < 0.05). 
Small plot: Relative extracellular hippocampal uric acid concentration normalized to the average level in the RIN SAL-T group. 
Bars represent mean ± SEM. RIN: modified Ringer’s solution; SAL-T: saline-Tween; ALLO: allopurinol; KA: kainic acid. #(#) and 
*(*) indicate a statistical significant difference between the RIN SAL-T and KA SAL-T group and the KA SAL-T and KA ALLO 
group respectively. *,#p < 0.05, **,##p < 0.01. 
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Effect of uric acid infusion on seizure-induced inflammation 
The display of seizures was associated with an increased expression of ASC (1.00 ± 0.21 vs. 2.42 ± 
0.17), NLRP3 (1.00 ± 0.31 vs. 3.65 ± 0.76), IL-1α (1.00 ± 0.11 vs. 2.72 ± 0.21), IL-1β (1.00 ± 0.28 vs. 
2.62 ± 0.52), IL-1Ra (1.00 ± 0.40 vs. 6.90 ± 1.39), IL-6 (1.00 ± 0.14 vs. 6.43 ± 0.9), TNF (1.00 ± 0.14 
vs.6.40 ± 0.75) and COX2 (1.00 ± 0.24 vs.2.43 ± 0.39) (Figure 2). The increase of local uric acid 
levels resulted in a trend towards an increase in the expression of IL-1α (1.00 ± 0.11 vs.1.44 ± 0.22) 
and IL-6 (1.00 ± 0.14 vs. 3.21 ± 1.41) and an increased expression of ASC (1.00 ± 0.21 vs. 1.75 ± 
0.45), NLRP3 (1.00 ± 0.31 vs. 2.84 ± 0.33) and IL-18 (1.00 ± 0.11 vs. 1.64 ± 0.29) in Ringer infused 
animals but did not result in further increases in seizure-induced expression of inflammatory 
markers, except for a trend towards an upregulation of IL-18 mRNA (0.80 ± 0.07 vs. 1.22 ± 0.13).  
Figure 2 │ Uric acid infusion increases the inflammatory state in animals infused with modified Ringer’s solution, but 
fails to further contribute to the seizure-induced inflammatory response in animals infused with kainic acid. mRNA 
expression levels are normalized relative to the geometric mean of the internal standard genes. For each gene, fold differences 
were calculated relative to the average expression levels in control animals continuously infused with modified Ringer’s solution, 
which were set at 1. The results of the two-way ANOVA showed a main effect of seizures on the expression of IL-1α (p < 0.01), 
IL-1β (p < 0.05), IL-18 (p = 0.063; trend), IL-1Ra (p < 0.01), IL-6 (p < 0.01), TNF (p < 0.01) and COX2 (p < 0.01); a main effect of 
treatment on the expression of CASP1 (p = 0.092; trend), IL-18 (p < 0.05 and IL-6 (p < 0.05) and an interaction between seizures 
and treatment on the expression of ASC (p < 0.01) and NLRP3 (p < 0.05). Small plot: Relative extracellular hippocampal uric acid 
concentration normalized to the average level in the RIN RIN group. Bars represent mean ± SEM. RIN: modified Ringer’s 
solution; UA: uric acid; KA: kainic acid. §(§), *(*) and #(#) indicate a statistical significant difference between the RIN RIN and 
RIN UA group; the RIN RIN and KA RIN group and the KA RIN and KA UA group respectively. *,§,#p < 0.05, **,§§,##p < 0.01. 
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Effect of overexpression of urate oxidase on seizure-induced inflammation 
Despite a main effect of seizures on the expression of ASC (p < 0.01), IL-1Ra (p < 0.05), IL-6 (p < 
0.05) and TNF (p < 0.01) and an interaction between seizures and genotype for the expression of 
CASP 1 (p < 0.01), only a significantly decreased expression of CASP1 (1.00 ± 0.26 vs. 0.50 ± 0.09) 
and increased expression of TNF (1.00 ± 0.32 vs. 2.29 ± 0.59) in wildtype animals infused with KA 
could be demonstrated (Figure 3). In Ringer infused animals overexpression of the UOx gene 
resulted in a decreased expression of ASC (1.00 ± 0.28 vs. 0.49 ± 0.13) and CASP1 (1.00 ± 0.26 vs. 
0.32 ± 0.03). In animals that displayed seizures, no differences between genotypes could be shown. 
Figure 3 │ Overexpression of urate oxidase reduces the expression of inflammatory markers in animals infused with 
Ringer’s solution, but does not seem to alter expression in animals infused with KA, although interpretation should be 
done with caution because of the high level of variation. mRNA expression levels are normalized relative to the geometric 
mean of the internal standard genes. For each gene, fold differences were calculated relative to the average expression levels in 
wildtype animals continuously infused with modified Ringer’s solution, which were set at 1. One outlier was removed based on the 
Grubb’s test (p<0.05). The results of the two-way ANOVA showed a main effect of seizures on the expression of ASC (p < 0.01), 
IL-1Ra (p < 0.05), IL-6 (p < 0.05) and TNF (p < 0.01); a main effect of treatment on the expression of ASC (p < 0.099; trend) and 
an interaction between seizures and genotype for CASP1 (p < 0.01). Small plot: Relative extracellular hippocampal uric acid 
concentration normalized to the average level in the BAS WT group. Bars represent mean ± SEM. BAS: baseline; RIN: modified 
Ringer’s solution; UOx OE: urate oxidase overexpressing; WT: wildtype KA: kainic acid. §(§), *(*) and #(#) indicate a statistical 
significant difference between the RIN (BAS) WT and RIN (BAS) UOx OE group; the RIN (BAS) WT and KA WT group and the 
KA WT and KA UOx OE group respectively. *,§,#p < 0.05, **,§§,##p < 0.01. 
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Effect of disruption of urate oxidase on seizure-induced inflammation 
The display of seizures was associated with an increased expression of IL-1α (1.00 ± 0.15 vs. 1.73 ± 
0.18), IL-1β (1.00 ± 0.39 vs. 2.72 ± 0.34), IL-1Ra (1.00 ± 0.21 vs. 5.46 ± 1.00), IL-6 (1.00 ± 0.32 vs. 
3.72 ± 1.08), TNF (1.00 ± 0.14 vs. 2.98 ± 0.46) and COX2 (1.00 ± 0.09 vs. 3.36 ± 1.11) in wildtype 
animals (Figure 4). In animals infused with Ringer’s solution, disruption of the UOx gene resulted in 
an increased expression of IL-1Ra (1.00 ± 0.21 vs. 2.72 ± 0.32) and a trend towards an increased 
expression of IL-1β (1.00 ± 0.39 vs. 2.11 ± 0.73) compared to wildtype animals. In animals that 
displayed seizures, disruption of the UOx gene resulted in a decreased expression of ASC (0.97 ± 
0.12 vs. 0.60 ± 0.08), CASP1 (0.87 ± 0.12 vs. 0.54 ±0.07), IL-1β (2.72 ± 0.34 vs. 1.65 ± 0.36), IL-1Ra 
(5.46 ± 1.00 vs. 2.68 ± 0.63) and a trend towards a decrease in the expression of TNF (2.98 ± 0.46 
vs. 2.28 ± 0.66). 
Figure 4 │ Disruption of urate oxidase increases inflammatory markers in animals infused with modified Ringer’s 
solution, but decreases the expression of these markers in kainic acid infused animals. mRNA expression levels are 
normalized relative to the geometric mean of the internal standard genes. For each gene, fold differences were calculated relative 
to the average expression levels in wildtype animals continuously infused with modified Ringer’s solution, which were set at 1. 
The results of the two-way ANOVA showed a main effect of seizures on the expression of NLRP3 (p < 0.078, trend), IL-1α (p < 
0.05), IL-6 (p < 0.01), TNF (p < 0.01) and COX2 (p < 0.01); a main effect of treatment on the expression of ASC (p < 0.05), CASP1 
(p < 0.05) and TNF (p = 0.090, trend) and an interaction between seizures and genotype for IL-1β (p < 0.01) and IL-1Ra (p < 
0.01). Small plot: Relative extracellular hippocampal uric acid concentration normalized to the average level in the BAS WT 
group. Bars represent mean ± SEM. RIN: modified Ringer’s solution; WT: wildtype; UOx KO: urate oxidase knock-out; KA: 
kainic acid. §(§), *(*) and #(#) indicate a statistical significant difference between the RIN (BAS) WT and RIN (BAS) UOx KO 
group; the RIN (BAS) WT and KA WT group and the KA WT and KA UOx KO group respectively. *,§,#p < 0.05, **,§§,##p < 0.01. 
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Discussion 
In a first study, we described a release of uric acid in the hippcoampus during seizure activity and an 
increased hippocampal inflammatory state one day after the induction of limbic seizures (see Chapter 
4). As uric acid has also been suggested to act as a pro-inflammatory danger signal, we examined 
whether manipulation of the seizure-induced uric acid release affects the inflammatory state one day 
after status epilepticus.  
A first finding was that allopurinol decreased seizure-induced inflammation. The lack of an effect in 
control conditions suggests that uric acid decreases in se does not affect inflammation despite the fact 
that uric acid levels are likely still suppressed up until the moment of RNA isolation, as oxypurinol, 
the active metabolite of allopurinol, has a half-life of 16-30 hours (Day et al., 2007). These findings 
seem to support the hypothesis that uric acid only acts on inflammation when there is damage and 
the associated acute increase in uric acid levels results in the formation of monosodium urate (MSU) 
crystals (Johnson et al., 2011, Rock et al., 2013). In the previous study, we showed that allopurinol 
reduced seizure generalization (Thyrion et al., 2016). As seizures are insults known to evoke an 
inflammatory response (Vezzani and Viviani, 2014), it is possible that the anti-inflammatory 
characteristics of allopurinol are indirectly due to the reduction of the number of generalized seizures 
rather than the consequence of a direct effect of reduced levels of uric acid. 
A second finding was that uric acid infusion increased the inflammatory state in animals that did not 
experience seizures, but failed to further contribute to the seizure-induced inflammatory response in 
animals infused with KA. That local uric acid infusion resulted in increased inflammation, 
consolidates our hypothesis that uric acid arrived in the brain in sufficient amounts to form MSU 
crystals (Thyrion et al., 2016). The fact that ASC and NLRP3 expression was similarly affected by 
uric acid, KA and KA + uric acid treatments indicates that this pathway is possibly saturated in KA 
infused animals at this point, preventing further uric acid increases from having any effect. These 
results suggest that an acute increase in uric acid is enough to evoke an inflammatory response, 
whether it is through infusion of uric acid or KA. 
A third finding was that overexpression of the UOx gene reduces the expression of ASC and CASP1 
in animals that did not experience seizures, which suggests that chronic uric acid decreases can 
induce a permanent decrease in the expression of inflammasome components. This reduction was 
however not sufficient to affect seizure susceptibility (Thyrion et al., 2016). Although the observed 
lack in difference between genotypes in KA-infused animals could suggest that a chronic reduction in 
uric acid levels does not prevent seizure-induced expression of inflammatory markers either, one 
needs to be cautious about drawing conclusions on the effect of UOx overexpression on KA-induced 
inflammation. Indeed, only TNF expression was significantly upregulated by KA infusion and there 
was a high level of variation in the KA groups for most markers. 
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A fourth finding was that disruption of UOx and chronically elevated levels of uric acid increased the 
expression of IL-1Ra (and possibly also IL-1β) in animals continuously infused with modified 
Ringer’s solution, but decreased the expression of these inflammatory markers in animals that 
experienced seizures. The latter is contradictory to what one could expect based on the increased 
number of generalized seizures in UOx KO mice, but could alternatively be related to the decrease in 
seizure susceptibility (i.e. seizure latency) in these animals.  
A limitation of this study was the low statiscital power, which resulted from the rather low, 
unequally distributed number of animals in several experimental groups and the high level of 
variation, especially in the UOx OE experiment. Variation was likely caused by an accumulation of 
technical and biological differences during the procedures leading up to RNA isolation, including 
surgery, probe implantation, treatment and seizure induction. Also differences in phenotypic 
expression of the genotype could contribute to the observed variability. Indeed, both baseline and 
induced uric acid levels could differ greatly in individual UOx OE and UOx KO animals. A second 
limitation of the study was that the KA-infused groups lacked a consistent alteration in 
inflammasome components, IL-1β and IL-18 expression, even when not taking into account the UOx 
OE data. Although this can be explained by variation in Ringer-infused control group in the 
allopurinol experiment for IL-1β and the biological significance of the found (statistically significant) 
reductions in expression is questionable in general for IL-18, this variation is more problematic for 
the interpretation of the ASC and NLRP3 data, where there was either a strong induction or none at 
all. This in turn may have been caused by intra- (Portelli et al., 2009) or extrastrain (McKhann et al., 
2003) differences, which are known to be able to affect seizure-related changes in neurophysiology. 
The UOx KO mice indeed had a mixed B6;129S7/J background, while the other animals had a pure 
B6 background. A final, more set-up related drawback of this study was that only one timepoint was 
included, while the inflammatory response is a highly dynamic process.  
Conclusions 
Our results show that only in the conditions where manipulation of uric acid levels resulted in the 
seizure-modifying effect, i.e. allopurinol treatment and UOx KO mice, an alteration in the post-
seizure inflammatory state was found. This suggests that the effect of uric acid manipulations on 
seizures rather than changes in uric acid levels itself are responsible for modulation of post-seizure 
inflammation. That both allopurinol treatment and UOx KO are associated with a downregulation of 
inflammatory markers, despite having opposing effects on seizure generalization, indicates that the 
mechanisms leading to a specific inflammatory profile are multiple.  
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Research Aims 
(1) develop and characterize a seizure model that allows to monitor the changes in local uric acid 
levels:  
(2) investigate the effects of pharmacological and genetic uric acid modulations on the seizure 
characteristics of this model 
(3) investigate the effects of these manipulations on the seizure-associated inflammatory 
response 
(4) examine if altering uric acid levels changes seizure characteristics in a different seizure 
model 
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Chapter 7 
Disruption, but not overexpression of urate oxidase 
alters susceptibility to pentylenetetrazole and 
pilocarpine induced seizures in mice 
 
Lisa Thyrion, Jeanelle Portelli, Robrecht Raedt, Griet Glorieux, Lars E. Larsen, Mathieu Sprengers, 
Wouter Van Lysebettens, Evelien Carrette, Jean Delbeke, Kristl Vonck, Paul Boon 
Epilepsia, In Press 
 
Abstract 
There is a continuous drive to find new, improved therapies that have a different mechanism of 
action in order to help diminish the sizable percentage of pharmacoresistant epileptic persons. Uric 
acid is increasingly recognized to contribute to the pathophysiology of multiple disorders and there 
are indications that uric acid might play a role in epileptic mechanisms. Nevertheless, studies that 
directly investigate its involvement are lacking. In this study we assessed the susceptibility to 
pentylenetetrazole- and pilocarpine-induced seizures in mice with genetically altered uric acid levels 
by targeting urate oxidase, which is the enzyme responsible for uric acid breakdown. We found that 
while disruption of urate oxidase resulted in a decreased susceptibility to all behavioral endpoints in 
both seizure models, overexpression did not result in any alterations when compared to their 
wildtype littermates. Our results suggest that chronic increase of uric acid levels may result in 
decreased brain excitability. 
 
Key words: pentylenetetrazole, pilocarpine, uric acid, urate oxidase, mice 
 
  
 
Introduction 
Although many persons with epilepsy are aided with the existing anti-epileptic drugs (AED), about 
30% remain resistant even after multidrug therapy. It has hence been suggested to focus on new 
AEDs that have a different mechanism of action than the ones currently available (Rogawski, 2006).  
Uric acid is a breakdown product of the purine metabolism that has been linked to an increasing 
number of disorders over the past decades(Alvarez-Lario and Macarron-Vicente, 2011). Increased 
serum uric acid levels are associated with gout, metabolic syndrome, cardiovascular disease, 
schizophrenia and bipolar disorder. Decreased serum uric acid levels are found in patients suffering 
from multiple sclerosis, Alzheimer’s and Parkinson’s disease. For many of these disorders there is a 
growing body of evidence that indicates that uric acid is not only a marker, but an active contributor 
to the underlying pathophysiology. In this regard, uric acid has been shown to be a therapeutic 
target in gout (Rock et al., 2013) as well as a therapeutic agent in multiple sclerosis (Markowitz et 
al., 2009).  
There are indications that uric acid might be involved in epilepsy as well. A number of clinical and 
preclinical epilepsy studies report elevated uric acid levels and, more importantly, suggest that 
lowering uric acid levels has anticonvulsant potential (Stover et al., 1997, Togha et al., 2007). 
However, its direct involvement has never been investigated thoroughly. 
The aim of this study was to assess the effect of uric acid on seizure susceptibility in the timed 
intravenous infusion seizure model, using genetically altered mice where urate oxidase (UOx), the 
enzyme responsible for uric acid breakdown, was targeted. Two different chemoconvulsants were 
infused to verify that potential seizure-modifying effects of uric acid manipulations were independent 
of the seizure-induction mechanism. In the first model seizures were induced by infusing 
pentylenetetrazole (PTZ), a GABAA-receptor antagonist. In the second model seizures were induced 
by pilocarpine, a muscarine receptor agonist (Vermoesen et al., 2011). 
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Material and methods 
Animals 
Hemizygous UOx overexpressing (UOx OE) mice (C57BL/6 background) were obtained from 
Kenneth Rock, Department of Immunology, University of Massachusetts, Worcester, USA. The 
UOx transgene in these mice is driven by a strong constitutive (β-actin) promoter (Kono et al., 2010). 
Homozygous UOx knock-out (UOx KO) mice were purchased from The Jackson Laboratory 
(B6;129S7/J background, Maine, USA) and crossbred. Offspring of these breedings were then 
genotyped for homozygosity and bred separately. The UOx KO mice have a constitutive disruption 
of the UOx gene, by insertion of a neomycin gene into exon 3. Allopurinol (200 mg/l) was provided 
in the drinking water of UOx KO breeding pairs and pups until 8 weeks of age to prevent lethality 
due to hyperuricemia (Wu et al., 1994). All mice were bred at the animal house of Ghent University 
Hospital and were housed at controlled temperature (21-22°C) and relative humidity (40-60%) 
conditions. They had a fixed 12-hour light/dark cycle (lights-on period from 7h to 19h) and food and 
water available ad libitum. Treatment and care were in compliance with guidelines from the 
European Committee (decree 86/609/EEC). The study protocol was approved by the Animal 
Experimental Ethical Committee of Ghent University (ECD 15/40). All animals were aged 3-5 
months when the experiment was performed. Different animals were used for the uric measurements. 
Uric acid measurements 
Anesthetized mice (n = 28, 6-8 in each genotypic group) were implanted with an obturator-enclosed 
guide cannula in the hippocampus (coordinates relative to bregma: anterioposterior: -3.3 mm ; 
mediolateral: -2.8 mm ; dorsoventral: -2.3 mm). A week after surgery, the obturator was replaced 
with a microdialysis probe (CMA/7; 2 mm membrane length; theoretical cut-off 6 kDa; CMA) which 
was continuously perfused with modified Ringer’s solution (147 mM NaCl, 2.3 mM CaCl2 and 4 mM 
KCl in ultrapure water, all Sigma Aldrich) at a flow rate of 1.25 µl/min. After an infusion period of 
minimum 12 hours, three dialysates of 50 minutes were collected (62.5 µl). Uric acid concentration 
was determined with an adaptation of the HPLC-method used by Fagugli and colleagues (Fagugli et 
al., 2002). In brief, 45 µl of dialysate was chromatographically separated on a reverse-phase C8 
column (3.5 µm, 150 mm x 4.6 mm, Waters) with an Ultrasphere ODS guard column (5 µm, 5 mm x 
4.6 mm, Beckman Instruments) using a linear gradient of methanol and ammonium formate buffer 
(50 mM, pH 3.0, 0 to 100% methanol in 15 min, 1 ml/min). Uric acid was analyzed by UV detection 
at 300 nm and quantified using calibration curves of standard solutions (Empower software, Waters). 
For concentrations below the limit of detection (LOD; 0.119 µM) the LOD itself was used. 
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PTZ and pilocarpine seizure threshold assessment 
Experiments were performed as described previously (Vermoesen et al., 2011). Mice were restrained 
to insert a 29 gauge needle into the tail vein, which was secured to the tail by adhesive tape. This 
was connected to a 2.5 ml Hamilton syringe mounted on an infusion pump (BASi) via polyethylene 
tubing (Novolab). Mice were infused with PTZ (7.5 mg/ml, Sigma Aldrich, n = 31) or pilocarpine 
(24 mg/ml, Sigma Aldrich, n = 32) at a flow rate of 0.125 ml/min, during which they were allowed 
to move freely in a Plexiglas cage (n = 7-9 in each genotypic group). The following behavioral 
endpoints of seizure activity were assessed: (1) PTZ: ear twitch, myoclonic twitch, forelimb clonus, 
falling (clonic convulsion with loss of righting reflexes), tonic hindlimb extension (THE) and death. 
(2) Pilocarpine: shivering, rearing, falling, THE and death. Latency from the start of PTZ or 
pilocarpine infusion until the onset of each endpoint was determined. Seizure threshold doses were 
calculated for each animal according to the following equation: dose (mg/kg) = [concentration 
(mg/ml) x infusion rate (ml/min) x infusion duration (min) x 1000 g]/ weight mouse (g)]. To 
minimize peripheral effects of pilocarpine, methyl scopolamine (1 mg/kg, Sigma Aldrich) was 
administered intraperitoneally 30 minutes prior to infusion. The investigator assessing the 
behavioral endpoints was blinded to the genotype.  
Statistical analysis 
All data are expressed as mean ± SEM. Mann-Whitney U tests were performed for comparisons of 
behavioral endpoints between experimental groups and their respective control groups. Differences 
were considered significant at the 5% level.  
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Results 
Targeting urate oxidase alters uric acid levels in the brain 
Extracellular uric acid levels in the brain of UOx KO mice and UOx OE mice were found to be 
respectively 5.5 times higher (Figure 1A) and 2.7 times lower (Figure 1B) than their respective 
wildtypes. 
 
Figure 1 │ Extracellular levels of uric acid in the hippocampus of urate oxidase (UOx) KO and OE mice and their 
respective wildtype (WT) controls. (A) Hippocampal uric acid levels in male UOx KO and WT mice, normalized to the 
average level in WT mice (B) Hippocampal uric acid levels in male UOx OE and WT mice, normalized to the average level 
in WT mice. Bars represent mean ± SEM. n = 6-8 for each group. *p < 0.05, Mann-Whitney U test. 
Disruption of urate oxidase decreases susceptibility to seizures induced by PTZ and 
pilocarpine infusion  
In UOx KO mice, seizure threshold was higher for all behavioral endpoints compared to their 
wildtype counterparts in both PTZ- and pilocarpine-induced seizure models. There was a significant 
effect of genotype on the threshold dose of PTZ for inducing ear twitch (WT: 38.6 ± 1.7 mg/kg; 
UOx KO: 62.7 ± 3.8 mg/kg), myoclonic twitch (WT: 47.8 ± 2.6 mg/kg; UOx KO: 69.8 ± 3.9 
mg/kg), forelimb clonus (WT: 60.3 ± 4.4 mg/kg; UOx KO: 83.6 ± 5.9 mg/kg), falling (WT: 73.5 ± 
3.0 mg/kg; UOx KO: 108.5 ± 4.5 mg/kg), THE (WT: 80.1 ± 4.6 mg/kg; UOx KO: 116.1 ± 2.7 
mg/kg) and death (WT: 89.5 ± 4.4 mg/kg; UOx KO: 126.1 ± 2.9 mg/kg) (Figure 2A). The 
difference in threshold dose of pilocarpine reached significance for shivering (WT: 86.3 ± 6.3 mg/kg; 
UOx KO: 128.7 ± 10.2 mg/kg), rearing (WT: 410.1 ± 19.0 mg/kg; UOx KO: 551.2 ± 17.2 mg/kg), 
falling (WT: 439.0 ± 19.6 mg/kg; UOx KO: 583.8 ± 17.3 mg/kg), THE (WT: 450.2 ± 20.9 mg/kg; 
UOx KO: 595.4 ± 16.9 mg/kg) and death (WT: 465.9 ± 20.8 mg/kg; UOx KO: 614.1 ± 17.9 mg/kg) 
(Figure 2B). 
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Overexpression of urate oxidase does not affect susceptibility to seizures induced by 
PTZ and pilocarpine infusion  
There were no significant differences between UOx OE mice and their wildtype littermates for any of 
the PTZ or pilocarpine induced behavioral endpoints (Figure 2C,D). 
Figure 2 │ Behavioral endpoints in urate oxidase (UOx) KO mice (A,B), UOx OE mice (C,D) and their wildtype 
controls after a timed (A,C) pentylenetetrazole (PTZ) and (B,D) pilocarpine tail infusion experiment. Bars represent 
mean seizure threshold doses ± SEM. n = 7-9 for each group. Mice are 3-5 months old. *p < 0.05, **p < 0.001, Mann-
Whitney U test. 
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Discussion 
Clinical and experimental studies mostly link high uric acid levels to epilepsy (Hamed et al., 2004, 
Hamed et al., 2007) and indicate that uric acid lowering drugs can be beneficial as add-on therapy 
(Zagnoni et al., 1994, Togha et al., 2007). Surprisingly, we demonstrated that disruption of the UOx 
gene results in a decreased susceptibility to all PTZ- and pilocarpine-induced behavioral endpoints, 
which suggest that chronically elevated levels of uric acid decrease brain excitability. 
Although the mechanism of action underlying the anticonvulsant-like effect of uric acid has yet to be 
elucidated, we can hypothesize that the anti-oxidative properties of uric acid are responsible for 
increasing seizure threshold. The involvement of oxidative stress in seizures, seizure susceptibility 
and epilepsy are increasingly recognized (Hosseini and Mirazi, 2015, Puttachary et al., 2015, Zhu et 
al., 2015). It has been shown that different anti-oxidants, including ascorbic acid, decrease seizure 
susceptibility to various chemoconvulsants, including pilocarpine and PTZ (Gonzalez-Ramirez et al., 
2010, Dong et al., 2013). As uric acid is known to inhibit the iron-dependent oxidation of ascorbate, 
higher uric acid levels might hence promote ascorbate function (Sevanian et al., 1991). In addition, 
uric acid dependent stabilization of anti-oxidative enzymes such as superoxide dismutase and 
scavenging of reactive oxygen species such as peroxynitrite could also contribute to the observed 
decrease in excitability (Kutzing and Firestein, 2008, Puttachary et al., 2015).  
Interestingly, in UOx OE mice the thresholds to the PTZ- and pilocarpine induced behavioral 
endpoints were not similarly decreased. This might be due to the fact that a minimum change in uric 
acid levels is necessary to affect seizure threshold and the phenotype was milder in UOx OE mice. 
Indeed, the reduction in brain uric acid levels was two- to threefold in UOx OE mice, compared to a 
fivefold increase in UOx KO mice. However, it is also possible that only a positive change in uric acid 
levels can evoke an effect on seizures, due to still unknown pharmacological mechanisms. 
Conclusion 
In summary, our results suggest that chronic elevation of uric acid levels due to disruption of urate 
oxidase increases seizure threshold in response to two chemoconvulsants. Most likely the anti-
oxidant effects of uric acid are responsible for these seizure-suppressing effects. Future studies in 
complementary (e.g. electrical) seizure models and chronic epilepsy models will be necessary to 
determine the significance of these results. 
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Chapter 8 
Conclusions, discussion and future perspectives 
 
 
Conclusions 
Due to the high percentage of pharmacoresistance in (temporal lobe) epilepsy, there is a continuous 
drive to search for therapies with a different mechanism of action and hence the need for a better 
understanding of the underlying pathophysiology. In this regard, there is an increased interest in 
inflammatory and (anti-) oxidative pathways to find potential new therapeutic targets. As uric acid is 
known to affect both processes and there are indications that it could play a role in epilepsy, we set 
out to investigate its role in experimental seizure models for the first time.  
In this thesis we have demonstrated the following: 
(1) The adapted version of the intrahippocampal KA model using microdialysis to infuse rather 
than inject KA, resulted in a limbic SE with clearly discernible clinical seizures and an 
inflammatory response a day later. Uric acid was released during SE and the markers of its 
inflammatory pathway were induced. The release of uric acid depended on the severity of 
limbic SE and correlated with the induction of NLRP3 expression. 
 
(2) In this model, blocking uric acid increases with allopurinol and raising uric acid levels 
through disruption of the UOx gene resulted in a twofold decrease and a twofold increase in 
the number of generalized seizures respectively. Uric acid infusion and overexpression of the 
UOx gene did not induce any electroclinical changes. UOx KO mice also displayed a delayed 
onset of the SE. 
 
(3) The day after limbic SE, only the seizure-modifying uric acid manipulations resulted in an 
altered inflammatory profile. Both allopurinol treatment and UOx KO mice had a reduction 
in the expression of several inflammatory markers. In the non-KA control animals, uric acid 
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infusion, overexpression and disruption of UOx altered the expression of several markers, 
while allopurinol did not influence the inflammatory profile. 
 
(4) Disruption of UOx resulted in a decreased seizure susceptibility in the PTZ and pilocarpine 
tail infusion seizure models. UOx OE mice did not alter the susceptibility when compared to 
their wildtype littermates. 
Discussion 
The increase of uric acid levels in the brain in response to a chemoconvulsant is in line with 
several previous reports (Beal et al., 1991, Layton et al., 1998, Oses et al., 2007, Rambo et al., 2013). 
Different factors could contribute to local increases in uric acid levels, such as seizure related 
neuronal injury, cell death and BBB leakage (Beal et al., 1991, Stover et al., 1997, Layton et al., 1998, 
Rambo et al., 2013). Cell damage and cell death result in the increased turnover of purine-containing 
molecules, such as DNA and RNA, into uric acid (Layton et al., 1998). BBB leakage distorts the 
relation between brain and serum uric acid levels, and as the latter has a tenfold higher 
concentration, this results in an inflow of uric acid in the brain (Tomioka et al., 2013). Importantly, 
in our study, the amount of uric acid release strongly correlated with the amount of spiking and 
largely paralleled the spiking activity over time, which might suggest it is a seizure related feature. 
This would be in line with a previous study where the extracellular uric acid levels doubled in the 
piriform cortex after intraperitoneal KA injection in rats. Analogous to our study, they found that 
the steady increase in uric acid aligned with seizure activity (Layton et al., 1998). Moreover, when 
they injected midazolam to block the seizures, uric acid increases were abolished, indicating it was 
independent from the direct excitotoxic effects of KA (Layton et al., 1998). It is unclear whether this 
also holds for our model, however, because the local concentration of KA and extent of the 
excitotoxic lesion in the intrahippocamal KA model is different compared to the intraperitoneal KA 
model (Levesque and Avoli, 2013). 
As we demonstrated a clear increase in uric acid levels and literature hinted on an anticonvulsive 
effect of uric acid decreases in clinical and experimental seizure models, we expected that our results 
would confirm that uric acid is a possible therapeutic target in epilepsy research. Although the 
results of this thesis indeed suggest that uric acid is more than an innocent bystander, they also 
show that the story is not that straightforward (Figure 1). On the one hand, allopurinol treatment 
and disruption of the UOx gene resulted in a twofold decrease and a twofold increase in the number 
of generalized seizures respectively, which suggest that uric acid can promote secondary 
generalization of seizures. Secondarily generalized tonic-clonic seizures (SGTCS) occur in 30% of 
the patients with refractory focal epilepsy and are a major cause of SUDEP (Hemery et al., 2014). A 
recent study suggested that targeting SGTCS might present an important parameter for add-on 
treatment choice in these group of patients (Hemery et al., 2014). In this regard, our results indicate 
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that targeting uric acid can be of particular interest in suppressing this type of seizures. This is in 
line with studies in patients with intractable epilepsy that found that allopurinol is most effective 
against SGTCS (De Marco and Zagnoni, 1988, Tada et al., 1991, Zagnoni et al., 1994, Togha et al., 
2007). On the other hand, we found that despite the promotion of seizure generalization, chronic 
increases of uric acid in UOx KO mice were associated with a delayed onset of the SE in the 
intrahippocampal KA model and a delayed onset to seizures in the PTZ and pilocarpine infusion 
seizure models. This indicates that chronically increasing uric acid levels increase seizure threshold 
and might have therapeutic potential as well.  
The question then arises how uric acid is able to affect these processes. Inflammation (Vezzani and 
Viviani, 2014) and recently also oxidative stress (Puttachary et al., 2015) are now recognized to 
increase neuronal excitability. Although speculative at this point, the effects of uric acid may be 
hence related to its pro-inflammatory and/or (anti-) oxidative traits (Kutzing and Firestein, 2008, 
Fang et al., 2013, Kang and Ha, 2014). Its anti-oxidative traits are likely the mechanism of action in 
the increase in seizure threshold observed in our models. As an anti-oxidant, uric acid can block the 
formation and actions of peroxynitrite, a powerful oxidant that causes oxidation/nitrosylation of 
proteins and DNA/RNA, inactivation of enzymes and the peroxidation of lipids (Pacher et al., 2007). 
Uric acid lowers peroxynitrite formation by preventing the degradation of superoxide dismutase, the 
converting enzyme of O2- (Kutzing and Firestein, 2008). Furthermore, uric acid can inhibit the iron-
dependent oxidation of the anti-oxidans ascorbate, preventing further increases of free radicals 
(Sevanian et al., 1991). In this regard, it has been shown that ascorbic acid can decrease seizure 
susceptibility to PTZ- and pilocarpine-induced seizures (Gonzalez-Ramirez et al., 2010, Dong et al., 
2013). Aside from these direct scavenging effects, the protective actions of uric acid against oxidative 
stress are suggested to be dependent on the upregulation of the glutamate reuptake transporter 
EAAT-1 by astrocytes, reducing the amount of extracellular levels of this excitatory 
neurotransmitter (Du et al., 2007). Uric acid has been shown to hamper disease progression due to 
its anti-oxidative abilities in neurodegenerative disorders such as multiple sclerosis, Parkinson’s and 
Alzheimer’s disease (Alvarez-Lario and Macarron-Vicente, 2011).  
The effects on seizure generalization might relate to its pro-inflammatory traits. Uric acid is 
believed to act as a pro-inflammatory danger signal in its crystallized form, which can increase brain 
excitability through activation of the IL-1β pathway (Vezzani et al., 2012). As uric acid is present at a 
higher concentration inside the cell (4 mg/ml) compared to the interstitial fluid compartment (6 
mg/dl), cell damage results in a steep increase in the local extracellular concentration. When the 
concentration exceeds the crystallization threshold (7 mg/dl), it crystallizes and engages the cell 
membrane. After phagocytosis it ruptures the endocytic vesicles, a process that activates the NLRP3 
inflammasome through yet an incompletely understood process (Rock et al., 2013). Activation of the 
inflammasome results in the cleavage and activation of caspase-1, which in turn converts pro-IL-1β 
and pro-IL-18 into their biologically active form. Importantly, uric acid is able to induce an 
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inflammatory response without inflammasome involvement as well, through Syk- and PI3-kinases 
(Ng et al., 2008, Kool et al., 2011).  
Our experimental set-up did not allow to determine if MSU crystals were present, and hence at this 
point in time, we cannot be certain that a crystal-induced inflammatory pathway is involved in 
seizure generalization. Not much is known about the formation of MSU crystals in vivo and even less 
outside the context of gouty arthritis, although the concentration of uric acid is considered a major 
contributing factor. In that regard, crystallization in the joint is assumed to occur above a threshold 
of 405 µM in humans (Rock et al., 2013), although it is becoming evident that the crystallization 
threshold is heavily dependent on other factors, such as temperature, pH, local calcium 
concentration, and mechanical stress. As such, gout is known to develop in patients with serum uric 
acid levels below 405 µM (Martillo et al., 2014). In a similar way, preclinical studies where increased 
uric acid levels were detected, crystallization was often assumed without the premise of reaching a 
certain threshold (Kono et al., 2010, Kool et al., 2011). It is also likely that the situation in in vitro 
studies or even in vivo studies in the joints, lungs or liver do not reflect the situation in the brain, as 
the local environment is completely different. Although crystallization is said to occur at a low pace 
in vivo, it is assumed that a sudden increase in uric acid concentration, as occurs during cell damage 
or cell death, can vastly promote crystal nucleation (Fiddis et al., 1983, Kono et al., 2010). In 
addition, in vitro studies suggest that growth starts immediately when MSU seeds are added to a 
supersaturated uric acid solution (Erwin and H., 1981). The fact that we were able to induce an 
inflammatory response upon infusion with uric acid, does suggest that at least in that condition, 
MSU crystals were formed in a 24-hour period. Together with the fact that in KA-animals, 
additional uric acid infusion did not increase NLRP3 expression above that in animals infused with 
KA alone, shows that the effects of these crystals already reached a maximum after KA-infusion. 
Assuming that MSU crystals are the driving factor of seizure generalization, the lack of effects after 
intrahippocampal uric acid administration and in UOx overexpression on the number of generalized 
seizures in the intrahippocampal KA model could be the result of a number of factors. First, 
intrahippocampal administration of uric acid might not have increased secondary generalization of 
hippocampal seizures because it did not diffuse far enough to affect brain regions responsible for 
seizure generalization, such as thalamus and substantia nigra (Gale, 1992, Blumenfeld et al., 2009, 
Yoo et al., 2014). In contrast, increases in uric acid levels are likely to extend beyond the region of 
the microdialysis probe in UOx KO mice (Chen et al., 2013). Secondly, the UOx OE mice displayed 
only a modest phenotype. Seizure-induced release of uric acid in these animals was not blocked to the 
same extent as with allopurinol treatment. There was still an induction of uric acid which at peak 
level was in average 1.5 times higher than baseline levels. Moreover, compared to UOx KO mice, the 
chronic change in uric acid levels was smaller (twofold vs. fivefold) and perhaps too small to evoke 
any effect. However, it remains to be determined if the steep increase in extracellular levels of uric 
acid is associated with sufficient crystallization to affect SE characteristics within the range of our 
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experiment. In this regard, it remains possible that MSU crystals are only formed in the UOx KO 
mice, where an acute increase in uric acid levels is superimposed onto chronically elevated uric acid 
levels. In that scenario the effects of allopurinol treatment did not directly relate to a decrease in uric 
acid levels but rather to other effects of blocking xanthine oxidase, such as increases in adenosine and 
inosine, which both have been reported to reduce seizure susceptibility (Boison, 2012, Kovacs et al., 
2015).  
A last explanation for our data could be that the acute release in uric acid does affect seizure 
generalization, but through a MSU-independent pro-oxidative pathway. There are several 
indications that its anti-oxidative actions are limited to the hydrophilic environment of biological 
fluids, such as plasma. In this regard, intracellular uric acid is believed to mainly contribute to 
oxidative stress, as shown in cultured cells and animal models of renal and vascular disease (Sautin 
and Johnson, 2008, Alvarez-Lario and Macarron-Vicente, 2011, Kang and Ha, 2014). As a pro-
oxidant, it has been suggested that the different radicals of uric acid can increase oxidative damage, 
mainly to lipids, by reacting with other radicals. In addition, it has been shown that it is able to 
engage an intracellular system of superoxide generation by NADPH oxidase. The intermediate steps 
leading to NADPH oxidase activation are still incompletely understood, although it has been put 
forward that its pro-inflammatory characteristics again might be involved (Sautin and Johnson, 
2008). 
 
Figure 1 │ Summary of our most important results (full lines) and the suggested potential role (dashed lines) of 
uric acid in seizure generation and seizure-associated inflammation. ~ indicates correlation between seizure severity 
and uric acid release. Red, green and grey line color indicates inhibitory, stimulatory and complex actions respectively. The 
complex action concerns the interplay between changes in seizure onset, seizure generalization and other factors in 
determining inflammatory outcome. MSU: monosodium urate; NLRP3: NOD-like receptor family, pyrin domain containing 
3; IH-KA: intrahippocampal kainic acid; TIS: timed intravenous infusion seizure. 
Our results suggest that uric acid has a dual role in seizures. In se it is not abnormal for one 
molecule to have multiple functions. It is actually a fairly common phenomenon which exemplifies 
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how complex and dynamic most disease processes are. TNF for example, has been reported to harbor 
both ictogenic and neuroprotective effects, through the receptor TNFR1 and TNFR2 respectively. 
The progressive reduction in TNFR2 expression and concomitant increase of TNFR1 that has been 
reported in animal models of epilepsy, shifts the balance towards the excitotoxic effects of this 
cytokine (Iori et al., 2016). However, it is difficult to explain how it is possible that both functions of 
the same molecule are expressed in the same model simultaneously, as found in the UOx KO mice. 
Perhaps these mice have an a priori lower susceptibility for seizures due to the increased anti-oxidant 
potential associated with elevated uric acid levels, but is the switch turned when an insult abruptly 
increases uric acid levels above crystallization threshold which then promotes its pro-inflammatory 
actions. However, the fact that our results suggest that these animals had an increased expression of 
IL-1Ra – and possibly IL-1β – compared to control animals, does indicate that MSU crystals might 
be already present in UOx KO animals, which could indicate that this turning point would concern a 
relative increase in the number MSU crystals, rather than crossing the crystallization threshold 
itself. Nevertheless, this is not necessarily the case, as the induction of IL-1Ra mRNA might also 
represent an increased anti-inflammatory potential, what could be in concordance with the delayed 
latency in these animals. Seizure initiation and seizure propagation might then be affected differently 
because the anti-oxidant and pro-inflammatory pathways engage distinct networks (Pinto et al., 
2005), although the level of the independence of these networks is still a matter of debate (Dudek, 
2006).  
The lack of a facilitating effect of increased uric acid levels on the threshold of generalized seizures in 
the PTZ and pilocarpine infusion seizure models could probably be explained by the completely 
different spatial and temporal dynamics in the infusion seizure models compared to the 
intrahippocampal KA model. In the infusion models the proconvulsant substances result in 
generalized seizures and subsequent death after three (pilocarpine) to five (PTZ) minutes. In the 
intrahippocampal KA model, KA is only infused in the hippocampus and the secondary generalized 
seizures only appear after tens of minutes to hours. It is likely that the time window in the infusion 
models does hence not allow to see the effects of the pro-oxidative/pro-inflammatory actions of 
seizure-induced uric acid increases, but only the effect of differences in the baseline uric acid 
concentration. Moreover, PTZ is known to affect the whole brain immediately, resulting in primary, 
not secondary generalized seizures (Loyens et al., 2012).  
Regarding seizure-associated inflammation we showed that one day after KA the hippocampal 
expression of inflammasome components NLRP3 and ASC was induced and that the induction of 
NLRP3 expression positively correlated with the amount of uric acid released during SE. This 
suggests that decreasing uric acid levels during SE might hamper the subsequent epileptogenic 
process. NLRP3 knock-down was recently shown to result in neuroprotection, decreased 
inflammation and suppression of the development and severity of spontaneous recurrent seizures 
(Meng et al., 2014). The results of our third study, where only the seizure-modifying uric acid 
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manipulations resulted in an altered inflammatory profile the day after KA infusion, however, 
suggest that the effect of uric acid modulation on inflammation may be largely indirect through its 
effect on seizure activity. Indeed, NLRP3 expression also correlated with epileptic spiking to some 
extent in our first study.  
Future Perspectives 
As many questions remain, more in-depth evidence is needed to further confirm a role for uric acid 
and to unravel the conditions and mechanisms involved in its pro- and anticonvulsant effects. 
There are some initial points of interest that call for future studies. First, all of our work in the 
intrahippocampal KA model was done on the ipsilateral side only. It would be interesting to also 
investigate the contralateral side, where seizures occur but direct toxic effects of KA are absent 
(Pernot et al., 2011). If uric acid levels show a similar profile compared to the ipsilateral side, this 
would consolidate the hypothesis that uric acid release is a direct consequence of seizure activity and 
not KA-induced cell death (Stover et al., 1997, Layton et al., 1998, Pernot et al., 2011). The release of 
other endogenous danger molecules have been shown to be both seizure-dependent (e.g. ATP (Dale 
and Frenguelli, 2009)) and cell-death dependent (e.g. HMGB1 (Luo et al., 2014)). With regard to 
seizure-associated inflammation, analyzing the contralateral inflammatory response would also 
eliminate the confounding KA factor, and would allow for a more direct investigation of the 
relationship between seizures, uric acid and the expression of cytokines and inflammasome 
components. It is to be expected that the response will be generally milder here, as the inflammatory 
and structural changes are most pronounced on the ipsilateral side in the intrahippocampal KA 
model (Pernot et al., 2011).  
Secondly, the visualization of MSU crystals could support an immune-based theory of seizure 
manipulation by uric acid and would be highly interesting for uric acid research in general. There are 
multiple procedures for the visualization of MSU crystals in the human joint and dermis, including 
histological and imaging techniques, as means to diagnose and monitor gouty arthritis 
(Parathithasan et al., 2016). Histologically, the demonstration of negatively birefrigent, needle-
shaped MSU crystals in eosin-stained samples using polarized microscopy is the most generally used 
method (Shidham et al., 2001). Imaging techniques include radiography, ultrasonography, 
conventional and dual energy CT and MRI (Dalbeth et al., 2012). However, to our knowledge, MSU 
crystallization has never been actually demonstrated in preclinical models, not for gout, nor for any 
other condition related to hyperuricemia. The most frequently used model for gout involves the 
injection of MSU crystals rather than awaiting their natural development (Moilanen et al., 2015), 
something that has been accepted in other research fields as well, e.g. the fields of asthma and liver 
injury (Kono et al., 2010, Kool et al., 2011). Conversely, crystallization is presumed when an increase 
in uric acid is observed (Kono et al., 2010, Kool et al., 2011). It would hence be interesting to 
optimize staining and/or imaging techniques for use in mice to confirm that MSU crystals are 
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indeed present in vivo and investigate the specific requisites for their development. One could then 
also examine if MSU crystals are present in pre- and post-KA brain tissue of UOx KO animals. 
Lastly, it is also worthwhile investigating further whether allopurinol could be used as add-on 
therapy for SE. Similarly to epilepsy, 30% of the SE cases are refractory to the first line of 
treatment. As it is a life-threatening emergency associated with a high morbidity and mortality, also 
here the need for new treatments with a different approach is high (Treiman, 2008, Gordon Boyd et 
al., 2012, Trinka and Shorvon, 2013). In that regard it would be interesting to examine if the SE 
severity or post-SE neuronal damage could be decreased when allopurinol is administered after SE 
induction, to probe its therapeutic potential. Subsequently, it could be tested in other chemically or 
electrically induced convulsive SE models, such as the intrahippocampal pilocarpine model (Portelli 
et al., 2012) or the perforant path stimulation model (Mazarati et al., 1998), alone or added to a 
cocktail of established treatments (Loscher, 2015). It would also be interesting to examine if the 
effectiveness of allopurinol is increased in hyperuricemic conditions, e.g. in UOx KO mice. Positive 
studies in SE models could then be extended to chronic models to re-evaluate its potential as an add-
on treatment for standard AEDs. Even if the effects of allopurinol turned out to be only partly 
dependent on uric acid, this would still be an interesting line to persue. 
This brings us to the next step in uncovering a role for uric acid in epilepsy. The seizure models we 
used in this thesis are relevant for studying the development, maintenance and termination of acute 
seizures. However, as these models are established in a healthy brain, they do not represent a 
chronic epileptic condition and hence do not give information on the mechanisms underlying 
epileptogenesis or ictogenesis (Pitkanen et al., 2006). It would hence be of interest to monitor 
serum/local uric acid levels and analyze the effects of uric acid manipulations at different timepoints 
after the intrahippocampal induced SE on the characteristics of spontaneous seizures. It might be 
that the increase in uric acid is limited to the SE which puts into motion a transient/permanent 
change in the inflammatory and/or oxidative state that alters the neuronal network, but that this is 
its only point of influence. However, another possibility is that the SE-associated neurodegeneration 
(Pernot et al., 2011) and spontaneous seizures stimulate additional uric acid release which could 
result in a sustained higher level of uric acid in the chronic phase, as found in serum of epilepsy 
patients (Hamed et al., 2004, Hamed et al., 2007). Perhaps the duality of uric acid function has a 
dynamic profile, and there is a specific time window to target or administer uric acid. Important here 
is that we will need to determine first if spontaneous recurrent seizures occur in our model, but a 
previous pilot trial in our group suggests this is indeed the case (Van Loo, 2011). Alternatively, the 
regular intrahippocampal KA model can be used (Pernot et al., 2011).  
Prior to the post-SE model one could consider the less labor-intensive kindling model, in which the 
hippocampus or amygdala is repeatedly stimulated chemically or electrically with an initially 
subconvulsive dose/pulse (Pitkanen et al., 2006). Each kindling stimulation evokes an epileptic 
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seizure, which increases in duration and severity, until the animal is fully kindled. This is a 
permanent state in which a generalized tonic-clonic seizure can be evoked with only one to a few 
stimulations. The seizure threshold is considered to reflect seizure susceptibility, the progression to 
the kindled state the epileptogenic process, and the fully kindled seizures the ictogenic events. Like 
the post-SE model, the kindling model is a focal model with secondary generalization, and used as a 
representation of pharmacoresistant TLE, where the need for new therapy development is the 
strongest (Pitkanen et al., 2006).  
To next uncover the mechanism of action of uric acid-induced effects on seizures and epilepsy, 
many techniques can be employed and numerous experiments can be set up. In this regard, it would 
be ideal to analyze the effects of acute and chronic uric acid changes in a combination of ex vivo, in 
vitro and in vivo models, while optionally blocking-disrupting/adding-overexpressing relevant 
receptors/players. In this way a broad range of complementary data can be collected to confirm a 
role for uric acid and maximize insight into its function. Ex vivo experiments could entail the 
comparison of chemoconvulsant-induced epileptiform activity in hippocampal slices of UOx KO and 
their wildtype counterparts (Portelli et al., 2012). To gain insight into its mechanism of action, the 
presumed pathways could then be blocked, for example by co-infusing UOx KO brain slices with 
inhibitors for NLRP3 (e.g. isoliquiritigenin) or the IL-1β receptor (e.g. anti-mouse IL-1β antibodies) 
to target the inflammatory pathway, or by adding ascorbate to target the oxidative pathway. Vice 
versa it would also be of interest to analyze if uric acid changes still affect epileptiform activity in 
mice lacking the NLRP3 gene. In vitro set-ups can aid in the determination of the cellular 
components of the uric acid mediated response, by analyzing the effects of uric acid on neuronal, 
microglial or astroglial function in pure or mixed cell-cultures. For example, one could analyze the 
difference in morphology and functionality of cells originating from UOx OE and UOx KO mice 
(Panicker et al., 2015) or examine the cytokine profile after uric acid addition in cells of mice lacking 
the NLRP3 gene. A dose-response curve of uric acid could then be useful in determining if e.g. 
cytokine expression is dependent on its concentration and form. In vivo, it would be of high interest 
to examine the oxidative and inflammatory state of the brain in naive and in KA-infused UOx KO 
mice at various timepoints. Oxidative parameters could include lipid peroxidation, presence of ROS 
and glutathione levels (Puttachary et al., 2015). Inflammatory parameters could include the 
visualization and overlay of potentially involved cellular and molecular markers via fluorescent 
immunohistochemistry. Using this technique the intramicroglial location and activation of the 
NLRP3-inflammasome was shown in a preclinical model of Alzheimer’s disease (Heneka et al., 2013). 
In addition, it would be worthwhile to look into the expression and release of cytokines, chemotactic 
and phagocytotic abilities and overall mobility of microglia in response to the presence of MSU 
crystals (Krabbe et al., 2012), as these crystals might specifically act as an ‘on-signal’ for microglia 
(Biber et al., 2007). Similarly, examining if the anti-oxidant effects are dependent on astrocytic 
glutamate transport, as was shown for spinal cord injury (Du et al., 2007), could shed light on the 
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involvement of this cell type. To investigate if the BBB is involved in a uric acid mediated response, 
BBB leakage between e.g. UOx KO/OE animals and their wildtype counterparts could be compared 
(van Vliet et al., 2016). As age is an important factor in excitability, this should be taken into account 
when conducting experiments and interpreting results (Kelly, 2010). Together, these and follow-up 
experiments may uncover the determinants in the effect and nature of uric acid’s actions on 
excitability.  
Uric acid is a metabolic product and not a protein resulting from a targetable gene. As a result its 
levels can mostly be manipulated indirectly only, by targeting the enzymes responsible for its 
production (xanthine oxidase) and breakdown (urate oxidase – UOx). Although the uric acid 
manipulations used in this dissertation are valuable, they have drawbacks. In general, the BBB is the 
biggest problem in systemic manipulations, as one does not exactly know the dynamics and extent of 
the corresponding changes in uric acid levels of the brain. This is an issue when one would want to 
pharmacologically target the liver-specific UOx enzyme (128 kDa), e.g. when blocking it through 
administration of potassium oxonate or when administering it directly (Wan et al., 2015). 
Intravenous uric acid administration has been shown to affect brain insults in a previous study on 
ischemia, but the local uric acid levels were not investigated (Romanos et al., 2007). Allopurinol, a 
xanthine oxidase-blocking agent, can cross the BBB due to its small size (0.136 kDa), but has the 
drawback of being rather nonspecific (Kim et al., 1987). Genetically targeting the UOx gene, as we 
did, has the advantage that it alters uric acid level in a specific way, and also manages to do so locally 
in the brain. However, a drawback here is that a permanent alteration of UOx activity only allows to 
investigate chronic uric acid changes and one can never exclude that compensatory mechanisms take 
place in these animals. Moreover, in the mice we used the entire animal was targeted, rather than 
only the area of interest. Local uric acid infusion has the advantage of only locally affecting uric acid 
levels, but has the drawback that it is labor-intensive and cannot be continued for long periods of 
time. Furthermore, we do not know how far uric acid diffuses in the brain and hence which areas are 
influenced. For an elaborate and unequivocal investigation of uric acid changes – especially in 
epileptogenesis and ictogenesis studies – one could consider developing inducible and/or conditional 
transgenic and knock-out animals for future experiments – if funding and manpower allows it. By 
manipulating the time- and/or location-dependent expression of UOx, one could gain much insight 
into the ‘where and when’ of its involvement. This can for example be achieved by using a Cre-Lox 
system that is transcriptionally controlled by a Tet-On system that itself is under the control of a 
cell type-specific promotor (e.g. NeuN for neurons) (Gunschmann et al., 2014). However, as the 
development of these models is expensive, it is likely that complementary pharmacological and 
genetic models like we used here will be the only option.  
Clinically, it would be worthwhile to further investigate whether higher uric acid levels occur more 
in untreated epilepsy patients than in healthy controls, to see if there is an association. In contrast to 
what was done in previous studies, it will be important that a clearcut postictal interval is respected 
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before blood is collected, and that patients are fasted overnight, to avoid dietary-induced variation in 
purine metabolism. Several subpopulations should also be considered that are clearly delineated in 
age, sexe, epilepsy syndrome, seizure type, etc. to avoid overlooking possible subcorrelations. 
Checking whether gout develops more in epilepsy patients or vice versa can give further credence to 
a uric acid based hypothesis. Measuring uric acid levels in surgery-obtained brain specimens of drug-
resistant epilepsy patients would be of particular interest, as this has strengthened the involvement 
for other danger signals in the past (Maroso et al., 2010). The presence of MSU crystals and 
increased NLRP3 expression in epileptic brain tissue could also be considered indicative for the 
involvement of a uric acid-dependent inflammatory pathway. 
A last important note on the translation of the experimental results on uric acid to the clinic is that 
there is a genetic difference in uric acid biology between humans and mice. Humans lack the UOx 
gene and hence have higher SUA levels (> 2.0 mg/dL) compared to mice (< 2.0 mg/dL) (Johnson et 
al., 2011). The expression of UOx is liver-specific, but with the existing correlation between uric acid 
levels in the brain and serum, this cannot be simply ignored (Tomioka et al., 2013). So although 
studying uric acid in experimental models can give fundamental insights into its involvement, as it 
did for Parkinson’s disease (Chen et al., 2013), multiple sclerosis (Hooper et al., 2000), asthma (Kool 
et al., 2011) and liver injury (Kono et al., 2010), preclinical data should always be interpreted with 
caution and should with no means be translated to the human condition without further 
confirmation. One could consider using UOx KO mice as the starting point for all further 
investigations, but as these animals underwent a forced genetic loss rather than an evolutionary loss 
of UOx, this would likely not represent the human condition either. Indeed, disruption of UOx KO is 
associated with nephropathy-induced death at young age in mice, if not treated with allopurinol, 
which is not the case in humans (Wu et al., 1994). Lastly, it should be noted that the bias in 
preclinical studies to solely use male animals also needs to be kept in mind when trying to translate 
results to humans. There is a difference in SUA levels between men (370 µM) and women (291 µM), 
which may be present in mice as well (Fang and Alderman, 2000).  
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Summary 
Epilepsy is a disabling chronic neurological disorder characterized by the occurrence of unprovoked 
seizures, which result from abnormal excessive or synchronous activity of neuronal populations in 
the brain. As it affects 65 million people worldwide and has a substantial negative impact on the 
patient’s life, it is considered a major public health concern. The first line of treatment entails the 
administration of anti-epileptic drugs (AEDs), and although they alleviate the symptoms in many 
patients, one third remains refractory, even after multi-drug therapy. A particularly refractory type 
of epilepsy is temporal lobe (limbic) epilepsy (TLE). TLE often develops after an initial precipitating 
event such as head trauma, encephalitis or status epilepticus (SE), which causes a set of molecular 
and cellular changes in the neuronal network that increase excitability. As the existing AEDs act 
purely symptomatic and mostly target the imbalance in excitatory and inhibitory neurotransmission, 
finding effective therapies with a different mechanism of action is of high priority in epilepsy 
research. This prompt the need for a better understanding of the underlying pathophysiology and 
hence requires extensive research in animal models. 
Targeting the increased inflammatory state associated with epilepsy is considered a promising 
strategy in epilepsy therapy development and recently also oxidative stress has become a field of 
interest. Uric acid is a purine breakdown product that has been shown to influence the 
pathophysiology of an increasing number of disorders, both through inflammatory and (anti-) 
oxidative pathways. Several clinical and experimental studies in epilepsy have reported elevated uric 
acid levels and suggest that lowering uric acid has anticonvulsive potential. Together, this implies 
that uric acid could be an active player in epilepsy, but its direct involvement was never examined. 
The aim of this thesis was hence to investigate a role for uric acid in experimental seizure 
models. 
We developed and characterized an adapted version of the intrahippocampal kainic acid model for 
limbic SE, that allowed us to monitor extracellular changes in local uric acid levels during seizure 
activity, using microdialysis. Infusion of kainic acid resulted in a limbic SE with clinical seizures, and 
was associated with hippocampal inflammation a day later. The objective of our first study in this 
model was to analyze the seizure-induced changes of uric acid levels and the expression of markers of 
the NLRP3 inflammasome pathway, the best described inflammatory pathway triggered by uric acid. 
We showed that uric acid is released during SE and that the markers of its inflammatory pathway 
are induced the day after kainic acid infusion. Moreover, the release of uric acid depended on the 
severity of limbic SE and correlated with the induction of NLRP3 expression. 
In a second study we aimed to unravel the contribution of uric acid to seizure generation, by 
analyzing the effects of pharmacological and genetic uric acid modulations on the seizure 
characteristics of the abovementioned model. Pharmacologically, we decreased uric acid levels using 
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allopurinol, an inhibitor of xanthine oxidase, the enzyme responsible for conversion of hypoxanthine 
into uric acid. We increased uric acid levels by infusing uric acid into the hippocampus. Genetically, 
we targeted urate oxidase (UOx), the enzyme responsible for the breakdown of uric acid. We used 
UOx overexpressing (OE) and UOx knock-out (KO) mice to respectively decrease and increase uric 
acid levels. We found that allopurinol treatment and disruption of the UOx gene resulted in a 
twofold decrease and a twofold increase in the number of generalized seizures respectively. 
Together, these results suggest that uric acid promotes secondary generalization of seizures. 
However, as the reasons for the lack of effect in animals infused with uric acid and mice 
overexpressing UOx can be multiple and are unknown at this point, the exact conditions necessary to 
evoke a uric acid-mediated effect remain elusive. Moreover, uric acid likely exerts both proconvulsive 
and anti-convulsive effects, as enhanced pre-seizure levels of uric acid in the UOx KO mice delayed 
the onset of the SE. 
The brain tissue of these animals was subject of a third study, which investigated the effects of these 
four uric acid manipulations on seizure-associated inflammatory response in the hippocampus one 
day after seizure induction. Relevant inflammatory markers and components of the NLRP3 
inflammasome were analyzed. Our results suggest that only the seizure-modifying conditions, i.e. 
allopurinol treatment and UOx KO mice, are associated with an alteration in the post-seizure 
inflammatory state. This would indicate that effects of uric acid manipulation on seizure-associated 
inflammation are mainly modulated by indirect effects on seizure activity. That both conditions are 
associated with a decreased expression of inflammatory markers, despite having opposing effects on 
seizure generalization, indicates that the mechanisms leading to a specific inflammatory profile are 
multiple. 
In a fourth study, we analyzed if altering uric acid levels could change seizure characteristics in a 
second model, the timed intravenous infusion seizure model. More specifically we assessed the 
susceptibility of UOx OE and UOx KO mice to pentylenetetrazole- and pilocarpine-induced seizures. 
We found that while disruption of UOx resulted in a decreased seizure susceptibility in both models, 
overexpression did not result in any alterations compared to the wildtype littermates. This suggests 
that a chronic increase of uric acid levels may result in an increased seizure threshold. 
Taken together, our results indicate that uric acid is more than an innocent bystander in seizure 
generation and its associated inflammatory response, but also suggest that the nature of its 
involvement is complex and possibly dual. On the one hand, the suppression of seizure 
generalization and reduction in seizure-induced inflammation when uric acid is decreased implies 
that it can be considered a therapeutic target. On the other hand, the increase in the latency to the 
first seizure and reduced inflammatory response to increases in uric acid, suggest exactly the 
opposite. More in-depth evidence will be needed to unravel the conditions and mechanisms in which 
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uric acid exerts pro- and anticonvulsive effects, but as it would potentially offer novel insights and 
therapy options, we believe it to be of great interest to conduct further research. 
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Samenvatting 
Epilepsie is een chronisch neurologische aandoening die gekarakteriseerd wordt door het voorkomen 
van spontane epileptische aanvallen, die ontstaan door het excessief of hypersynchroon vuren van 
neuronale populaties in de hersenen. Omdat wereldwijd meer dan 65 miljoen mensen lijden aan 
epilepsie en de ziekte een uiterst negatieve impact op het leven van de patiënt heeft, wordt epilepsie 
beschouwd als een groot gezondheidprobleem. De eerstelijnsbehandeling is het toedienen van anti-
epileptische geneesmiddelen (AEGs), en ondanks het feit dat veel patiënten hiermee geholpen zijn, 
blijft één derde refractair, zelfs wanneer meerdere AEGs gecombineerd worden. Een bijzonder 
refractaire vorm van epilepsie is hierbij temporale kwab (limbische) epilepsie (TKE). TKE ontwikkelt 
zich vaak na een initieel precipiterend insult, zoals een hoofdletsel, encefalitis of status epilepticus 
(SE). Dit brengt een reeks moleculaire en cellulaire veranderingen in het neurale netwerk tot stand 
die leiden tot een verhoogde exciteerbaarheid. Omdat de bestaande AEGs louter symptomatisch 
werken en zich meestal rechtstreeks richten op het onevenwicht tussen exciterende en inhiberende 
neurotransmissie, is de zoektocht naar nieuwe doeltreffende therapieën met een ander 
werkingsmechanisme van hoge prioriteit binnen epilepsie onderzoek. Hierbij is het nodig de 
onderliggende pathofysiologie beter te begrijpen, wat uitgebreid preklinisch onderzoek vereist. 
Een veelbelovende strategie in de ontwikkeling van nieuwe AEGs is het beïnvloeden van de 
verhoogde inflammatoire staat die gepaard gaat met epilepsie en ook oxidatieve stress krijgt recent 
steeds meer aandacht als potentieel therapeutisch doelwit. Urinezuur, een afbraakproduct van het 
purine katabolisme, wordt in groeiende mate erkend als spelende factor in the pathofysiologie van 
verschillende aandoeningen, via zowel inflammatoire als (anti-)oxidatieve mechanismen. 
Verschillende klinische en preklinische studies rond epilepsie hebben verhoogde urinezuurniveaus 
aangetoond en suggereren dat het verlagen ervan een anticonvulsief potentieel heeft. Dit alles geeft 
aan dat urinezuur een actieve rol kan spelen in epilepsie, maar de directe betrokkenheid ervan werd 
nooit onderzocht. Het doel van deze thesis was dan ook om de rol van urinezuur in experimentele 
aanvalsmodellen na te gaan. 
We hebben een aangepaste versie van het intrahippocampaal kainaat model voor limbische SE 
ontwikkeld en gekarakteriseerd, dat ons toeliet om de extracellulaire veranderingen in de lokale 
urinezuurconcentratie te monitoren tijdens de aanvalsactiviteit, door middel van microdialyse. 
Infusie van kainaat resulteerde in een limbische SE met klinische aanvallen, en was geassocieerd met 
hippocampale inflammatie een dag later. Het doel van onze eerste studie in dit model was om 
aanvalsgeïnduceerde veranderingen in urinezuurniveaus na te gaan, alsook de expressie van merkers 
van de NLRP3 inflammasoom pathway, wat de best beschreven inflammatoire pathway is die 
geactiveerd wordt door urinezuur. We toonden aan dat urinezuur vrijgesteld wordt tijdens SE en dat 
de expressie van de merkers van zijn inflammatoire pathway geïnduceerd worden de dag na 
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kainaatinfusie. Bovendien was de vrijstelling van urinezuur afhankelijk van de ernst van de SE en 
correleerde dit met de inductie van NLRP3 expressie. 
In een tweede studie hebben we getracht de betrokkenheid van urinezuur in aanvalsontwikkeling te 
bepalen, door het effect van farmacologische en genetische urinezuurmodulaties op de 
aanvalseigenschappen na te gaan. Farmacologisch hebben we de urinezuurniveaus verlaagd door 
gebruik te maken van allopurinol, een inhibitor van xanthine oxidase, het enzym verantwoordelijk 
voor omzetting van hypoxanthine in urinezuur. Een stijging in urinezuurniveaus werd bekomen 
door urinezuur via de microdialyse probe in de hippocampus te infuseren. Genetisch hebben we uraat 
oxidase (UOx) gemanipuleerd, het enzym verantwoordelijk voor de afbraak van urinezuur. Hierbij 
hebben we UOx overexpresserende (OE) en UOx knock-out (KO) muizen gebruikt om de 
urinezuurniveaus respectievelijk te verlagen en te verhogen. We vonden dat een behandeling met 
allopurinol en de uitschakeling van UOx resulteerde in respectievelijk een tweevoudige daling en een 
tweevoudige stijging in het aantal gegeneraliseerde aanvallen. Samen suggereren deze resultaten dat 
urinezuur secundaire generalisatie promoot. Het gebrek aan effect in dieren geïnfuseerd met 
urinezuur en dieren die UOx overexpresseren kan meerdere oorzaken kennen, waardoor de exacte 
condities waarin urinezuur dit effect veroorzaakt, evenwel onopgehelderd blijven. Bovendien heeft 
urinezuur waarschijnlijk zowel pro- als anticonvulsieve effecten, aangezien de verhoogde 
urinezuurniveaus in de UOx KO dieren resulteerden in een latere start van de SE. 
Het hersenweefsel van deze dieren werd gebruikt in een derde studie, waarin onderzocht werd wat 
het effect is van deze vier urinezuurmanipulaties op de aanvalsgeassocieerde inflammatoire respons 
in de hippocampus een dag na aanvalsinductie. Relevante inflammatoire merkers en componenten 
van het NLRP3 inflammasoom werden geanalyseerd. Onze resultaten suggereren dat enkel die 
condities die een effect hadden op aanvallen, i.e. de behandeling met allopurinol en de UOx KO 
dieren, de aanvalsgeassocieerde inflammatoire staat beïnvloedden. Dit doet vermoeden dat het effect 
van urinezuur op manipulatie van aanvalsgeassocieerde inflammatie voornamelijk indirect 
gemoduleerd wordt, via indirecte effecten op aanvalsactiviteit. Het feit dat beide condities 
geassocieerd zijn met een verlaagde expressie van inflammatoire merkers, ondanks het feit dat ze een 
tegengesteld effect hadden op de generalisatie van aanvallen, toont aan dat er meerdere 
mechanismen spelen in het vormen van een specifiek inflammatoir profiel. 
In een vierde studie gingen we na of de modulatie van urinezuurniveaus de aanvalseigenschappen in 
een tweede model, het intraveneuze infusie aanvalsmodel, kon veranderen. Meer specifiek 
onderzochten we de gevoeligheid van UOx OE en UOx KO muizen voor pentylenetetrazol- en 
pilocarpine-geïnduceerde aanvallen. We vonden dat de uitschakeling van UOx resulteerde in een 
verlaagde gevoeligheid voor aanvallen in beide modellen, terwijl overexpressie van UOx geen enkele 
verandering ten opzichte van zijn wildtype tegenhanger met zich meebracht. Dit suggereert dat een 
chronische stijging in urinezuur kan leiden tot een verhoogde aanvalsdrempel. 
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Samengenomen suggereren deze resultaten dat urinezuur meer is dan een onschuldige bijstaander 
in de ontwikkeling van aanvallen en aanvalsgeassocieerde inflammatoire respons, maar dat de aard 
van de betrokkenheid complex en mogelijk tweezijdig is. Aan de ene kant duidt de 
onderdrukking van aanvalsgeneralisatie en de reductie in aanvalsgeassocieerde inflammatie bij 
urinezuurdalingen erop dat urinezuur kan gezien worden als een therapeutisch doelwit. Aan de 
andere kant suggereren de toegenomen latentie tot de eerste aanval en de gereduceerde 
inflammatoire respons op de toegenomen urinezuurniveaus, exact het tegenovergestelde. 
Doortastend onderzoek zal nodig zijn om de precieze condities en mechanismen te ontrafelen waarin 
urinezuur pro- dan wel anticonvulsieve effecten uitoefent. Aangezien het mogelijk nieuwe inzichten 
en therapeutische opties met zich mee kan brengen, geloven we er echter sterk in dat verder 
onderzoek waardevol zou zijn. 
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Epilepsia, IF: 4.571, Q1 Clinical Neurology 
Participation (inter)national conferences 
2011 Stimulating (the) brain: neuromodulation and cognitive neuroscience  
12/12/2011 – Institute for Neuroscience – Ghent, Belgium 
IUAP Meeting: Molecular and Cellular Mechanisms of Electrical 
Excitability 
16/12/2011 – Interuniversitaire Attractiepolen – Ghent, Belgium 
2012 SWO midwinter meeting  
“New therapies in pharmacoresistant epilepsy” 
10/02/2012 – Nederlandse Liga tegen Epilepsie – Amsterdam, The Netherlands 
Spring meeting of the Belgian Society of Physiology and Pharmacology  
“Microglia – active sensor and versatile effector cells in the normal and 
pathologic brain” 16/03/2012 – National Committee of Physiology and 
Pharmacology – Brussels, Belgium  
14th Annual international clinical symposium Kempenhaeghe  
23/03/2012 – Kempenhaeghe Centre – Heeze, The Netherlands 
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2nd Ghent International Epilepsy Workshop  
26-27/10/2012 – LCEN3 – Ghent, Belgium 
Belgian Brain and Cognition Congress  
27/10/2012 – Belgian Brain Council – Liège, Belgium  
2nd Ghent Institute for Neuroscience Symposium  
12/12/2012 – Institute for Neuroscience – Ghent, Belgium 
2013  SWO midwinter meeting  
“Temporal Lobe Epilepsy with Hippocampal Sclerosis”  
01/02/2013 – Nederlandse Liga tegen Epilepsie – Amsterdam, The Netherlands  
15th Annual international clinical symposium Kempenhaeghe 
22/03/2013 – Kempenhaeghe Centre – Heeze, The Netherlands 
Knowledge for Growth Life Sciences Convention 
30/05/2013 – FlandersBio – Ghent, Belgium 
PhD Day Institute for Neuroscience: Connecting the regions of Interest 
13/12/2013 – Institute for Neuroscience, Ghent University – Ghent, Belgium 
2014 SWO midwinter meeting 
“Status Epilepticus: basic mechanisms and therapy”  
14/02/2014 – Nederlandse Liga tegen Epilepsie – Amsterdam, The Netherlands 
Oral presentation/Poster presentation: Allopurinol reduces seizure severity and 
the inflammatory response in a mouse model for status epilepticus: a potential role 
for uric acid in ictogenesis 
16th Annual international clinical symposium Kempenhaeghe  
28/03/2014 – Kempenhaeghe Centre – Heeze, The Netherlands 
Poster presentation: Allopurinol reduces seizure severity and the inflammatory 
response in a mouse model for status epilepticus: a potential role for uric acid in 
ictogenesis. Awarded “Best poster” prize. 
Students research symposium │ Studenten Onderzoekssymposium 
29/04/2014 – Ghent University – Ghent, Belgium 
Poster presentation: Allopurinol reduces seizure severity and the inflammatory 
response in a mouse model for status epilepticus: a potential role for uric acid in 
ictogenesis 
Knowledge for Growth Life Sciences Convention  
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08/05/2014 – FlandersBio – Ghent, Belgium 
Poster presentation: Allopurinol reduces seizure severity and the inflammatory 
response in a mouse model for status epilepticus: a potential role for uric acid in 
ictogenesis 
Neuroscience Forum  
19/06/2014 – Institute for Neuroscience – Ghent, Belgium 
Oral presentation: The role of uric acid in status epilepticus and its associated 
inflammatory response 
11th European Congress on Epileptology  
29/06-03/07/2014 – International League Against Epilepsy – Stockholm, 
Sweden 
Oral presentation: Allopurinol reduces seizure severity and the inflammatory 
response in a mouse model for status epilepticus: a potential role for uric acid in 
ictogenesis 
Autumn meeting of the Belgian Society of Physiology and Pharmacology  
17/10/2014 – National Committee of Physiology and Pharmacology – Brussels, 
Belgium 
Poster presentation: Allopurinol reduces seizure severity and the inflammatory 
response in a mouse model for status epilepticus: a potential role for uric acid in 
ictogenesis  
2015 LCEN3 International Peer Review  
13/02/2015 – LCEN3 – Ghent, Belgium 
Oral presentation: The role of uric acid in status epilepticus and its associated 
inflammatory response 
Science Day of the Faculty of Health sciences and Medicine  
05/03/2015 – Ghent University – Ghent, Belgium 
Oral presentation: Allopurinol reduces seizure severity and the inflammatory 
response in a mouse model for status epilepticus: a potential role for uric acid in 
ictogenesis 
SWO midwinter meeting  
“Mechanisms of epileptogenesis and potential treatment targets” 
11/03/2015 - Nederlandse Liga tegen Epilepsie – Amsterdam, The Netherlands 
Oral presentation/Poster presentation: Characterization of status epilepticus 
induced by intrahippocampal kainic acid infusion in freely moving mice 
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17th Annual international clinical symposium Kempenhaeghe  
27/03/2014 – Kempenhaeghe Centre – Heeze, The Netherlands 
Poster presentation: Characterization of status epilepticus induced by 
intrahippocampal kainic acid infusion in freely moving mice 
2nd PhD Day Institute for Neuroscience: Connecting the regions of Interest 
03/04/2015 - Institute for Neuroscience, Ghent University – Ghent, Belgium 
9th World Congress on Neuroscience  
07-11/07/2015 – International Brain Research Organization – Rio De Janeiro, 
Brazil  
Poster presentation: Characterization of status epilepticus induced by 
intrahippocampal kainic acid infusion in freely moving mice 
Courses and trainings 
2010 FELASA-C Laboratory Animal Science 
Ghent University – Ghent, Belgium    
2012 Advanced Epilepsy course  
Vlaamse Liga tegen epilepsie – UZ Jette – Brussels, Belgium 
Biosensor Workshop 
Sarissa Biomedical – Warwick University – Coventry, UK 
Isolation of microglia using flow cytometry 
Department of Neuroscience – UMCG – Groningen, The Netherlands 
The 10th Summerschool of Neuroscience 
“Neuroinflammation in CNS disorders: priming a target for new therapies”  
EPHAR – University of Catania – Catania, Sicily 
Statistical analysis using SPSS 
Ghent University – Ghent, Belgium 
qPCR experiment design and data-analysis 
Biogazelle – Ghent, Belgium 
Concepts of Neurology │ Begrippen van Neurologie 
Regular Course Bachelor Audiology and Logopedy sciences 
Ghent University – Ghent, Belgium 
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2013 Advanced course on Epilepsy 
Kempenhaeghe Academic Centre – Heeze, The Netherlands 
Advanced Academic English Writing Skills: Life science and medicine 
UCT – Ghent University – Ghent, Belgium 
 
2014 Species-specific welfare in a laboratory environment 
“Rat and mouse” 
Ghent University, ILVO, UFAW – Ghent, Belgium 
Workshop on general anesthesia and monitoring in rat and mouse 
Carfil Quality – Ghent, Belgium 
2015 Popular scientific writing │ Schrijven voor niet-vakgenoten en pers 
Ghent University – Ghent, Belgium 
Teaching, supervision and other activities 
2011-2012 Master thesis supervision Tineke Desmet 
“Neurotransplantatie in een diermodel voor partiële epilepsie” 
Biomedical Sciences 
 
2012-2014 Research internship │ Master thesis supervision Isabel Follebout 
“De rol van urinezuur in epileptogenese” 
Biomedical Sciences 
Hands-on epilepsy workshop on EEG and design of electrodes 
1° Master Students Biomedical Sciences (# 5, three times) 
2014-2016 Research Internship │Master thesis supervision Lien Delmulle 
“De rol van urinezuur in epilepsie” 
Biomedical Sciences    
Lecture on epilepsy research 
1° Master Students Biochemistry and Biotechnology (# 30)  
Lab representative of animal welfare cell  
Attendance of meetings and implementation of guidelines 
 
 
